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General introduction and Outline of the thesis
Background
 In the spring of 2007, a medical microbiologist from the Canisius Wilhelmina 
Hospital reported two patients admitted to the hospital with severe pneumonia, both 
not responding to standard antibiotic therapy. Four days later, a general practitioner 
informed the Municipal Health Service of an unusual number of ten patients with 
atypical pneumonia in his practice in a small village “Herpen” in the province of Noord-
Brabant 1. A similar report by another general practitioner from the same area was received 
2 weeks later. Serological tests revealed in first instance antibodies against Mycoplasma 
pneumoniae. Within a few weeks, the number of patients in the affected area increased 
and more samples were serologically tested. Indirect immunofluorescence assay (IFA) 
and complement fixation test (CFT) revealed high titres of Coxiella burnetii phase II 
antibodies indicating acute Q fever infection.
The total number of Q fever cases increased from 11 annual cases between 1997-2006 to 
168 cases in 2007. In 2008, it became clear that the 2007 outbreak was not an isolated 
incident. This was the beginning of an ongoing outbreak, resulting in the largest Q 
fever outbreak worldwide. In total, 4,176 human cases and 25 notified deaths related 
to Q fever were reported from 2007-2012 2. Re-analyses confirmed the presence of 
M. pneumoniae in two patients. The other patients were infected by C. burnetii and 
appeared to be the first Q fever patients of the outbreak.
Clinical signs of Q fever can be divided in an acute and chronic phase, which will be 
explained in the following chapter. However, each clinical phase has its own diagnostic 
challenges. For acute Q fever; before 2007 Q fever was mainly diagnosed by serology 
using IFA and/or CFT. The disadvantage of these serological methods however, is that 
specific antibodies are absent in the early phases of the disease (≤ 2 weeks). Therefore 
these methods alone are not suitable for early diagnosis and clinical treatment of 
acute Q fever. Real-time PCR specific for C. burnetii was developed in 2007 and rapidly 
been implemented in the Canisius Wilhelmina Hospital as a first-line diagnostic 
test to identify patients infected with C. burnetii in the acute phase of the disease. 
Consequently, this will close the diagnostic gap between onset of the disease and the 
presence of specific antibodies in serum. C. burnetii was identified as the causative 
agent for pneumonia in 22 % of clinical cases al based on a fourfold increase in CFT 
3. Real-time PCR however, identified C. burnetii in clinical pneumonia cases with 
negative CFT, showing the added value of molecular methods to the early diagnosis 
and clinical treatment of acute Q fever. Before 2007, patients with Q fever may also 
have been diagnosed with an unexplained or atypical pneumonia solely based on the 
results of serology without further investigation.
Current follow-up strategy includes serological follow-up to determine evolution to 
chronic Q fever 4. The diagnosis of chronic Q fever by serology can be a real challenge by 
the lack of validated cut-off values 4. Real-time PCR can also contribute to the diagnosis 
of chronic Q fever, especially among immunocompromised patients with atypical low 
phase I antibodies and clinically suspected chronic Q fever 5. The sensitivity of the 
PCR might be up to 100 % in chronic Q fever cases when performed on valve tissue 
compared to blood samples 5, 6. Although serology is the main tool for the diagnosis of 
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Q fever, molecular techniques have an added value to the diagnosis of acute Q fever and 
for the clinical follow-up. These techniques have now been implemented in the Dutch 
guideline on acute and chronic Q fever diagnostics. Chronic Q fever is a combined 
diagnosis based on C. burnetii diagnostics (PCR and IFA-phase I IgG antibodies), 
presence of risk factors, clinical symptoms and radiological findings.
No specific source of the outbreak could be identified in 2007, but it was postulated 
that the high number of abortions on the surrounding dairy goat farms might be the 
source of the human Q fever outbreak and control measures were focused on these 
animal species 7, 8. Genotyping methods were implemented in the Canisius Wilhelmina 
Hospital to understand the distribution of C. burnetii genotypes present in the region. 
With this information, the major sources of infection can be identified, important for 
implement efficient farm-based control measures to reduce human exposure to the 
pathogen. Molecular characterization of C. burnetii may display important information 
about:
 - The sources of the human Q fever outbreak 9, 10, 11.
 - The distribution of genotypes in a region 9, 10, 12, 13. 
 - Involvement of multiple genotypes during the subsequent outbreak  
  years 9, 10.
 - Differences between genotypes from incidental acute and chronic Q  
  fever patients with differences in clinical outcome 10, 12, 13.
 - A correlation with genotypes found in Europe 11, 12, 13, 14. 
 - Possible additional sources 14, 15, 16.
The work presented in this thesis started during the Q fever outbreak episode of 2008 
and focussed on the molecular detection of C. burnetii in humans, possible caveats in the 
diagnostic pathway and on the genotypic characterization of C. burnetii in ruminants 
and humans in the Netherlands compared to internationally known genotypes. This 
work was carried out in collaboration with nationally and internationally research 
laboratories.
Epidemiology and pathogenesis of C. burnetii
Bacteriology
 Coxiella burnetii is a non-motile obligate intracellular Gram-negative bacterium 
and replicates in host monocytes and macrophages. It possesses a cell membrane similar 
to other Gram-negative bacteria, but is usually not stainable by the Gram technique 17, 
18-20. The Gimenez method 21 is usually used to stain C. burnetii in clinical specimens 
or laboratory cultures. C. burnetii has two distinct life cycle stages: a large-cell variant 
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(LCV) and a small-cell variant (SCV). The vegetative form of the bacteria (LCV) is seen 
in infected cells and the SCV may be metabolically inactive and is the extracellular 
and presumably infectious form of the organism 19, 22. This SCV form is likely to be 
long-lived in the environment and resistant to osmotic stress and to chemical and 
physical agents. Coxiella is classified in the family Rickettsiaceae, tribe Rickettsiae. 
Recently, phylogenetic investigations have shown that the Coxiella genus belongs to 
the gamma subdivision of the Proteobacteria, with the genera Legionella, Francisella 
and Rickettsiella as its closest relatives 19. The genome of C. burnetii is approximately 2 
Mb and about twice the size of genomes of most other obligate intracellular bacteria. 
Furthermore, the organism’s central metabolic pathways are largely intact. The absence 
of extensive genome reduction suggest that adaption to an intracellular lifestyle 
is a recent evolutionary event 23. A recent study showed the loss of 4 putative genes 
associated with virulence, fuelling the hypothesis that bacterial pathogenicity is driven 
more by gene loss than gene gain 24.
Another characteristic of C. burnetii is its antigenetic variation (phase variation) of 
the outer cell surface antigens due to changes in the lipopolysaccharides (LPS) layer 25, 
26. Phase I cells, are highly infectious (a single bacterium may infect a human), found 
in infected human and animals and correspond to smooth antigenic variants of other 
Gram-negative variants 17, 19. Phase I LPS blocks access of antibody to surface proteins 
due to its extended carbohydrate structure 18. Phase II, which corresponds to the rough 
variants of Gram-negative bacteria, is less infectious and is obtained after serial passages 
in cell culture systems or embryonated eggs 17, 19. Phase II LPS makes surface proteins 
accessible for antibodies. This variation is of relevance to the serologic diagnosis of Q 
fever. Differential antibody responses to phase I and phase II antigens are useful for 
distinguishing acute from chronic Q fever in humans.
Epidemiology
 Q fever is a worldwide zoonosis. The first outbreak was described in 1935 in 
Queensland Australia and affected abattoir workers. Patients could not be diagnosed, 
therefore the disease was could Q fever (query virus) 27. The most commonly identified 
sources of human infection are domesticated ruminants, cattle, sheep and goats 
and are often asymptomatic carriers of C. burnetii for several years, probably life-
long 18, 19, 28, 29. Prevalence among cattle seems to be slightly higher than in sheep and 
goats 30. In small ruminants, C. burnetii can cause abortion among sheep/goats and 
reproductive disorders among cattle 19. Huge numbers of C. burnetii can be released 
into the environment via birth products, faeces and mucus 29, 31. Lower numbers are 
usually shed in milk, even in asymptomatic herds 32-37. Although consumption of raw or 
insufficiently pasteurized milk is very rarely identified as a source of Q fever infection, 
asymptomatic cattle herds can be considered potential C. burnetii reservoirs capable 
of transmitting the disease to humans. Vegetation and soil moisture are relevant 
factors in the transmission of C. burnetii from infected farms to humans. Intensive goat 
and sheep husbandry should thus be avoided in areas with little vegetation and deep 
groundwater 38. During lambing, infected birth products can contaminate the ground. 
14
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Since, C. burnetii is highly resistant by extreme environmental conditions it can form a 
highly infectious dust 39. Furthermore, C. burnetii is able to survive in a spore-like state 
for months to years in the environment and therefore, no direct contact with animals 
is necessary 28. Outbreaks have been caused by contaminated dust carried by wind 
over large distances, in abattoirs, among wool sorters and staff in research facilities 
using sheep as experimental animals or visiting a sheep farm on lamb-viewing days. C. 
burnetii seroprevalence is considerable among veterinary students and Dutch livestock 
veterinarians, especially among culling workers during the Q fever outbreak episodes 
28, 39-45. In Great Britain, an outbreak was linked to passage of farm vehicles containing 
contaminated straw and manure 39. Q fever might even present as a travel-associated 
disease 46-49. Transmission of Q fever during autopsies or infection from a patient to the 
hospital staff are rare 19, 28, 47, 50, 51. There is a theoretical possibility that C. burnetii can 
be transmitted through blood transfusion, semen, tissue and organ donation. Before 
symptoms occur, chronically infected blood donors may be infectious. The risk of 
transmission via blood transfusion remains even in non-outbreak situations 52. Cats, 
dogs, pigeons, rabbits and rat, living close to domesticated ruminants, may be infected 
by C. burnetii and should be considered as possible sources of human infection 2, 16, 50, 
53, 54. Being reservoirs, ticks are not considered as a main vector for transmission the 
disease to humans 24, 53, 55.
Pathogenesis
Clinical signs
 In humans infection with C. burnetii remains asymptomatic in ~60% of 
infected persons. In symptomatic patients, acute Q fever usually presents as a flu-
like, self-limiting disease, atypical pneumonia or hepatitis. In most cases men develop 
significant more Q fever than women. The age group 25 – 64 years old is found 2 – 3 
times more positive than other groups. This is probably caused by more outdoor activity 
than other age groups and therefore more likely to be exposed to C. burnetii. Only 
women in the age group of 70 years and older are found more Q fever positive than 
men 41, 51, 56. Children develop Q fever less frequently 57. Working in agricultural related 
occupations increases the risk for Q fever 58. The infectious dose is very low; inhalation 
of a single viable organism can cause infection 59. The incubation period ranges from 
2 to 3 weeks, depending on the C. burnetii inoculums 19, 51, 56. Doxycycline is nowadays 
used for the treatment of Q fever and fluoroquinolones as a reliable alternative 28.
Especially pregnant women are at risk, because they are highly susceptible to infection. 
Infection in pregnancy may lead to adverse pregnancy outcomes, such as spontaneous 
abortion or premature delivery during the first trimester of pregnancy 19. No evidence 
of an association between Q fever infection and spontaneous abortion in humans in 
the last trimester has been found 60. Serological monitoring of Q fever in pregnant 
women is recommended in endemic areas 61. However, in contrast to the present 
literature no evidence was found between premature delivery and Q fever infection in 
the Netherlands in high risk areas, probably due to a different genotype of the Dutch 
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strain. Routine screening during pregnancy seems not to be related with a relevant 
reduction in obstetric complications and therefore routine screening of C. burnetii 
infection of pregnant women living in Q fever high-risk areas is not maintained in the 
Netherlands 62. Nevertheless, pregnant women with clinical symptoms will be treated 
with doxycycline or hydroxychloroquine and monitored through serological follow-
up.
About 1–5% of all Q fever cases may progress into a chronic infection due to an ineffective 
immune response and consequently resulting in continuous multiplication of C. 
burnetii in macrophages, often leading to life-threatening cardiovascular complications, 
mainly endocarditis, and also aortic aneurysms and vascular-graft infection 20, 63-68. 
Previous valvular surgery, vascular prosthesis, aneurysms, renal insufficiency and age 
are indentified as major risk factors for the development of chronic Q fever among 
humans infected with C. burnetii. The diagnosis of Q fever endocarditis has important 
clinical implications, as this requires long-term treatment, has poor prognosis if left 
untreated with a high mortality and the need for surgery 69, 70. However, estimating the 
incidence of chronic Q fever is rather difficult, because diagnosis of chronic Q fever can 
be made up to 10 years after the primary infection 71. Therefore, patients with acute Q 
fever should be monitored through serological follow-up to exclude chronic infection. 
New diagnostic criteria are proposed for screening of chronic Q fever 6. Approximately 
1-5% of all cases are hospitalized and fatal cases are reported 19, 72. Patients, who died 
within approximately one month following hospitalisation for acute Q fever, had 
often serious underlying conditions including chronic cardiovascular disease, chronic 
lung disease, diabetes mellitus and malignancy 72. In some outbreaks the prolonged 
continuous exposure may have caused more severe illness resulting in higher proportion 
of hospitalizations 56. While relatively few acute Q fever cases will result in chronic Q 
fever, a larger group of acute Q fever patients suffers from persistent fatigue and other 
long-term effects. Although fatigue is not a life-threatening condition, it can seriously 
affect the quality of life 73.
Laboratory diagnosis
 Acute and chronic infections are characterized by different serological profiles. 
In acute infection, phase II antibodies (IgM) appear early in infection, while phase I 
antibodies arise later at relatively low levels. Chronic infections however are characterized 
by very high titres of anti-phase I immunoglobulin G (IgG) and IgA antibodies and may 
remain elevated for years. An increase of four dilutions is considered to be a significant 
rise in antibody titres. Laboratory diagnosis of Q fever is usually performed by 
serological methods such as the indirect immunofluorescence assay (IFA), complement 
fixation test (CFT), or enzymelinked immunosorbent assay (ELISA), but these tests 
are of limited use in the early phase of the disease, as it may take up to 2 weeks for a 
detectable immune response to develop. Several PCR-based diagnostic methods, such 
as conventional PCR, nested PCR, or real-time PCR, have successfully been applied for 
the direct detection of C. burnetii DNA in clinical samples. The sequences targeted by 
these tests varied from plasmids (QpH1 or QpRS) to chromosomal genes, such as the 
isocitrate dehydrogenase gene (NADP) or the transposase gene of the C. burnetii IS1111a 
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insertion element 58, 74-77. The multicopy IS1111a insertion element is present in 20 copies 
in the genome of the C. burnetii Nine Mile RSA493 strain. Copy numbers per isolate 
vary and can reach up to ~100 copies per genome 59. Due to the multicopy nature of this 
DNA element, it provides a highly sensitive target for detection of C. burnetii DNA in 
serum samples.
Diagnosis of chronic Q fever is a real challenge, in 2.5 to 31 % of all infective endocarditis 
cases, routine blood cultures are negative by serology. Real-time PCR however, is a 
reliable method when applied to serum for the confirmation of the diagnosis of blood 
culture negative endocarditis, since in these patients C. burnetii DNA can be detected 
in serum over long periods of time 58, 78. A new clinical tool, Coxiella ELISPOT has been 
developed for diagnosing chronic Q fever presumptive more sensitive than serological 
tests 79. Recently, a feasible antigen-specific interferon-gamma (IFN-g) assay was 
developed to diagnose previous infection with C. burnetii 80. Furthermore, a multiplex 
cytokine assay for detection of IFN-g and interleukin (IL) 2  production can distinguish 
patients with chronic Q fever from individuals with a past infection. However, its 
use for clinical monitoring during treatment of chronic Q fever needs to be further 
investigated 81.
Genotyping
 Molecular characterization of C. burnetii by genotyping is instrumental 
for recognition of specific strains. This is an indispensable tool for epidemiological 
investigations of Q fever outbreaks and for surveillance purposes. Genotyping may 
allow identification of the source of the outbreak so that specific measures can be 
implemented to contain of the source. Over the years various genotyping techniques for 
C. burnetii have been published. Methods such as pulsed field gel electrophoresis and 
PCR restriction fragment length polymorphism analysis (PCR-RFLP) have been used to 
recognize different groups of C. burnetii isolates. Differentiation between strains could 
also be achieved by sequence based determination of the Com1 and MucZ encoding 
genes, by whole-genome comparison using a microarray-based method as well as by 
studying differences in plasmid types 82-89. Furthermore, Infrequent Restriction Site-
PCR (IRS-PCR), IS1111a insertion sequence PCR-based and tandem mass spectrometry 
coupled to nanoscale ultraperformance liquid chromatography (LC-MS/MS) have been 
developed for typing of C. burnetii isolates 90-92. All these methods however, have relied 
on the cultivation of the isolate prior to analysis using cell culture techniques or using 
embryonated chicken eggs, which requires specific expertise as well as biosafety level 
3 conditions 86, 90. Cultivation of the isolates prior to analyses creates also a potential 
for generation of genotypic variation due to multiple sequential cell divisions. Several 
other genotyping methods have the potential to be used directly in clinical samples 
eliminating this caveat, in particular; multispacer sequence typing (MST), single-
nucleotide polymorphism (SNP) based typing and multiple-locus variable number 
tandem-repeat analysis (MLVA) 9, 10, 90, 93-96. A new genomotyping method revealed 
the presence of 10 genomotypes organized into 3 groups comparable to MST. Four 
of these genomotypes were specifically associated with acute Q fever, whereas all of 
the genomotypes could be associated to chronic infection. These results implicate 
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that genotypes from chronic Q fever patients are more divers than from acute Q fever 
patients 24.
Outline of the thesis
 The aim of the study described in this thesis was to investigate the C. burnetii 
genotypes in ruminants and humans from the Q fever outbreak in the Netherlands 
in contrast to genotypes throughout Europe in collaboration with nationally and 
internationally research laboratories (part 1). Furthermore, the molecular detection 
of C. burnetii in serum samples used in diagnostic and public health laboratories in 
the Netherlands was compared and possible caveats in the diagnostic pathway are 
highlighted (part 2). To achieve this objective, at first the current epidemic and the 
historical background of Q fever in the Netherlands were reviewed in chapter 2 
according to national and international publications. An overview of the history of Q 
fever in the Netherlands, both in animals and humans, the emergence of the disease 
and the control measures that have been taken are highlighted.
Part 1  Genotypic diversity of Coxiella burnetii in ruminants 
and humans
 The objective of the study described in chapter 3 was to show the genetic 
background of C. burnetii in domestic ruminants (cattle, goats and sheep) presumably 
responsible for the human Q fever outbreak. The geographical distribution of the 
C. burnetii genotypes across the Netherlands was determined by an updated 10-
locus MLVA panel. In chapter 4, the temporal and spatial genotypic diversity of C. 
burnetii in acute and chronic Q fever patients collected during the 2007 – 2010 Q fever 
outbreak episodes from the entire affected part of the Netherlands was determined 
by an improved 6-locus MLVA panel. Placenta samples from goats were included to 
display a correlation between human and animal Q fever cases. In chapter 5, the 
correlation between human and animal Q fever cases was further investigated by MST 
in cooperation with researchers from France and compared to an internationally MST 
database. In chapter 6, the prevalence of C. burnetii genotypes in consumer milk 
products was determined by a MLVA-6 panel. This study, initially set up to determine if 
cattle are also involved in the Dutch outbreak, is the first report of genotypic diversity of 
C. burnetii among cattle throughout Europe. Integration of these data in international 
databases can be instrumental to understand the global epidemiology of Q fever in 
cattle. Chapter 7 and chapter 8 describe the genotypic diversity of C. burnetii in acute 
and chronic Q fever patients and ruminants (cattle, goat and sheep) from Portugal 
and Spain determined by MLVA and MST in cooperation with researchers from both 
countries. This information is important to understand the European context of Q 
fever epidemiology. Finally, the performance of both MST (chapter 5) and the different 
MLVA panels (chapter 3 and 4) for the genotypic characterization of C. burnetii from 
clinical samples were compared in chapter 9.
18
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Part 2  Molecular detection of Coxiella burnetii in humans
 Real-time PCR has rapidly been implemented in many diagnostic laboratories 
in the Netherlands together with serology, as a first-line diagnostic test to identify 
patients infected with C. burnetii in the acute phase of the disease and for the diagnosis 
of chronic Q fever. In chapter 10, the differences in performance of DNA extraction 
methods and real-time PCR assays which are being used in diagnostic or public health 
laboratories in the Netherlands are described. With the application of molecular 
techniques to detect microbial DNA in clinical samples, it has become apparent 
that these techniques may have caveats at multiple stages in the diagnostic process 
that may lead to false-positive PCR results. Especially for Q fever; a contamination 
of a commercially available PCR Master Mix with DNA from C. burnetii with clinical 
consequences is described in chapter 11. The antigen preparations of the serological 
methods (CFT and IFA) contain antigens isolated from infected cells and might also 
contain DNA from C. burnetii. Chapter 12 describes a laboratory contamination traced 
back to the antigen preparation used in the commercially available CFT.
Finally in chapter 13 the findings reported in this thesis are summarized and 
discussed.
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Abstract
 The 2007–2009 human Q fever epidemic in the Netherlands attracted 
attention due to its magnitude and duration. The current epidemic and the historical 
background of Q fever in the Netherlands are reviewed according to national and 
international publications. Seroprevalence studies suggest that Q fever was endemic 
in the Netherlands several decades before the disease was diagnosed in dairy goats 
and dairy sheep. This was in 2005 and the increase in humans started in 2007. Q fever 
abortions were registered on 30 dairy goat and dairy sheep farms between 2005 and 
2009. A total of 3,523 human cases were notified between 2007 and 2009. Proximity 
to aborting small ruminants and high numbers of susceptible humans are probably 
the main causes of the human Q fever outbreak in the Netherlands. In general good 
monitoring and surveillance systems are necessary to assess the real magnitude of Q 
fever.
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Introduction
 Q fever is a zoonosis caused by Coxiella burnetii, an intracellular Gram-negative 
bacterium that is prevalent throughout the world 1. Domestic ruminants are considered 
to be the main reservoir for Q fever in humans 2, although other animal species, including 
pet animals, birds and reptiles, may also be responsible for human cases. Transmission 
to humans is mainly accomplished through inhalation of contaminated aerosols. The 
main clinical symptom of Q fever in goats and sheep is abortion and in cattle reduced 
fertility. With abortion, 1,000,000,000 C. burnetii/g placenta can be excreted 3. Duration 
of shedding of C. burnetii by infected livestock varies depending on the excretion route 
and species. In milk, C. burnetii can be excreted for 8 days in ewes and up to 13 months 
in cattle. In faeces, C. burnetii can be excreted up to 8 days after lambing in ewes and 
up to 20 days in goats 4. Goats may shed  C. burnetii in two successive kidding periods 
5. Most animal species carrying C. burnetii show no symptoms at all 4.
In humans infection with C. burnetii remains asymptomatic in ~ 60% of infected 
persons. In symptomatic patients, acute Q fever usually presents as a flu-like, self-
limiting disease, atypical pneumonia or hepatitis. Infection in pregnancy may lead 
to adverse pregnancy outcomes, such as spontaneous abortion or premature delivery. 
About 1–5% of  all Q fever cases may progress into a chronic infection, often leading to 
life-threatening endocarditis 4, 6-9. Since 2007, a Q fever outbreak has been ongoing in 
the Netherlands and this is referred to as the largest outbreak of Q fever ever reported 
in the literature 10. However, Q fever is not an entirely new disease in the Netherlands. 
In this review we give an overview of the history of Q fever in the Netherlands, both 
in animals and in humans, the emergence of the disease and the control measures 
that have recently been taken. In conclusion, we put the outbreak in an international 
perspective.
Q fever becomes endemic, 1956–2005
Situation of Q fever in humans between 1956 and 2005
 In the 1950s a comprehensive survey of the global distribution of Q fever was 
commissioned by the World Health Organization. In the Netherlands, between 1951 
and 1954, almost 10,000 human sera were tested for Q fever with a complement-fixation 
test and all were negative 11, 12. In 1956, the first three human cases were reported in the 
Netherlands 13. Two patients might have been linked to imported cattle or a visit abroad, 
while in the third patient there was no obvious cause. In 1958 and 1967 two human Q 
fever cases were described associated with the handling of imported wool 14, 15.
The notification of infectious diseases started in the Netherlands in 1865. The law 
changed several times and the list of notifiable diseases became longer with every 
change. Q fever was made notifiable in 1975, although it was a very rare disease at that 
time 16. Between 1975 and 2006 the annual number of cases increased from 0 to 32 per 
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year (Fig. 1). Thirty-three of the cases notified between 1979 and 1983 were investigated 
more thoroughly. Twenty-two (67%) of these patients were probably infected in the 
Netherlands through contact with animals or animal products 17. A survey in 1982/1983 
among 432 persons, considered to be at high risk because of close contact with animals 
and animal products, showed high percentages (58% in taxidermists to 84% in 
veterinarians) of seropositive responders with mainly IgG antibodies against C. burnetii 
phase-II antigen, indicating that Q fever had become endemic in the Netherlands 18.
The increase in human cases between 1977 and 1983 (Fig. 1) was assessed by Richardus 
et al. 18 by testing serum samples from persons, not considered to be at high risk, taken 
in 1968, 1975, 1979, and 1983 with an indirect immunofluorescence test (IFT) for specific 
IgG antibodies against C. burnetii phase-II antigen. In adults an average seroprevalence 
of 46% in 1968 and of 48% in 1983 was found. In children seroprevalences varied from 
on average 54% in 1975 to 28% in 1979 and 1983. These results showed no significant 
increase in the percentage of infected persons over the years 1968–1983. The increased 
number of notified cases since 1980 was explained by the introduction of a sensitive 
indirect immunofluorescence test for IgM antibodies against C. burnetii. In the same 
study 18 occupational groups with a high risk of infection showed a significantly higher 
proportion of seropositives compared to the low-risk control group, in 1983 84%of 
221 veterinarians and 68% of 94 residents of dairy farms were positive, whereas in 
the control group on average 29% tested positive for IgG antibodies against phase II 
of C. burnetii. The age distribution suggested an early onset of infection as antibody 
percentages over all age groups between 1 and 64 years were comparable 18. It remains 
unclear why seroprevalence in the non-high-risk groups, varying between 30% and 
50%in the 1980s, was high while on average 23 clinical Q fever cases were detected. 
Protective immunity from childhood 19 and under-diagnosis 20 could have played a role, 
but the serological test methods that were used in the 1980s were developed in-house 
and are no longer available, so the sensitivity and specificity of these tests can no longer 
be verified.
Figure 1. Number of notified human cases in the Netherlands between 1975 and 2006.
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Situation of Q fever in animals between 1956 and 2005
 Surveys in the early 1950s indicated that the bovine population was free of Q 
fever at that time 11, 12. Between 1981 and 1987 the endemic state of Q fever in farm animals 
was confirmed by seroprevalence studies in cattle, sheep and goats 21, 22. In 1981, 55% of 
20 sampled cattle on one farm were tested positive. In 1987, 10% of 1320 non-dairy 
cattle, 21% of 1,160 dairy cattle and 3% of a total of 494 dairy heifers were seropositive. 
At the herd level, about 36% were found positive with an average of 35% seropositive 
animals per herd. The occurrence of C. burnetii in cattle herds seemed to be associated 
with abortions, as 77% of the herds with abortions had a mean seroprevalence for Q 
fever of 39%. For the 31% of the herds without abortions, the mean seroprevalence was 
only 17%. In sheep 3.5% (127/3,603 sheep sera from 191 flocks) of the animals were found 
positive with a herd prevalence of 27%. In goats 2/594 sera from individual goats from 
54 flocks were positive. In 1992 prevalence in 220 representative cat sera was 10% and in 
400 representative dog sera 13% (D. J. Houwers, et al. unpublished data).
Transition period, 2005–2007
Changing situation of Q fever in animals since 2005
 Clinical Q fever in animals was diagnosed in the Netherlands for the first time 
in 2005 23. In two dairy goat herds with abortion problems C. burnetii was detected by 
immunohistochemistry (IHC) on placentas 24. From 2005 to 2007 Q fever abortions were 
diagnosed on 15 dairy goat farms and one dairy sheep farm (Table 1). Abortions, with 
herd rates up to 60%, were seen mainly in the final month of pregnancy without signs 
of general illness, although some goats were temporarily a little sluggish with reduced 
appetite. After abortion some goats showed symptoms of endometritis. Full-term kids 
were weak, with low body weight and high mortality. In several apparently healthy 
kids the rearing period was complicated by respiratory and digestive tract disorders. 
Treatment of pregnant goats with oxytetracyclines did not reduce the abortion rate 
24. Retrospectively, C. burnetii could be detected by IHC in one preserved dairy goat’s 
placenta from a farm with abortion problems in 2001. In dairy cattle herds C. burnetii 
antibodies were detected on 57% of 344 farms using ELISA on bulk tank milk (BTM) 
samples during 2005–2006. It was calculated that on 35% of the farms at least 30% of 
the cattle could be positive 25.
Table 1. Number of dairy goat and dairy sheep farms with confirmed Q fever abortions.
2005 2006 2007 2008 2009 Total
Diary sheep farms - 1 - 1 - 2
Dairy goat farms 2 6 7 7a 6 28
a Including one farm with animals at two locations.
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Changing situation in humans since 2007
 In 2007, individual human Q fever cases were reported, occurring after visits 
to dairy goat farms with abortion problems 24, 26. The first documented outbreak of Q 
fever in the Netherlands was described by Karagiannis et al. 27 and Van Steenbergen et 
al. 28. A total of 168 human cases were notified in 2007 (Fig. 2). The epidemic became 
apparent by a number of indicators: first, a medical microbiologist reported two 
patients admitted to hospital with severe pneumonia, who did not respond to standard 
antibiotic therapy. Four days later, a general practitioner informed the Municipal 
Health Service (MHS) of an unusual number of ten patients with atypical pneumonia 
in his practice. A similar report by another general practitioner from the same area 
was received 2 weeks later. Finally, an increase in the number of notifications for Q 
fever was noticed in the national registration system of the National Institute for Public 
Health and the Environment (RIVM). No specific source could be identified, but it 
was postulated that the high number of abortions on the surrounding dairy goat farms 
might be the source of the human Q fever cases in the province of Noord-Brabant. 
Airborne transmission of contaminated dust particles could have been facilitated by 
the unusually hot and dry weather in the spring of 2007.
Figure 2. Number of notified human Q fever cases with a known first day of illness according to 
the week of onset of symptoms, from 1 January 2007 to 11 May 2010. 2007 (n=168), 2008 (n=1,000), 
2009 (n=2,354), 2010 (n=208). Total number of human cases in 2007–2009 (n=3,522) (compiled 
by F. Dijkstra).
In 2007, the outbreak was concentrated around a single village and in this village a 
case-control study was performed 29. Contact with manure, hay, and straw proved to be 
a risk factor. Moreover, people living in the eastern part of the village close to ruminant 
farms, of which one dairy goat farm had a recent history of abortion problems, were at 
higher risk than people living in other parts of the village. Contact with animals and 
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consumption of raw milk products were not significant risk factors in the multivariable 
analysis. Notification criteria for a confirmed human Q fever case were a clinical 
presentation with fever or pneumonia or hepatitis and confirmation of the diagnosis 
in the laboratory by at least a fourfold rise in IgG antibody titre against C. burnetii in 
paired sera or the presence of IgM antibodies against phase II or antibodies against 
C. burnetii phase I 30. A probable case was defined as clinical signs with a single high 
antibody titre 31.
Response phase, 2008–2010
Continuation of the human outbreak
 In 2008, it soon became clear that the 2007 outbreak was not an isolated 
incident. In May 2008 an outbreak of Q fever occurred in a psychiatric care institution 
in Nijmegen, province of Gelderland, ~15 km from the 2007 outbreak area 32. At least 
28 in-patients, employees, and visitors had laboratory confirmed Q fever illness and 
several patients of the institution developed atypical pneumonia. A small flock of 
sheep without clinical symptoms of Q fever was present at the location. Patients had 
close contact with lambs, including cuddling as part of the patients’ therapy sessions. 
Furthermore, on a dairy goat farm close to the city of Nijmegen, a large number of 
goats unexpectedly aborted their offspring. Q fever was confirmed by PCR on vaginal 
swabs. The farmer showed no clinical symptoms indicative for Q fever. The farmer’s 
wife suffered from only moderate flu-like symptoms, including fever and coughing, 
and for both persons Q fever was confirmed by PCR on serum, throat swabs, urine and 
faecal samples. To determine the genetic relatedness between the human and animal 
clinical samples from both locations multiple-locus variable number tandem repeat 
analysis (MLVA) was carried out. Clinical samples from other patients from different 
locations in the same high-risk area were included in the study. All genotypes showed a 
high degree of similarity with most genotypes differing from each other by only a single 
marker, suggesting a clonal origin (J.J.H.C. Tilburg & C.H.W. Klaassen, unpublished 
observations) 33, 34.
Eventually, 1000 human Q fever cases were notified in 2008 (Fig. 2). The centre of the 
outbreak and the area with the most human cases were the same as in 2007, but there 
was a clear geographical spread to adjacent areas (Fig. 3). The age distribution (range 
7–87 years, average 51 years) was similar to 2007, but the hospitalization rate decreased 
from 50% in 2007 to 21% in 2008 10, 35. The high hospitalization rate of 50% in 2007 
might be biased by active case-finding in a retrospective survey among hospitalized 
cases 35. The overall gender breakdown was the same in 2008 as in 2007: the female to 
male ratio was 1:1.7 10.
In April 2009 a sharp increase in human cases was observed again resulting in a total 
number of 2,354 cases (Fig. 2). Again most of the human cases were from the same area 
as in 2007 and 2008, with yet again a wider geographical spread (Fig. 4). Pneumonia is 
the predominant presentation of Q fever in the Netherlands. For patients notified in 
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2008 for whom clinical details were available, 545 were diagnosed with pneumonia, 33 
with hepatitis and 115 with other febrile illness 31. The age median of 50 years in 2009 did 
not differ from that in 2008, neither did the hospitalization rate of 20% nor the gender 
break down of 1:1.7 female to male ratio 35.
Figure 3. Map of the Netherlands. Left: Number of human cases in 2007 and 2008. The red 
line shows the dairy goat and dairy sheep voluntary vaccination area in 2008. Right: Dairy goat 
farms (green) [24] and dairy sheep farms (blue) [2] with Q fever abortion history between 2005 
and 2008. [Compiled by National Institute for Public Health and the Environment (RIVM) and 
Animal Health Service (GD).]
The overall outbreak in humans consisted of at least 10 separate clusters with multiple 
sources of exposure. One cluster became apparent in 2008 with a strong connection to 
one goat farm with abortion problems. Patients were living downwind of the goat farm. 
Living within 2 km of the goat farm was associated with a higher risk of Q fever infection 
compared to living >5 km from the farm 35. In 2009, no abortions were notified on this 
farm, nor in this area, and veterinary measures such as the handling of manure, hygiene 
measures and a visitors ban were implemented (measures are clarified in the section 
‘Response in the veterinary field’), but the number of human cases still increased. 
To date, the source of this increase in 2009 remains unclear 31. In general, 59% of the 
notified human cases in 2009 lived within a 5-km zone around a notified dairy goat or 
dairy sheep farm, while 12% of the Dutch population live within such zones 35. In 2010 
criteria for detection of C. burnetii in blood, serum or a sample from the respiratory 
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tract were added to the notification criteria for human Q fever cases. In addition, only 
acute cases with the day of first illness within 90 days of notification are recorded in 
the national infectious disease notification databases 37. During the period January to 
May 2010, 208 human cases were registered which indicates a decrease in the number 
of notified human cases compared to 2009 (Fig. 2). Although weather conditions may 
have been unfavourable for transmission, it is hoped that the decrease in the number of 
human Q fever cases was caused by reduced exposure due to veterinary interventions.
Figure 4. Map of the Netherlands. Left: Human Q fever incidence/100,000 inhabitants per 
municipality in 2009. The blue line shows the dairy goat and dairy sheep mandatory vaccination 
area in 2009. Right: Dairy goat farms with Q fever abortion history between 2005 and 2009. 
Darker blue indicates more goats/km2. [Compiled by National Institute for Public Health and the 
Environment (RIVM) and Animal Health Service (GD).]
Dairy goat industry and prevalence of Q fever in small ruminants
 The dairy goat industry in the Netherlands is concentrated in the province of 
Noord-Brabant, with farm sizes ranging from 300 to 7,000 goats with an average of at 
least 600 animals in 2007. Goat density was 38,1 goats/km2. These farms often bordered 
close to villages and cities 38. The total number of registered small ruminant farms in 
the Netherlands in 2008 was 52,000. The number of professional dairy goat farms with 
more than 200 adult goats was 350 and the professional dairy sheep industry consisted 
of 40 farms 39. Dairy goat farming in the Netherlands started after the introduction of 
the European milk quotation system for dairy cattle in 1984 and increased after the 
outbreaks of classical swine fever in 1997 and foot-and-mouth disease in 2001. The total 
number of goats increased from 7,415 in 1983 to 178,571 in 2000 and to 374,184 in 2009. 
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The total number of dairy goats aged >1 year increased from 98,077 in 2000 to 231,090 
in 2009 (Table 2) 40, 41.
Table 2. Number of goats in the Netherlands 40, 41.
Year Total no. of goats Total no. of dairy goats aged > 1 year
1983 7,415 n.r.a
1995 76,063 n.r.
2000 178,571 98,077
2009 374,184 23,109
a n.r. =  No registration
In 2008, nationwide Q fever seroprevalence in all small ruminants was low; only 
7.8% of goats and 17.8% of goat farms were positive, and 2.4% of sheep and 14.5% of 
sheep farms were positive. In 26% of the BTM samples from 306 dairy goat and dairy 
sheep farms C. burnetii DNA could be detected. Analysis of the first 13 goat farms with 
abortions showed an average number of goats per farm of 900 of which 20% aborted. 
The average number of sheep on the two affected dairy sheep farms was 400 with an 
abortion rate of 5% 39.
Response in the veterinary field
 In June 2008, Q fever became notifiable for small ruminants kept for milk 
production following the advice of experts (Table 3). Additional measures were taken 
to reduce the assumed risk associated with the spread of manure and to restrict the 
number of visitors to infected farms. In October 2008, voluntary vaccination of goats 
was made possible by the Ministry of Agriculture in the high-risk Q fever area in Noord-
Brabant with the so far unregistered phase-I Q fever vaccine for ruminants (Coxevac1, 
Ceva Sante´ Animale, France; Fig. 3 (red line), Table 3) 42. A total of 36,000 goats were 
vaccinated in an area within a radius of 45 km around the village of Uden. This was 
the first time a Q fever vaccine had been used with the ultimate goal of reducing the 
number of human Q fever cases. In order to reduce the number of human cases the 
exposure of humans to C. burnetii should be reduced. To achieve this, excretion of C. 
burnetii from the animal host should be minimized, particularly by the prevention of 
abortion due to Q fever. Phase-I Q fever vaccines, contrary to phase-II vaccines, strongly 
reduce the number of abortions and excretion of C. burnetii in challenged pregnant 
goats that were initially Q fever-negative 43. In clinically Q fever infected goat herds 
vaccination with a phase-I vaccine should reduce the excretion of C. burnetii, especially 
in young animals vaccinated before the breeding season 44. In general, vaccination with 
a phase-I Q fever vaccine is expected to be effective in noninfected goats. The effect of 
vaccination in Q fever infected goats is not clear and may imply a continuation of the 
risk of shedding C. burnetii and exposure to humans. According to the summary of 
product characteristics (SPC), the phase-I Q fever vaccine is not indicated for use in 
pregnant sheep. Assessment of the efficacy of the phase-I vaccine in pregnant cattle 
235
The Q fever epidemic in the Netherlands 
showed a similar probability of the animals becoming shedders when vaccinated while 
pregnant compared to non-vaccinated animals 45.
In February 2009, measures taken by the government were tightened with a stringent 
hygiene protocol made mandatory for all professional dairy goat and dairy sheep farms 
in the Netherlands, independent of their Q fever status. The hygiene protocol included 
vermin control, measures for handling manure (farmers were not allowed to remove 
manure from their deep litter stables for at least 1 month after the kidding season, 
were obligated to cover manure during storage and transport, and had to underplough 
manure immediately when spreading on farming land or had to store it for at least 
3 months), compulsory rendering of aborted foetuses and placentas and improved 
general farm hygiene (such as the prevention of dust and aerosol formation, protective 
industrial clothing, clean delivery equipment and the use of sufficient high-quality 
bedding material). In addition, farmers were advised to submit aborted foetuses for 
pathological examination 39, 46. Vaccination became mandatory for all dairy goats 
and dairy sheep, and the vaccination area was extended from the 45-km zone around 
Uden in 2008 (red line in Fig. 3) to the whole province of Noord-Brabant and small 
neighbouring areas in 2009 (indicated by the blue line in Fig. 4).
In response to the increasing number of human cases in 2009, additional measures 
were implemented in October 2009: PCR positivity of BTM on dairy goat and dairy 
sheep farms became a notification criterion of Q fever in small ruminants in addition 
to unexpectedly high abortion rates (>5%) ; a transport ban of animals from Q 
fever-positive farms and a visitors ban at Q fever-positive farms (Table 3). Improved 
monitoring of farm infection status with BTM monitoring was advised by experts. 
The background of this advice was that the abortion rate is difficult to measure in a 
flock with over 600 animals, and on infected farms C. burnetii can also be excreted in 
large quantities during normal birth. In large infected herds with many animals having 
normal deliveries, the total amount of excreted bacteria can also be very high with a 
subsequent risk for public health. BTM monitoring could give insight to the number 
of farms where C. burnetii is present. Initially, BTM monitoring was take place every 
2 months, but with the increased awareness of the risk of Q fever and the possible 
risk that Q fever-positive farms might pose during kidding season, the frequency of 
monitoring was increased to every 2 weeks. Due to BTM monitoring the number of 
Q fever-positive dairy goat and dairy sheep farms had increased to 88 on 17 April 2010 
(Fig. 5).
With changing public and political awareness of Q fever, the Outbreak Management 
Team or expert panels advised the Ministries of Health and Agriculture about 
additional risk reduction measures. At a meeting in December 2009, experts stated 
that they expected vaccination would not be sufficiently effective in reducing the 
excretion of C. burnetii in the 2010 kidding season, due to the fact that not all dairy 
goats and dairy sheep had been vaccinated before the 2009 breeding season. A more 
considerable reduction in the possible excretion of C. burnetii and thus, environmental 
contamination, thereby attempting to reduce human exposure and potential risk to 
public health in 2010, might be achieved by preventing pregnant Q fever-positive goats 
on Q fever-positive farms from kidding. These animals were identified as high-risk 
animals. 
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Table 3. Overview of legislation concerning Q fever in small ruminants in the Netherlands 42.
Date Document code Measure
12 June 2008 TRCJZ/2008/1622 Q fever notifiable in dairy goats and dairy sheep; 
notification when over 5% abortions within 30 days at 
farms with more than 100 animals and when over 3% 
abortions within 30 days at farms with fewer than 100 
animals (abortion rates up to 5% are considered to be 
more or less normal).
12 June 2008 TRCJZ/2008/1645 Prohibited from removing manure from the stable for 
90 days after notification Visitors ban in place for 90 
days after notification.
16 October 2008 TRCJZ/2008/2817 Special dispensation for Coxevac (CEVA) Q fever 
vaccine to be used in the Netherlands. Voluntary 
vaccination in dairy sheep and dairy goats at farms 
with more than 50 sheep or goats, petting zoos and 
nursing farms in the restricted 45-km zone (Fig. 3).
2 February 2009 TRCJZ/2009/244 Prohibited from farming more than 50 dairy goats 
and dairy sheep if certain hygienic measures are 
not implemented, such as vermin control, manure 
measures, rendering foetuses and placentas (see text).
20 April 2009 TRCJZ/2009/1142 Mandatory vaccination of dairy sheep and dairy goats 
on farms with more than 50 animals, on care farms, 
petting zoos and zoos in the extended area (Fig. 4) 
before 1 January 2010.
1 October 2009 Regulation 40823 Mandatory bulk tank milk monitoring for Q fever 
every 2 months. Prohibited from transporting dairy 
sheep and dairy goats from a positive farm. Vaccinated 
animals may be transported to positive farms. Visitors 
ban in place at positive farms.
9 December 
2009
Regulation 96744 Ban on increase of numbers of dairy goats and dairy 
sheep on a farm. Ban on reproduction of goats.
1 January 2010 Regulation 72246 Mandatory vaccination of dairy sheep and dairy goats, 
on care farms, petting zoos, zoos, on farms open to the 
public, mobile sheep flocks, and in natural reserves 
nationwide before 2011.
14 December 
2009
Regulation 98748 Mandatory bulk tank milk monitoring for Q fever 
every 2 weeks.
16 December 
2009
Regulation 99604 Prohibited from removing manure from the stable 
within 30 days after ending of lambing season. If 
manure has to be removed from the stable, it should 
be stored on the farm for 90 days.
16 December 
2009
Letter to 
Parliament; VDC 
09.2695/CPM
Culling of all pregnant goats and sheep on Q fever-
positive dairy goat and dairy sheep farms. 
18 December 
2009 
Regulation 101785 Prohibited from adding sheep or goats to a farm.
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Figure 5. Map of the Netherlands with all 88 bulk tank milk-positive dairy goat and dairy sheep 
farms known on 17 April 2010. The red zone is the 5-km zone around a positive farm. [Compiled 
by Dutch Ministry of Agriculture, Nature and Food Quality (LNV).]
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Veterinary experts from the national veterinary reference institute (the Central 
Veterinary Institute of Wageningen UR), taking consideration of the findings of 
Rousset et al. 47, believed it impossible to distinguish infected pregnant animals from 
non-infected pregnant animals by laboratory testing prior to the start of the kidding 
season. This was the basis of the decision to cull all pregnant animals on Q fever-
positive farms. In addition, breeding dairy goats and dairy sheep was prohibited until 
at least June 2010. The culling started in late December 2009 and was completed in June 
2010, when a number of temporary animal measures imposed by the government ended 
and now require revision. The measures in the veterinary field were taken to identify 
risk farms and to reduce the excretion of C. burnetii from these farms. Although the 
effectiveness of certain measures is still unclear and the lag time of the measures and 
the contribution of environmental contamination with C. burnetii to the exposure of 
humans is unknown, the decreasing numbers of human cases in 2010 indicate that the 
measures taken since 2008 have been effective.
The Dutch Q fever epidemic in perspective
 Q fever was present in the Netherlands long before it became a problem in 
public health and animal husbandry. In this period, Q fever appeared to be neither a 
major health problem for humans, or for domestic animals. This situation, with high 
seroprevalence in animal populations but few human cases, exists in most European 
countries 48. In the years 2005 and 2006, Q fever became a problem in the dairy goat 
and dairy sheep industry. Abortion storms in small ruminants were not confirmed 
prior to 2005, although abortions with unknown aetiology are part of small ruminant 
husbandry with abortion rates up to 5%. It is not clear why Q fever became a major 
problem in the Netherlands but not elsewhere. Several factors could have facilitated a 
change in epidemiology in goats: first, an increase in goat density in specific areas of the 
Netherlands and second, extension of the farms over the years. These two factors could 
have affected in-herd and between-herd dynamics of Q fever, resulting in outbreaks. 
Third, there could be pathogen-related factors with circulation of a highly virulent C. 
burnetii strain. In the years 2007 and 2008 it became clear that Q fever also posed a 
problem to public health. The connection between Q fever problems in the dairy goat 
and dairy sheep industry and in the human population was made by several authors 
based on epidemiological and C. burnetii typing-based findings 28, 33, 35. The increase in 
goat density took place in the highly populated province of Noord-Brabant (average 
population density in Noord-Brabant is 497 inhabitants/km2, compared to an average 
of 398 inhabitants/km2 for the Netherlands). This proximity to a source excreting high 
numbers of C. burnetii during abortion, with transmission facilitated by dry weather 
and high numbers of susceptible humans is probably the main cause of the human Q 
fever outbreak in the Netherlands.
The relationship between the change in epidemiology of Q fever in humans and changes 
in animal husbandry has been shown earlier. After the collapse of the large state farms 
in Bulgaria in the 1990s individual farmers started to raise goats, which resulted in a 
more than doubling of the number of goats to 1 million in 7 years 49. This increase, 
together with a change to a more extensive husbandry system, was believed responsible 
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for the increase of human cases. The increase in human Q fever in Germany was also 
probably related to socio-geographical factors associated with urbanization of rural 
areas 50. Despite these examples no general conclusions can be drawn, as C. burnetii 
is endemic in domestic animals throughout Europe and infection can be maintained 
in a wide range of husbandry systems. Although risk factors, such as an association 
between human infection and small ruminants, the proximity of animals (especially 
during parturition) and human populations, and specific weather conditions are clear, 
there is still an incomplete understanding of transmission pathways with regard to the 
maintenance of Q fever within the animal reservoir and its transmission to humans 
48. In addition, to date there are no indications of Dutch Q fever spreading to adjacent 
areas in Germany 35. 
The question can be raised if the Dutch outbreak is indeed the largest of its kind. A 
posteriori, it would be difficult to establish if the current epidemic in the Netherlands, 
with 3,523 human cases within three consecutive years, represents a unique phenomenon. 
In Paragyurische in Bulgaria, more than 2,000 cases that were probably due to Q fever 
were diagnosed in a 6-month episode in 1993. Although confirmation of Q fever was 
hampered, these numbers of patients were comparable to the 2,355 in 2009 in the 
Netherlands. The Q fever outbreak of the Balkans, named ‘Balkangrippe’, during the 
Second World War was at least comparable in size. In 1941 over 1,000 cases were reported 
among German troops and during the years 1942–1945 comparable outbreaks were 
reported in general terms 51. However, in these epidemics, no systematic investigations 
were performed. The importance of this in combination with the availability of 
diagnostic tests was also shown in the epidemic in a Swiss Alpine valley in 1983 52. The 
hospitalization of seven patients with atypical pneumonia was able to be diagnosed 
as due to Q fever as a result of newly available diagnostic tests. This detection was 
followed by a very large retrospective study in which infection was identified in nearly 
15% of the inhabitants of the valley, probably correlated with migration of sheep. This 
showed that the proportion of patients presenting sufficiently severe symptoms to be 
hospitalized accounted for only 2%, and that 56% were completely asymptomatic. This 
means that for each patient being diagnosed, an additional 50 patients probably remain 
undiagnosed. This is solely based on systematic testing of the hospitalized patients 
with fever. Under these conditions, it is very difficult to evaluate the true incidence of 
Q fever, and it is highly likely that some epidemics have gone completely unnoticed. 
Thus, the reported incidence of Q fever depends on three distinct elements. First, it 
depends on the true incidence of the disease including existence of epidemics. Second, 
the reported incidence depends on sensitivity and specificity of the diagnostic tools 
used. In the Dutch epidemic the use of serological tests, which are now commercially 
available and the use of real-time PCR on various clinical specimens allowed a better 
assessment of the incidence. 
Finally, the interest of the clinicians and the awareness of the general public 
incontestably reinforce the quality of detection and the percentage of detected 
patients. With monitoring systems more cases might be detected, but few data exist 
on large-scale monitoring of Q fever in the human population. In France, preliminary 
data showed a regular increase in the number of diagnosed cases of acute Q fever 
which probably testifies to the growing interest and the diagnostic capacities for this 
disease. Retrospective research in the Netherlands also shows that real-time syndrome 
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surveillance might have detected clusters of human Q fever cases up to 2 years earlier 
than 2007 53.
Conclusions
 The Q fever epidemic in humans in the Netherlands arose from an endemic 
state and was preceded by severe Q fever abortion problems in dairy goats and dairy 
sheep. Dairy goats and dairy sheep are considered to be the main source of human 
outbreaks and control measures were focused on these animal species. Although it 
is too early to evaluate the magnitude of the human Q fever epidemic in 2010, the 
decrease in the number of human cases compared to the previous year is promising. 
The proximity to small ruminants excreting high numbers of C. burnetii during 
abortion, with transmission facilitated by dry weather and high numbers of susceptible 
humans is probably the main cause of the human Q fever outbreak in the Netherlands. 
In general good monitoring and surveillance systems are necessary to assess the real 
magnitude of Q fever.
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Abstract
 Q fever is a zoonosis caused by the bacterium Coxiella burnetii. One of the 
largest reported outbreaks of Q fever in humans occurred in the Netherlands starting 
in 2007; epidemiologic investigations identified small ruminants as the source. To 
determine the genetic background of C. burnetii in domestic ruminants responsible 
for the human Q fever outbreak, we genotyped 126 C. burnetii–positive samples from 
ruminants by using a 10-loci multilocus variable-number tandem-repeat analyses panel 
and compared them with internationally known genotypes. One unique genotype 
predominated in dairy goat herds and 1 sheep herd in the human Q fever outbreak 
area in the south of the Netherlands. On the basis of 4 loci, this genotype is similar 
to a human genotype from the Netherlands. This finding strengthens the probability 
that this genotype of C. burnetii is responsible for the human Q fever epidemic in the 
Netherlands.
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Introduction
 Q fever is a zoonosis caused by Coxiella burnetii, an intracellular gram-negative 
bacterium that is prevalent throughout the world 1. Domestic ruminants are considered 
the main reservoir for Q fever in humans 2. However, other animal species, including 
pet animals, birds, and several species of arthropods, can be infected by C. burnetii 
and cause human cases of Q fever 2-5. The main clinical manifestations of Q fever in 
goats and sheep are abortion and stillbirth. In cattle, Q fever has been associated with 
sporadic abortion, sub fertility, and metritis 4, 6. With an abortion, up to 1 billion C. 
burnetii per gram of placenta can be excreted 7. Most animal species that carry C. burnetii 
show no symptoms 4. Transmission to humans occurs mainly through inhalation of 
contaminated aerosols 4, 5, 8-10.
Recently, 2 DNA-based methods for typing C. burnetii were reported 11-13. Multispacer 
sequence typing is based on DNA sequence variations in 10 short intergenic regions 
and can be performed on isolated C. burnetii strains or directly on extracted DNA from 
clinical samples 12, 14, 15. Multilocus variable-number tandem-repeat analyses (MLVA) is 
based on variation in repeat number in tandemly repeated DNA elements on multiple 
loci in the genome of C. burnetii and might be more discriminatory than Multispacer 
sequence typing 13, 15. MLVA also can be performed on C. burnetii strains 11, 15 or directly 
on DNA extracted from clinical samples 16. A total of 17 different minisatellite and 
microsatellite repeat markers have been described 11.
Starting in 2007, the Netherlands has been confronted with one of the largest Q 
fever outbreaks in the world, involving 3,921 human cases in 4 successive years. On 
28 dairy goat farms and 2 dairy sheep farms, abortion storms (with abortion rates up 
to 80%) caused by Q fever were diagnosed during 2005–2009. These small ruminants 
are considered the source of the human Q fever outbreak in the Netherlands 17. The 
connection between Q fever abortion storms in small ruminants and human Q fever 
cases is based primarily on epidemiologic investigations 18-21. A limited investigation by 
genotyping with MLVA recently showed that farms and humans in the Netherlands are 
infected by multiple different, yet closely related, genotypes of C. burnetii 16. Although 
dairy goats and dairy sheep appear to be the source of the human Q fever outbreak 
in the Netherlands, no information is available about the genetic background of C. 
burnetii in these populations. This knowledge is essential for gaining insight into the 
molecular epidemiology of the organism and the origin of the outbreak, as well as for 
outbreak management purposes. Our objective was to show the genetic background 
of C. burnetii in domestic ruminants responsible for the human Q fever outbreak. 
This information is necessary to evaluate the epidemiologic link between the source 
and human cases and to compare the outbreak genotypes with internationally known 
genotypes. During 2008–2010, a total of 125 C. burnetii–positive samples from 14 dairy 
goat farms, 1 dairy cattle farm, and 2 sheep farms were typed by MLVA. In addition, we 
show the geographic distribution of these C. burnetii genotypes across the Netherlands 
and compare the genotypes with what is internationally known.
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Materials and Methods
Animal Samples
 Our study comprised 14 dairy goat farms (farms A–E, H, J, M, N, O, P, Q, AE, 
and AF), 1 dairy cattle farm (farm R), and 2 sheep farms (1 dairy sheep farm Y and 1 
sheep farm Z) sampled during the Q fever outbreak in the Netherlands (Table 1; Figure 
1). On 12 of the 14 dairy goat farms, multiple abortions had occurred. On 2 dairy goat 
farms (farms J and M) and on the dairy sheep farm (farm Y), no abortions had occurred. 
On 1 dairy cattle farm and on the sheep farm (farm Z), C. burnetii was detected in a 
placenta after abortion. One goat farm (farm AG) sampled in 2001 was included with an 
archived histologic section of paraffin-embedded placenta from an abortion outbreak 
caused by C. burnetii infection. Vaginal swabs and milk samples from dairy goats and 
dairy sheep were sent to the national reference laboratory for notifiable animal diseases 
(the Central Veterinary Institute, part of Wageningen UR) by the Dutch Food and 
Consumer Product Safety Authority in accordance with the regulation in place at that 
time. These samples were submitted for confirmation testing of farms with clinically 
suspected Q fever (farms A–D, N, O, P, and Q), for tracing the source of human Q fever 
cases (because of proximity to human case-patients, farms H, J, and M) or for bulk tank 
milk monitoring (farm Y).
Samples of immunohistochemically confirmed Q fever–positive goat and sheep 
placentas (farms N, AE, AF, and Z) and foetal tissue (farm E) were provided by the 
Animal Health Service, including 1 archived histologic section of paraffin-embedded 
placenta from a C. burnetii abortion outbreak in a goat farm in 2001 (farm AG), which 
was diagnosed retrospectively 22. The sampled dairy goat farms represent 60% of the 
farms with known abortion problems during 2007–2009.
Testing of Samples before MLVA Typing
 DNA was extracted from vaginal swabs and milk by using Chelex resin 
(InstaGene; Bio-Rad, Hercules, CA, USA). A vaginal swab tip or 200 μL of milk was 
added to 400 μL of Chelex suspension and incubated and shaken for 30 min at 56°C, 
followed by an incubation step for 8 min at 100°C. The clarified supernatant was used for 
PCR and MLVA. DNA from placentas was extracted by using a DNA tissue kit (DNeasy 
Blood and Tissue Kit; QIAGEN, Hilden, Germany). DNA from the paraffin-embedded 
placenta was extracted by using MagneSil Genomic Fixed Tissue System (Promega, 
Madison, WI, USA). All samples were tested by an in-house real-time PCR directed 
toward the C. burnetii–specific IS1111a element 23. An inhibition control was constructed 
by using the primes of the IS1111a element (Table 2). 
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Table 1. Overview of Coxiella burnetii genotyping results for farms sampled during human Q 
fever outbreak, the Netherlands, 2007–2010 a.
Farm 
ID
Animal 
species
Appr. 
herd 
size
Year
Appr. 
abortions 
in year of 
sampling, 
%
Sample type
No. 
samples 
tested
No. 
samples 
included 
in study
MLVA 
IDb
No. 
samples
A Dairy goats 617 2008 25 Vaginal swabs 20 9 CbNL01 7
CbNL05 1
CbNL07 1
B Dairy goats 598 2008 20 Vaginal swabs 20 5 CbNL01 5
C Dairy goats 546 2008 25 Vaginal swabs 20 20 CbNL01 20
D Dairy goats 1,498 2008 19 Vaginal swabs 39 7 CbNL01 6
CbNL04 1
E Dairy goats 1,568 2008 8 (2007) Fetal tissue 3 3 CbNL01 1
CbNL09 1
CbNL11 1
H Dairy goats 606 2008 80 Vaginal swabs 13 8 CbNL01 7
CbNL02 1
J Dairy goats 459 2008 None Vaginal swabs 3 3 CbNL01 2
CbNL08 1
M Dairy goats 769 2008 None Vaginal swabs 2 1 CbNL10 1
N Dairy goats 1,187 2009 25 Vaginal swabs 20 20 CbNL01 20
Placenta 1 1 CbNL01 1
O Dairy goats 83 2009 7 Vaginal swabs 40 16 CbNL01 14
CbNL03 1
CbNL06 1
Milk 1 1 CbNL01 1
P Dairy goats 548 2009 10 Vaginal swabs 20 6 CbNL01 6
Q Dairy goats 340 2009 10 Vaginal swabs 25 19 CbNL01 19
AE Dairy goats 500 2007 >5 Placenta 1 1 CbNL12 1
AF Dairy goats 2 2007 >5 Placenta 1 1 CbNL01 1
AG Dairy goats 590 2001 >5 Paraffin-
embedded 
placenta
1 1 1
R Dairy cattle 70 2007 <5 Placenta 1 1 CbNL13 1
Y Dairy sheep 184 2010 None Vaginal swabs 5 1 CbNL10 1
Bulk tank 
milk sample
1 1 CbNL10 1
Z Sheep 2 2009 50 Placenta 1 1 CbNL01 1
a ID, identification; bMLVA, multilocus variable-number tandem-repeat analysis.
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Figure 1. Map of the Netherlands showing locations of farms sampled during the Q fever 
outbreak, 2007–2010. Farms are indicated by letter and ruminant species (red squares, goats; 
blue squares, sheep; yellow squares, cattle); genotypes of Coxiella burnetii found per farm are 
indicated by bars at each farm’s location. The height of the bar indicates numbers of isolates per 
genotype.
PCR was performed on a 7500 Fast Real Time PCR system (Applied Biosystems, Foster 
City, CA, USA) by using 400 nmol/L of primers and 200 nmol/L of probes in 7 μL 
PerfeCTa Multiplex qPCR Supermix, uracil-N-glycosylase (2×) (New England Biolabs, 
Ipswich, MA, USA] with Low Rox dye (Quanta BioSciences, Gaithersburg, MD, USA 
), 1 μL of inhibition control, 5 μL of sample, and 7 μL of water. An initial uracil DNA 
glycosylase (UDG) incubation for 5 min at 45°C and denaturation/activation for 60 s 
at 95°C was followed by 40 cycles of denaturation for 10 s at 95°C, annealing for 30 s at 
60°C. Results were generated with 7500 Fast System Software (Applied Biosystems).
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MLVA Typing
 MLVA typing was performed by using a selection of 10 of the 17 loci described 
by Arricau-Bouvery et al. 11 according to the Multiple Loci VNTR Analysis databases for 
genotyping (http://minisatellites. upsud. fr/ MLVAnet /querypub1.php), except that 
Ms12 was omitted because of poor performance, and Ms24 was added (Table 2). New 
primers were designed for Ms27 and Ms28 to improve performance. The annotation of 
Ms30, Ms31, and Ms36 was updated (P. Le Flèche, pers. comm.). The PCR amplification 
was performed by using an Applied Biosystems 9700 thermocycler in a total volume of 
25 μL containing 1× reaction buffer, 1 U True Start Taq DNA polymerase (Fermentas, 
Glen Burnie, MD, USA), 2 mmol/L MgCl2, 0.2 mmol/L of each nucleotide (dATP, dGTP, 
dCTP, dUTP), 0.5 μmol/L of each primer, 0.5 U UDG (New England Biolabs), and 2–5 μL 
template. An initial UDG incubation for 5 min at 37°C and denaturation/activation for 
2 min at 95°C was followed by 40 cycles of denaturation for 30 s at 95°C, annealing for 30 
s at 60/65°C, elongation for 30 s at 72°C, followed by a final extension step for 5 min at 
72°C. After the amplification, 0.5 U UDG inhibitor (New England Biolabs) was added to 
the PCRs to prevent further UDG activity. Up to 4 different PCR products with different 
fluorescent dyes were diluted, depending on the PCR efficiency, and pooled. From 
these pooled PCR products, 4 μL was mixed with 15 μL of Hi-Di formamide (Applied 
Biosystems) and 0.5 μL of GeneScan 600 LIZ Size Standard (Applied Biosystems). After 
denaturation for 3 min at 96°C the samples were cooled on ice. The PCR products were 
separated on a 3130 Genetic Analyzer (Applied Biosystems) with a 36-cm array by using 
POP7 polymer. The fragments were sized by using GeneMapper version 4.0 software 
(Applied Biosystems). The accuracy of the sizing obtained by capillary electrophoresis 
was determined by comparing sequencing data from the reference strain with the 
obtained fragment size from the capillary electrophoresis and corrected if necessary. 
The number of repeats for each locus was determined on the basis of the published and 
corrected annotation of the various loci (Table 2). Non–whole repeat numbers were 
rounded off mathematically. Reproducibility was checked with positive controls.
Data Analysis
 The reference strain Nine Mile was used as reference 11. Analyses were 
performed, including only genotypes of C. burnetii containing <2 loci with missing 
values. Numerical typing data were imported into BioNumerics v 6.1 (Applied 
Maths, Sint-Martens-Latem, Belgium) and analyzed with the multistate categorical 
similarity coefficient by using unweighted pair group method with arithmetic mean 
clustering. Missing values were imported as question marks. The genotypic diversity 
of the population under study was calculated by using the adapted Simpson index of 
diversity (Hunter-Gaston diversity index [HGDI]) 11, 24. Found MLVA patterns based on 
the number of repeats per locus were called MLVA types and identified as CbNLxx. We 
compared MLVA types with MLVA types in the publicly accessible Multiple Loci VNTR 
Analysis databases for genotyping: Coxiella2007 and Coxiella2009_Netherlands (access 
date 2009 Jan 11). The Nine Mile strain was used as reference.
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Figure 2. Phylogenetic tree with genotypes of Coxiella burnetii of all samples in the study, the 
Netherlands, on the basis of 10 multilocus variable-number tandem-repeat analyses (MLVA). 
Repeats per locus are shown; open spots indicate missing values. NM, Nine Mile reference 
strain.
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Results
 The study comprised 122 samples from 15 dairy goat farms, 2 samples from 
1 dairy sheep farm, and 1 sample each from 1 sheep farm and 1 dairy cattle farm were 
included in this study (Table 1). Of the farms sampled during the outbreak, 13 were 
situated in the southern part of the Netherlands; 3 dairy goat farms (farms M, N, and 
AE) and 1 dairy sheep farm (farm Y) were located outside this area (Figure 1). From 
the 238 Q fever PCR-positive samples from the farms in this study, 125 (53%) yielded 
a genotype with <2 missing values: 52 with a complete genotype, 48 with 1 missing 
value, and 25 with 2 missing values. 113 (47%) PCR-positive samples represented partial 
genotypes with 3–10 missing values. From the paraffin-embedded placenta (farm AG), 
only a partial genotype could be shown, with 6 repeats on Ms03 and 10 repeats on Ms34. 
We distinguished 13 genotypes in the 125 samples (CbNL01–CbNL13; Table 1; Figures 1, 
2). All C. burnetii genotypes could be associated with abortion, except for 2 (CbNL10, 
farm M and Y; and CbNL08, farm J; Figure 1). 
Figure 3. Phylogenetic tree with genotypes of Coxiella burnetii that are most closely related to the 
Dutch genotypes on the basis of 4 multilocus variable-number tandem-repeat analyses (MLVA). 
Genotypes are derived from the Multiple Loci VNTR Analysis databases for genotyping (http://
minisatellites.u-psud.fr/MLVAnet/querypub1.php: Coxiella2009_Netherlands [accessed 2011 Jan 
11]). Repeats per locus are shown; open spots indicate missing values. NL, the Netherlands. 
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The relationship between the genotypes in all samples is shown in Figure 2, including 
the genotype of the reference strain Nine Mile and the reference genotype of the 
reference strain Nine Mile from Arricau-Bouvery et al. 11, which were identical. The 
13 genotypes are separated in 2 clusters (Figure 2). One cluster containing a genotype 
represented by 111 (90%) of the samples (CbNL01); 1 genotype (CbNL10) represented by 
3 samples (1 from a dairy goat farm and 2 from a dairy sheep farm); and 10 genotypes 
(CbNL02–CbNL09 and CbNL11) represented by 1 sample, all from dairy goat farms. The 
second cluster was distinctly separated from the other cluster, representing 2 genotypes 
in 1 dairy goat sample (CbNL12), in 1 dairy cattle sample (CbNL13) and the paraffin-
embedded placenta. In samples from dairy goat farms with abortion problems, the 
same genotype (CbNL01) was present in 110 (91%) of 121 samples. One sheep sample 
also showed this genotype (farm Z). The geographic distribution of the genotypes 
according to the location of the originating farm is given in Figure 1. The relationship 
between the genotypes found in this study and the internationally known genotypes 
are presented in the phylogenetic trees in Figure 3 on the basis of 4 loci and in Figure 
4 on the basis of 9 loci.
Discussion
 We performed MLVA typing of C. burnetii based on 10 loci on a large 
number of Q fever–positive samples to show the genetic background of C. burnetii 
in the domestic ruminants associated with the Q fever outbreak in humans in the 
Netherlands. In 125 (53%) of 237 samples, an adequate genotype for C. burnetii 
was generated. Previously, MLVA typing was performed on C. burnetii strains after 
primary isolation and cultivation 11, 13, 15 or, in the Netherlands, on only 11 clinical 
samples from humans, sheep, and goats with a selected number of 3 loci 16. The main 
drawback of typing on clinical samples is the variable quality and amount of DNA. 
These drawbacks influence the typability of samples, resulting in partial genotypes; 
whether the missing values are caused by insufficient DNA concentrations and 
quality or by an absence of loci is unclear. If loci are absent, partial genotypes also 
are expected to be found in samples with high DNA loads. Such is not the case in 
our study. Typing of placenta material that contains high quantities of C. burnetii, 
as well as vaginal swabs with PCR cycle threshold (Ct) values <32, yielded complete 
genotypes. In samples with Ct values of 32–34, only partial genotypes were obtained. 
Samples with a Ct value >34 were poorly typeable. Arricau-Bouvery et al. 11 calculated 
diversity indices for the 17 loci used in the MLVA, which varied from 0.28 for locus 
Ms22 to 0.86 for locus Ms34. The HGDI for the combined panels 1 and 2 of the MLVA 
typing method for C. burnetii can be calculated on 0.99 and for panel 2 on 0.92. These 
HGDIs are in the upper part of the 0.438–0.997 range reported by Hunter and Gaston 
24 for typing methods for various bacteria and yeasts. The high diversity indices for 
the MLVA of C. burnetii indicate a high discriminating power, and this capability 
makes MLVA typing suitable for distinguishing C. burnetii isolates. With this highly 
discriminatory typing method, we found that 1 genotype of C. burnetii predominated 
on all dairy goat farms in the southern part of the Netherlands. On 12 of 14 dairy goat 
farms, this genotype was found in 91% of samples, varying per farm from 33% (farm 
E) to 100% (farms B, C, N–Q, Table 1, Figures 1 and 2).
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Figure 4. Phylogenetic tree with genotypes of Coxiella burnetii that are most closely related 
to the Dutch genotypes on the basis of 9 multilocus variable-number tandem-repeat analyses 
(MLVA). Genotypes are derived from the Multiple Loci VNTR Analysis databases for genotyping 
(http://minisatellites.u-psud.fr/MLVAnet/querypub1.php: Coxiella2007 [accessed 2011 Jan 11]). 
Repeats per locus are shown; open spots indicate missing values. NL, the Netherlands; Slovak 
Rep, Slovak Republic.
Although the sample size was small compared with the number of animals on the farm 
(Table 1), these data show that 1 genotype was far more common than other genotypes 
found on these farms. The 9 other genotypes occurred once, each representing only 
0.8% of all found genotypes on dairy goat farms. The most predominant genotype 
was found on all 11 dairy goat farms in the southern Netherlands and on a farm in the 
eastern part of the country (farm N). This finding strongly suggests a clonal spread 
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of C. burnetii with this predominant genotype over the dairy goat farms in the south-
eastern part of the Netherlands. The clonal spread of 1 genotype of C. burnetii could be 
explained by 2 phenomena. First, the dairy goat industry in the Netherlands sharply 
increased from almost 100,000 dairy goats in 2000 to >230,000 dairy goats on ~350 farms 
in 2009 17. Most of these goats were bred in the Netherlands, which probably resulted 
in a microbial relationship between many of the dairy goat herds. In this theory, the C. 
burnetii strain with the most predominant genotype was present in the Netherlands for 
a long period before the abortion problems in dairy goats started in 2005. This theory 
is not supported by the results of the typing of the paraffin-embedded placenta from 
an aborted dairy goat who in 2001. The typing result differs on 2 loci from the most 
predominant genotype found in this study. Second, clonal spread could have been 
facilitated by emergence of a genotype of C. burnetii causing abortion in dairy goats 
that could then spread successfully over the dense goat population in the south-eastern 
part of the country. Whether this genotype is more virulent is subject to research.
On the basis of comparison of MLVA types on 4 loci (Figure 3), CbNL01–06 could not be 
distinguished and were similar to the genotype of a person in the Netherlands (QPK2) 
and 2 genotypes from persons in France (Cb#88, Cb#97). The sample from a person in 
the Netherlands is derived from patient 2 reported by Klaassen et al. 16. Patient 2 is the 
farmer of farm A, where genotype CbNL01 predominated, as well as CbNL05 (Table 1). 
This shows a genetic link between the C. burnetii DNA from the farmer and his abortive 
goats, which suggests that the farmer was infected by his own goats. However, this link 
is based on only 4 loci on 1 human sample. To further confirm the link between dairy 
goats and humans, more samples need to be typed with more MLVA loci to increase 
the discriminatory power.
The human sample with ID QKP6 is the same sample as that from patient 4 reported 
by Klaassen et al. 16 and is most closely related to CbNL07. Human sample QKP1 is the 
same as that of patient 1. Patient 5 fits in the genotype cluster in the Netherlands, as does 
patient 2. The sheep reported by Klaassen et al. did not abort, and their samples show a 
difference of 1 repeat on Ms34 compared with CbNL01. On the basis of the comparison 
of MLVA types on 9 loci (Figure 4), all genotypes in this study can be distinguished. The 
most predominant genotype CbNL01 clusters with other genotypes (CbNL02–CbNL09, 
CbNL11) and with 1 human sample (Cb#97) from France. CbNL01 differed from this 
human isolate on 2 loci (Ms30 and 36), which shows that the most predominant 
genotype in the Netherlands is unique. Whether this finding can be attributed to the 
small number of strains and clinical samples typed or is really a unique genotype is 
not yet clear. The closest relation to an isolate from France might give a clue about the 
origin of the genotype from the Netherlands.
The human Q fever outbreak in the Netherlands started in the southern part of 
the country and resulted in >3,500 human cases during 2007–2010. Dairy goats and 
dairy sheep are considered to be the source of this outbreak, primarily on the basis 
of epidemiologic findings 10, 17, 20, 21, 25, 26. In our study, samples were typed from farms 
suspected of being the source of the human Q fever outbreak. Results show that 1 
genotype of C. burnetii predominated in the dairy goats and sheep in the human Q 
fever outbreak area in the southern part of the Netherlands, and this genotype also 
was present in a human case-patient in the Netherlands. This C. burnetii genotype is 
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expected to have played a key role in the Q fever outbreak in small ruminants in the 
Netherlands and was also transmitted widely to humans, causing Q fever in the human 
population. If this hypothesis holds true, C. burnetii with the same genotype as in dairy 
goats should be found in most samples from human Q fever patients. To this end, a 
study was performed to show the genetic background of human C. burnetii isolates in 
the Netherlands by using a concordant MLVA typing method (J.J.H.C. Tilburg et al., 
unpub. data). Furthermore, the uniqueness of the predominant genotype of C. burnetii 
for the Netherlands can be part of the explanation why the magnitude of the Q fever 
outbreak in the Netherlands has never been seen elsewhere.
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Abstract
The genotypic diversity of C. burnetii in clinical samples obtained from the 
Dutch Q fever outbreak episodes of 2007 – 2010 was determined by using a 6-locus 
variable-number tandem repeat analysis panel. The results are consistent with the 
introduction of one founder genotype that is gradually diversifying over time while 
spreading throughout the Netherlands.
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Introduction
 From 2007 to 2010, the Netherlands was confronted with a large and 
unprecedented Q fever outbreak, with thousands of affected individuals 4. The 
increase in human cases coincided with an increase in abortions among goats 2, 4, 6. 
Genotypic characterization of the involved isolates can give fundamental insight into 
the epidemiology of Q fever in the Netherlands, allowing, for example, spread of the 
involved genotype(s) throughout the Netherlands during the subsequent outbreak 
years and/or display a correlation between human and animal Q fever cases. Recently, 
genotyping by using a 10-locus multiple-locus variable-number tandem repeat analysis 
(MLVA) panel revealed one predominant genotype among goats and sheep throughout 
the affected area 5. A 3-locus MLVA panel performed directly on clinical samples from 
a minor part of the affected region showed that Dutch farm animals and patients 
appeared to be infected by different but closely related MLVA genotypes 3. In this study 
we determined the temporal and spatial genotypic diversity of C. burnetii genotypes in 
human samples collected during the 2007 - 2010 Q fever outbreak episodes from the 
entire affected part of The Netherlands using a 6-locus MLVA panel.
Materials and methods
 The presence of C. burnetii DNA in a variety of clinical samples was 
determined using a real time PCR targeting the IS1111a insertion element of C. burnetii 
as described earlier 8. We determined the MLVA genotype using 3 hexanucleotide 
repeat markers (Ms27, Ms28 and Ms34) and 3 heptanucleotide repeat markers (Ms23, 
Ms24 and Ms33) 1 directly in 46 Q fever positive clinical specimens collected from acute 
and chronic Q fever patients. These samples were collected during the 2007 – 2010 
outbreak episodes (Table 1 and Fig. 1). A multicolor multiplex format was chosen to 
make more efficient use of the small amounts of C. burnetii DNA generally obtained 
from clinical samples. The MLVA primers for markers Ms27, Ms28 and Ms34 have 
been described before 3. MLVA primers were 5’-HEX-CGCMTAGCGACACAACCAC-
3’and 5’-GACGGGCTAAATTACACCTGCT-3’ for Ms23, 5’-FAM-TGGAGGGACTCCGAT 
TAAAA-3’ and 5’-GCCACACAACTCTGTTTTCAG-3’ for Ms24, and 5’-TAMRA-
TCGCGTAGCGACACAACC-3’ and 5’-GTAGCCCGTATGACGCGAAC-3’ for Ms33, 
where HEX is hexachlorofluorescein, FAM is 6-carboxyfluorescein, and TAMRA is 
6-carboxytetramethylrhodamine.
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Figure 1. Geographical locations of the MLVA genotypes obtained from the 2007-2010 outbreak. 
Syllables correspond to the genotypes identified in Table 1. 
Results
 Multiple different but apparently closely related MLVA genotypes A – H 
were identified in 33 clinical samples covering both acute Q fever patients (e.g. sputa, 
bronchoalveolar lavage [BAL] fluid, throat swabs) as well as chronic Q fever patients 
(e.g. heart valves, aorta tissue) (Table 1). A partial MLVA genotype (assigned as ‘p’) 
was obtained from another 13 samples that contained insufficient DNA to obtain a full 
profile. In all but one of the clinical samples that yielded a partial genotype, the same 
alleles were identified as those found in samples yielding a full genotype (Table 1).
Clustering of the MLVA genotypes using the minimum spanning tree method showed 
a high degree of genetic similarity between the Dutch MLVA genotypes (Fig. 2). 
Specifically, all but one of the obtained Dutch MLVA genotypes are interconnected by 
repeat number changes in one of the six markers (this involved either Ms23, Ms24, 
Ms27 and Ms34). One sample (Q056) yielded a genotype that differed in two markers 
from the other genotypes and the alleles that were found in these two markers were 
also different from those observed in the other Dutch samples (Table 1). In contrast, the 
genotypes from five sequenced C. burnetii strains all differed in at least 3 markers from 
the Dutch genotypes. Negative control samples neither yielded a positive PCR result 
nor an MLVA result. The geographical distribution of the MLVA genotypes is shown 
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in Fig. 1. From the two genotypes that were observed most frequently (i.e. genotypes A 
and G), the G genotype apparently has spread across the entire affected area whereas 
the distribution of genotype A appears to be restricted to the North-Eastern part of the 
affected region.
Figure 2. Minimal spanning tree showing the relationship between the obtained MLVA 
genotypes identified in this study and five sequenced C. burnetii strains, i.e., Dugway (Genbank 
accession number CP000733), RSA331 (CP000890), Nine Mile RSA493 (AE016828), CbuG Q212 
(CP001019) and CbuK Q154 (CP001020). Each circle represents a unique genotype, the size of 
the circle corresponds to the number of samples with that genotype. Only full MLVA genotypes 
were included in this analysis. Branch labels and connecting lines correspond to the number of 
different markers between the genotypes. Genotypes connected by a gray background differ in 
only one marker from each other and may represent microvariants of one founder genotype.
The diversity index (D) of the individual markers for the Dutch population, calculated 
according to Simpson 7 were 0.48, 0.12, 0.06, 0.00, 0.06, and 0.31 for Ms23, Ms24, 
Ms27, Ms28, Ms33 and Ms34 respectively, versus 0.67, 0.79, 0.73, 0.74, 0.75, and 0.86, 
respectively, obtained from a reference collection of C. burnetii isolates from ticks, 
animal placenta, vaginal secretions and milk and from human liver and blood 1. The 
D values observed in the Dutch population were much lower than in the reference 
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population, indicating that the Dutch genotypes are much more closely related to each 
other and maybe arose from one founder genotype. The fact that multiple genotypes 
were obtained allows a certain degree of fine-structuring within the outbreak region.
Discussion
 Genotyping by using a 10-locus MLVA panel, including 4 out of the 6 markers 
used in our study revealed one predominant MLVA genotype among goats and sheep 
throughout the affected Q fever area 5. In these samples, alleles were found in markers 
Ms24, Ms27, Ms28, and/or Ms34 that were identical to those in the human samples, 
implicating the goats and/or sheep as most likely source of the outbreak. To substantiate 
this hypothesis, we included placenta samples from goats using all 6 markers from our 
MLVA panel. These goat samples were from 3 different locations in the outbreak area 
and contained the predominant ruminant C. burnetii genotype. MLVA genotype G was 
identified in all tested samples, illustrating the genotypic identity between C. burnetii 
from humans and goats. Compared to the 10-loci MLVA method, we chose the markers 
that seemed to be among the most discriminatory markers described 1, which enabled 
us to develop an easy to use and clearly distinguishable MLVA genotyping method. 
Our results are consistent with a scenario where one MLVA genotype was introduced in 
the dairy animal population, where it is gradually diversifying over time while spreading 
over the country and being transmitted to humans. We believe that the sudden increase 
of Q fever infections in humans could have been facilitated by the expansion of intensive 
goat farming in the South-east of the Netherlands in the last 2 decades 4. Another 
possibility is that the Dutch C. burnetii isolates are from a hypervirulent lineage that 
may be disseminating more rapidly than other genotypes. Both explanations, however, 
require further investigation. In conclusion, this study shows that the unprecedented 
and ongoing Q fever outbreak in the Netherlands involved not only multiple different 
but closely related MLVA genotypes found at several locations spread across the entire 
affected area during the Q fever outbreak years of 2007 to 2010, indicating a clonal 
spread of C. burnetii across the Netherlands.
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Abstract
 Multispacer sequence typing shows the presence of an identical epidemic 
genotype of C. burnetii among the Dutch ruminant population and humans whereas in 
the cattle population, a different genotype is observed. Our results confirm that goats 
and sheep but not cattle are the most likely source of the Dutch Q fever outbreak.
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Introduction
 The 2007-2010 Q fever epidemic among humans in the Netherlands was among 
the largest reported to date, both in magnitude and duration 1. The increase in human 
Q fever cases coincided with an increase in spontaneous abortions among dairy goats 
in the South-eastern part of the Netherlands, an area that is densely populated with 
goat farms 1. Genotypic analyses of the involved isolates could confirm the possible 
link between the human and animal Q fever cases. In previous studies, genotypic 
investigation of human and animal samples in the Netherlands were performed by using 
a 3-locus multiple locus variable-number tandem-repeats analysis (MLVA) panel and 
single-nucleotide polymorphism genotyping 2, 3. The first study, performed on relatively 
few samples from a minor part of the affected area, showed that Dutch farm animals 
and persons were infected by different but apparently closely related genotypes. More 
recently, genotyping by using a 10-locus MLVA panel provided additional information 
about the genotypic diversity of C. burnetii among ruminants in the Netherlands: 1 
dominant MLVA genotype was identified among goats and sheep throughout the 
entire affected Q fever area 4. A different panel of MLVA markers was applied to human 
samples 5. Four markers that are shared between both panels showed identical alleles 
in human and animal samples, again implicating goats and sheep as possible sources of 
the outbreak.
MLVA, which is based on relatively unstable repetitive DNA elements, is sometimes 
criticized for producing results that are too discriminatory or difficult to reproduce in 
different settings 6. Because of their instability, use of tandem repeats as genotyping 
targets can lead to problems with data interpretation, and to an overestimation of 
genotypic diversity, by showing small variations in MLVA genotypes in isolates of 
otherwise identical background. We used a more stable, sequence-based typing 
method, multispacer sequence typing (MST), on samples from humans and a group of 
ruminant animals (goats, sheep, and cattle) to establish a firmer correlation between 
Q fever cases in humans and animals 7. We identified MST genotypes using a web-
based MST database ((http://ifr48.timone.univmrs. fr/MST_Coxiella/ mst) containing 
genotypes from several countries in Europe. Ultimately, this study could answer the 
question of whether the current outbreak situation could have been caused by a specific 
C. burnetii strain in the ruminant population in the Netherlands.
Materials and methods
 Real-time PCR positive specimens from 10 humans and 9 Q fever-positive 
specimens from goats and sheep collected from various locations throughout the entire 
affected area were used 8. We also included Q fever-positive specimens from cattle to 
rule out cattle as a possible source of Q fever infection. Five samples of cow’s milk and 
1 bovine vaginal swab sample were analyzed (Table 1).
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Results
 MST33 was identified in 9 of 10 tested human samples and in the remaining 8 of 
9 clinical samples from goats and sheep (Table 1). MST33 has been isolated incidentally 
in nonoutbreak situations in human clinical samples obtained in France during 1996, 
1998 and 1999, and from a placenta of an asymptomatic ewe in Germany during 1992. 
All samples from cattle, in the Netherlands, 1 goat, and cow’s milk contained genotype 
MST20. Genotype MST20 has also been identified in human clinical samples from 
France, in a cow’s placenta from Germany isolated in 1992 and in rodents from the 
United States isolated in 1958. In 1 human bronchoalveolar lavage sample, a novel 
(partial) MST genotype was found. This may be an incidental Q fever case unrelated 
to the outbreak situation. Because no historical genotyping data for the period before 
the outbreak of Q fever in the Netherlands are available, this explanation needs further 
research.
Discussion
 MST genotyping shows the presence of genotype MST33 in clinical samples 
from humans, goats and sheep. These results confirm that goats/sheep are the source 
of human Q fever in the Netherlands. Few worldwide genotyping studies have been 
conducted and therefore information of a potential global persistence of this genotype 
is missing. This study also indicates that the outbreak among humans is not linked to 
C. burnetii in cattle, although the infection is widespread among diary herds in the 
Netherlands 9, exemplifying that most outbreaks are related to goats rather than to 
cattle. In conclusion, the increase in the number of Q fever cases in the Netherlands 
among humans most likely results from MST33 in the goat population in the Netherlands 
and could have been facilitated by intensive goat farming in the affected area and its 
proximity to the human population.
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Abstract
 Real-time PCR shows the widespread presence of C. burnetii DNA in a broad 
range of commercially available milk and milk products. MLVA genotyping shows that 
this is the result of the presence of a predominant C. burnetii genotype in the dairy 
cattle population.
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Introduction
 Q fever is a zoonosis caused by the pathogen Coxiella burnetii which is prevalent 
throughout the world 1. Ruminants (sheep, goats and cattle) are often asymptomatic 
carriers of C. burnetii and are considered to be a source of infection to humans 1. C. 
burnetii can cause abortion in small ruminants such as sheep and goats and may cause 
reproductive disorders in cattle 7. Huge numbers of C. burnetii can be released into 
the environment via birth products 6. Lower numbers are usually shed in milk, even in 
asymptomatic herds 2, 3, 4, 5, 8, 9. Although consumption of raw or insufficiently pasteurized 
milk is very rarely identified as a source of Q fever infection, asymptomatic cattle herds 
can be considered potential C. burnetii reservoirs capable of transmitting the disease to 
humans.
Materials and methods
 We applied real-time PCR, targeting the multicopy IS1111a insertion element of 
C. burnetii as described earlier 11 and a 6-locus multiple-locus variable number tandem-
repeat analysis (MLVA) panel 12 to a broad range of milk and milk-products with the aim 
to determine the prevalence and genotypes of C. burnetii in milk (Table 1). The study 
included commercially available semi-skimmed milk samples from cows (obtained 
from large supermarket chains) and milk products, such as coffee creamer, obtained 
throughout Europe and from an additional 10 non-European countries. Samples were 
collected from different brands, and according to the information on the packages they 
were produced by the (local) dairy industry in these countries. The origin of the milk 
samples from Egypt, Saudi-Arabia and Qatar could not be identified.
Results
 Eighty-eight out of 116 (76 %) milk samples or milk products from 28 countries 
contain significant amounts of C. burnetii DNA (Table 1). No C. burnetii DNA was 
detected in milk obtained from Finland, Norway, Costa Rica and New Zealand. MLVA 
genotypes I - O were identified in samples from France, Germany, the Netherlands, 
Portugal, Slovak Republic, Spain, Switzerland, United Kingdom, Qatar and Saudi 
Arabia. MLVA genotypes P, Q and R were identified in samples from Slovak Republic, 
Qatar and Russia respectively. A partial MLVA genotype (Table 1, ‘part’) was obtained 
from samples that contained insufficient DNA to obtain a full profile. In 4 samples from 
Slovak Republic we observed more than one allele per locus, suggesting the presence 
of at least two or more different genotypes in these samples (Table 1). Clustering of the 
MLVA genotypes using the minimum spanning tree method showed a high degree of 
genetic similarity between the MLVA genotypes I to O (Fig. 1). These MLVA genotypes 
are interconnected by repeat number changes in only one of the six markers and may 
represent microvariants of one founder genotype.
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Table 1. Prevalence of C. burnetii DNA in commercially available bulk tank cow milk and milk 
products from 18 countries throughout Europe and from 10 non-European countries a.
Location Origin
Ct
-value
No. of PCR 
pos / total
of samples
tested
No. of
MLVA
types
Ms
23
Ms
24
Ms
27
Ms
28
Ms
33
Ms
34
MLVA
type
Austria Semi-skimmed milk 37.4 1/1 1 6 - 2 7 4 - Part
Belgium Semi-skimmed milk 33.6 1/1 1 6 13 - 7 4 10 Part
Croatia Semi-skimmed milk 34.1-35.2 4/4 4 - 9 - - - - Part
Denmark Semi-skimmed milk 34.5 1/1 1 6 13 - - 5 - Part
Finland Semi-skimmed milk - 0/1
France Semi-skimmed milk 30.4-34.1 6/6 1 6 13 2 7 4 9 I
2 6 13 2 7 4 10 J
1 6 - 2 5 - 10 Part
1 6 - 2 7 4 - Part
1 6 - - - 4 9 Part
Germany Low fat and 32.0-37.3 6/6 1 6 13 2 7 4 - Part
semi-skimmed milk 1 6 13 2 6 4 10 K
1 - - 2 7 - 10 Part
1 6 13 - - 4 9 Part
2 - - - - - - -
Ireland Semi-skimmed milk 32.5 1/1 1 - 11 - - - 9 Part
Italy Semi-skimmed milk 33.2 1/1 1 6 - - 7 4 11 Part
Netherlands Low fat and semi- 31.5-41.2 16 / 27 1 6 13 2 7 4 9 I
skimmed milk, 1 6 13 2 - 4 9 Part
coffee creamer 1 6 13 - 7 4 9 Part
and milk powder 2 6 13 2 7 4 10 J
1 - - 2 7 - 7 Part
10 - - - - - - -
Norway Semi-skimmed milk - 0 / 2
Poland Semi-skimmed milk 35.2 1/1 1 - 13 - - - - Part
Portugal Semi-skimmed milk 31.5-36.8 10/12 2 6 13 2 7 4 9 I
1 6 13 2 7 4 - Part
1 5 13 2 - 4 - Part
1 6 13 - - 4 13 Part
1 6 - - 7 4 9 Part
4 - 13 2 - - 9 Part
Slovak Semi-skimmed milk 33.0-35.5 11/11 1 6 13 2 7 5 10 L
Republic 1 6 12 4 7 4 5 P
1 9 - 4 4 - 5 Part
1 5 13 - - 4 - Part
1 6 - - - 4 - Part
2 - - - - - - -
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1 4/6 7 3 3/6 4 3/5 Mix
1 4 27 3/4 3/6 4 3/5 Mix
1 - 13 2/4 7 4 10/11 Mix
1 6/9 8/13 - 3/6 4 3 Mix
Spain Low fat and 31.9-35.6 7/7 2 6 13 2 7 4 9 I
semi-skimmed milk 2 6 13 2 7 4 10 J
1 6 13 2 7 4 11 M
1 5 13 2 7 4 9 N
1 5 - 2 8 4 - Part
Switzerland Semi-skimmed milk 33.3-37.7 6/6 1 6 13 2 7 4 9 I
1 5 13 2 7 4 - Part
1 5 - - 7 4 9 Part
3 - - - - - - -
Sweden Semi-skimmed milk 36.2 1/1 1 - - - 2 - - Part
UK Semi-skimmed milk 31.6 1/1 1 6 13 2 7 5 9 O
Australia Semi-skimmed milk 33.9-36.7 4/6 1 - 1 - 5 - - Part
and coffee creamer 1 - 18 - - - - Part
2 - - - - - - -
Canada Semi-skimmed milk 32.7 1/1 1 6 13 - 7 4 11 Part
Costa Rica Milk powder - 0/2
Cuba Semi-skimmed milk 38.1 1/2 1 - - - - - - -
Egypt Semi-skimmed milk 34.1-36.0 2/2 2 5 13 - - 4 - Part
India Coffee creamer 34.8-37.3 2/3 1 6 - - - 5 - Part
incl. milk powder 1 - - - - - - -
New Zealand Semi-skimmed
(powder) milk
- 0/5
Qatar Semi-skimmed milk 30.3-32.6 2/2 1 6 12 4 5 4 2 Q
1 6 13 2 7 4 10 J
Russia Semi-skimmed
(powder)  milk
33.3 1/2 1 4 14 2 6 3 11 R
Saudi Arabia Semi-skimmed milk 33.5 1/1 1 6 13 2 7 4 10 J
C. burnetii Dugway ? 5 4 4 3 3
C. burnetii RSA331 4 7 3 3 -1b 3
C. burnetii RSA493 DNA 9 27 4 6 4 5
C. burnetii CbuG_Q212 ? 8 3 4 2 2
C. burnetii CbuK_Q154 ? 9 4 5 2 2
Total 88 / 116
(76 %)
a The number of repeats in each marker was determined by extrapolation using the sizes of the obtained fragments 
relative to those obtained using DNA from the Nine Mile strain. Furthermore, the genotypes of four additional C. burnetii 
strains, i.e., Dugway (Genbank accession number CP000733), RSA331 (CP000890), CbuG Q212 (CP001019) and CbuK Q154 
(CP001020) were determined in silico using published sequences; -, no result obtained; Part, partial genotype; Mix, 2 or 
more genotypes; ?, the number of repeats could not be determined due to apparent sequence assembly errors. b In Silico 
analysis resulted in a 5-repeat number difference compared to the NM strain, which by convention was assigned 4 repeats.
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Figure 1. Minimal spanning tree showing the relationship between the obtained MLVA 
genotypes identified in this study and five sequenced C. burnetii strains, i.e., Dugway (Genbank 
accession number CP000733), RSA331 (CP000890), Nine Mile RSA493 (AE016828), CbuG Q212 
(CP001019) and CbuK Q154 (CP001020) 12. Each circle represents a unique genotype, the size of 
the circle corresponds to the number of samples with that genotype. Only full MLVA genotypes 
were included in this analysis. Branch labels and connecting lines correspond to the number of 
different markers between the genotypes. Genotypes connected by a gray background differ in 
only one marker from each other and may represent microvariants of one founder genotype.
In contrast, MLVA genotypes P and R and the genotypes of five sequenced C. burnetii 
strains all differed in at least 3 markers from the MLVA genotypes I to O. The MLVA 
genotypes were compared to an in-house database containing 57 different C. burnetii 
MLVA genotypes from 197 human, caprine, ovine and cattle clinical samples from 
Canada, France, Germany, the Netherlands, Portugal, Spain and USA. MLVA genotypes 
I and J have also been recognized incidentally in 8 human clinical samples (placenta and 
Dugway
cbuG_Q212
cbuK_Q154
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RSA331
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valve) from France and in 2 animal samples (cattle and goats) from the Netherlands. 
However, very different MLVA genotypes (A to H) were identified in human, ovine and 
caprine clinical samples from the Q fever outbreak in the Netherlands using a 6-locus 
and 10-locus MLVA panel 10, 12, indicating that the Dutch Q fever outbreak is not related 
to the presence of C. burnetii in cattle.
Discussion
 The presence of highly similar C. burnetii genotypes in consumer milk 
products may indicate a widespread dissemination of a specific cattle-adapted strain. 
Alternatively, this genotype may have been introduced into different countries by 
transport of asymptomatic C. burnetii positive cattle, as well as by export of milk and 
milk products from a restricted number of countries, to other countries (e.g. Egypt, 
Saudi Arabia, Qatar) by the dairy industry. By testing bulk milk products instead of 
milk from individual animals, any positive milk specimen is likely to be diluted with 
negative milk specimens leading to an average lower DNA concentration resulting in 
higher threshold cycle (CT) values as well as partial genotypes. This is the first report of 
genotypic diversity among C. burnetii from cow milk throughout Europe and beyond. 
Integration of such data in international databases can be instrumental to understand 
the global epidemiology of Q fever in animals.
In conclusion, this study demonstrated the presence of C. burnetii DNA in a broad 
range of commercially available cow(s) milk and milk products, indicating a high 
prevalence of C. burnetii among the dairy cattle population worldwide and a possible 
clonal spread of C. burnetii among the European dairy cattle population. In addition, 
since the involved genotype is only incidentally found in humans, the risk of obtaining 
Q fever via exposure to infected cattle may be much lower than via exposure to infected 
small ruminants. The incidental observation of mixed alleles does not exclude the 
possibility of the presence of other minority genotypes in cattle that may be relevant to 
humans after all.
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Abstract
 The temporal and spatial diversity of Coxiella burnetii genotypes associated 
with human and animal disease in Portugal was analyzed using a 6-locus multiple-
locus variable number tandem-repeat analysis (MLVA) and a 10-locus multispacer 
sequence typing (MST) panel. Fifteen cultured C. burnetii isolates from 13 Q fever 
patients and a stillborn goat, and 6 additional PCR-positive ruminant tissue samples 
obtained during 2006-2011 were included in this study. Seven MLVA genotypes (types 
S-Y) were obtained, including 4 new MLVA types (U, V, W and X), all corresponding 
to 3 MST profiles (types 4, 8 and 13) previously reported from France and Spain. MLVA 
types U-Y, all belonging to MST type 4, were found in acute Q fever patients from the 
districts of Évora, Faro, Lisbon and Setúbal. Different MLVA types were associated to 
goats from Castelo Branco district (S) and chronic Q fever patients from both Castelo 
Branco and Lisboa districts (S and T), matching with MST type 13 and 8, respectively. In 
conclusion, a genotypic diversity of C. burnetii consistent with a non-outbreak situation 
was identified. The involvement of different genotypes in acute and chronic Q fever was 
found, linking one of the chronic genotypes to goats from the Eastern region of the 
country.
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Introduction
 Coxiella burnetii, the causative agent of Q fever in humans, is a zoonotic 
gammaproteobacteria with increasing interest in Europe due to the number and 
proportion of recent outbreaks 1. The latest events that occurred in the Netherlands 
(2007-2010), has particularly called attention to Q fever and to the need of updated 
information even in countries that usually present a low and stable disease rate, which 
also has characterized the Dutch situation until the outbreak episodes 1, 8. In Portugal, 
Q fever is a mandatory report disease mainly described in the Central and Southern 
Regions. The disease is characterized by a low incidence rate of 0.08 cases (2004-2008), 
but could be largely underestimated 4, 9. Limited veterinary awareness also determines 
that few animal clinical cases are attributed to C. burnetii infection annually, although 
a recent study has put in evidence the importance of this agent in domestic ruminant 
abortion pathology 3. Moreover, there is no information available on the genotypic 
diversity of the agent that circulates in the country, data that is important for both 
surveillance purposes and epidemiological investigation. In this study C. burnetii from 
both human and animal clinical samples collected between 2006 and 2011 for routine 
laboratory diagnosis were genotyped. Making use of multiple-locus variable number 
tandem-repeat analysis (MLVA) and multispacer sequence typing (MST), C. burnetii 
variant diversity and its temporal and spatial distribution were assessed in order to 
characterize the disease pattern and to identify potential sources of human infection.
Materials and methods
Samples
 Fifteen in-vitro C. burnetii cultures were included in the study obtained from 
different hosts (Table 1): a stillborn goat (Goat 747); 3 confirmed chronic Q fever 
patients that presented with endocarditis and IFA compatible titers (phase I IgG 
≥ 1.600 and IgA ≥ 50); and 10 confirmed acute Q fever patients that presented with 
febrile illness, pneumonia or hepatitis, 2 cases also with transient renal failure, and 
IFA results evidencing a recent infection (no detectable antibodies against C. burnetii, 
seroconversion to phase II antigen or a single titer of phase II IgM ≥ 50 IgG ≥ 200 and 
phase I IgG < 1.600 IgA < 50). Six C. burnetii PCR-positive ruminant tissue samples 
were additionally studied, including 5 liver and one lung sample obtained from a lamb 
fatality, stillborn cattle (n=2) and goats (n=2) (both liver and lung were available only 
for Goat 685, Table 1). C. burnetii isolation was performed in BSL3 conditions using the 
canine macrophage line DH82 (ATCC CRL-10389) and following standard shell-vial 
assay methods 6. DNA was extracted from C. burnetii isolates and animal samples using 
the QIAamp Tissue and Blood kit (Qiagen GmbH, Hilden, Germany) and the High 
Pure PCR Template Preparation kit, version 16 (Roche, Germany), respectively. An 
initial screening by real-time PCR targeting the multicopy IS1111a insertion element of 
C. burnetii was performed to determine sample cycle threshold (Ct) values, according 
to a previously described procedure 10. 
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Multiple-locus variable number tandem-repeat analysis (MLVA)
 MLVA was performed using 6 of the most variable loci out of 17 loci described 
by Arricau-Bouvery et al. 2. Two multicolor multiplex PCR assays, were applied targeting 
six microsatellite markers containing either six or seven base pairs (bp) repeat units: 3 
hexanucleotide repeat markers (Ms27, Ms28 and Ms34) and 3 heptanucleotide repeat 
markers (Ms23, Ms24 and Ms33). Primer sequences and PCR conditions were described 
before 7, 13. PCR was performed in a total volume of 20 µl containing 1 U of FastStart 
Taq DNA polymerase (Roche diagnostics, Almere, the Netherlands), 0.2 mM dNTP’s, 4 
mM MgCl2 in 1x reaction buffer, 0.1 – 1.0 µM of amplification primers and 5 µl of DNA 
sample. The analysis of the amplification products were performed on a MegaBACE 
500 automated DNA analysis platform  and  electropherograms using the Fragment 
Profiler 1.2 (GE Healthcare, Diegem, Belgium). DNA from the Nine Mile strain (RSA 
493) was used as a reference. The number of repeats in each marker was determined by 
extrapolation using the sizes of the obtained fragments relative to those obtained using 
DNA from the Nine Mile strain. According to the in silico analysis, the genotype of 
the Nine Mile strain is 9-27-4-6-4-5 for markers Ms23-Ms24-Ms27-Ms28-Ms33-Ms34, 
respectively.
Multispacer sequence typing (MST)
 At least one sample per obtained MLVA type according to animal species was 
used for MST genotyping. MST was performed as previously described and consisted 
of 10 different spacers of the C. burnetii genome: Cox2, 5, 6, 18, 20, 22, 37, 51, 56 and 
57 5, 11. Each 20 µl amplification reaction contained 0.5 µM of amplification primers, 1 
U of FastStart Taq DNA polymerase (Roche diagnostics, Almere, The Netherlands), 
0.2 mM dNTP’s, 1.5 mM MgCl2 in 1x reaction buffer and 5 µl of DNA sample. After 
amplification, PCR products were cleaned and sequencing was performed using the 
forward and reverse primer. Sequence products were analyzed on a MegaBACE 500 
automated DNA analysis platform  and using BioNumerics software (Applied Math, 
Sint-Martens-Latem, Belgium), and MST genotypes were identified using a web based 
MST database (http://ifr48.timone.univ-mrs.fr/MST_Coxiella/mst). 
Results and discussion
 Overall, 7 MLVA genotypes were obtained in 18 of the 21 studied samples (type 
S-Y), including 4 new MLVA types (U, V, W and X) as presented in table 1. MLVA types 
U-Y were only identified in acute Q fever patients. Different genotypes were found in 
chronic Q fever patients (S and T) and goats (S). In 2 cases (patient 10639 and goat 
685) the same MLVA type was obtained from different samples confirming single 
colonization by a C. burnetii genotype. No result or only a partial genotype (assigned 
as ‘part’) was obtained from animal samples that contained insufficient DNA (Ct > 35, 
n=3).
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Clustering of the MLVA genotypes using the minimum spanning tree method showed a 
high degree of genetic similarity between the types V–Y, differing from each other only 
in one of the six markers, and in two markers from genotype U. In contrast, genotypes S 
and T differed at least 3 markers from the genotypes U-Y. The schematic representation 
of the obtained MLVA genotype compared to five C. burnetii reference strains (Nine 
Mile RSA493, Dugway, RSA331, CbuG Q212 and CbuK Q154) are presented in Figure 
1. MLVA genotypes associated with acute disease cases (U-Y) presented a broader 
geographical range and were identified in 4 out of 5 districts, contrasting with chronic 
diseases genotypes (S and T) found only in Lisboa and Castelo Branco districts (Fig 
1). Of note is the identification of genotype S in goat stillborns that occurred in the 
same geographical region but from different time periods: 2009 (Idanha-a-Nova, goat 
390) and 2011 (Castelo Branco, goat 747), both cases originated from Castelo Branco 
District. This genotype has also been found across the border in 2010 in Spain (Ituero 
de Azaba, goat 685), 10 km East from Guarda District, suggesting the occurrence of this 
genotype in goat populations from the Central Eastern area of the country and in the 
neighbouring Spanish region.
The obtained genotypes were compared to an in-house database containing 57 different 
C. burnetii MLVA genotypes from 211 human, caprine, ovine and cattle samples from 
Canada, France, Germany, the Netherlands, Qatar, Russia, Saudi Arabia, Slovak Republic, 
Spain, Switzerland, United Kingdom and USA. Based on the available information, 
only the genotypes U, V, W and X represented new MLVA profiles. Genotypes S and T 
were recognized in 5 human clinical samples (blood and valve) from France and in 14 
ruminant samples (mainly goats and sheep) from Spain, whereas genotype Y  were found 
in 3 human blood samples from France.  Moreover,  all the MLVA profiles identified in 
this work differed in at least 3 markers from the Dutch genotypes obtained from acute 
and chronic Q fever patients associated to recent outbreak episodes (genotypes A-H) 
13. They also differed in 3 or more markers from genotypes (I-R) found in consumer 
milk products from cows throughout Europe, including Portugal, adding more data 
to support the hypothesis of a limited link between human infection and the presence 
of C. burnetii in dairy cattle 12. Regardless of this, the partial genotype obtained from 
a stillborn calf studied in this work (cattle 384 from Estremoz district) presented a 
number of repeats in both loci Ms23 and Ms33 that differed from the genotypes in milk 
described by Tilburg et al. 12, suggesting that other variants might also be associated 
with bovines in Portugal.
MLVA typing is less laborious and has a more discriminatory power than MST. 
However, MST has the advantage of using standardized nomenclature, and having 
databases that allow easy comparison of results between laboratories. A subset of 10 
samples, representing MLVA genotypes S–Y, was selected for MST analyses (Table 1). 
The obtained results, although less discriminatory, confirmed the close relatedness 
between certain MLVA genotypes and enabled further comparison with the MST 
database. Two different MLVA genotypes T and S that were involved in chronic Q fever 
cases and goat infections corresponded to MST genotype 8 and 13, respectively. These 
MST genotypes had been previously identified in France and Spain associated to sheep, 
goats and human infection, including chronic cases.
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Figure 1. Geographical location of MLVA genotypes found in animals () and humans () 
and the correspondent minimum spanning tree, showing a representation of the differences 
between those genotypes and the reference strain Nine Mile RSA493 (AE016828). Four 
additional sequenced C. burnetii strains, i.e., Dugway (Genbank accession number CP000733), 
RSA331 (CP000890), CbuG Q212 (CP001019) and CbuK Q154 (CP001020) were determined in 
silico using the published sequences  13. Each circle represents a unique genotype, the size of 
the circle corresponds to the number of samples with that genotype. Only full MLVA genotypes 
were included in this analysis. Branch labels and connecting lines correspond to the number of 
different markers between the genotypes. Genotypes connected by a gray background differ in 
only one marker from each other. Hosts are identified in the map by the reference number that 
appears in Table 1, geographical origin column.
Noteworthy is that MST 8 is associated with QpRS plasmid found almost exclusively 
in chronic infection and MST 13 is associated with QpH1 plasmid found in acute and 
chronic infections 5. The 5 other apparently closely related MLVA genotypes U to Y, 
including the new MLVA genotypes (U, V, W and X), observed in acute Q fever patients 
all belonged to MST genotype 4. According to MST database, this genotype was only 
described in humans from France and Spain, and is associated mainly with QpDV, 
plasmid correlated to acute infections 5.
In conclusion, our study identified a genetic diversity in Portuguese variants associated 
to clinical disease that is expected in a non-outbreak situation. It shows the presence 
of C. burnetii genotypes that have been described in other Mediterranean countries 
and their involvement either in acute or chronic disease, an aspect that requires further 
investigation. The genotyping of animal samples were only achieved for goats, but the 
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results obtained thus far link the C. burnetii genotype found in this domestic ruminant 
from the Central eastern region of the country to a chronic Q fever patient. The analysis 
of more samples by both MLVA and MST genotyping methods, but also including 
plasmid characterization as a goal, will help to confirm these findings and to elucidate 
the source of some of the described genotypes, especially those MLVA genotypes that 
match into MST 4 group.
This is the first report of genotypic diversity among C. burnetii strains from Portugal. 
Continuing active surveillance and strain genotyping, and the integration of such data 
in international databases is important to understand the European context of Q fever 
epidemiology.
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Abstract
 Information on the genotypic diversity of Coxiella burnetii isolates from 
infected domestic ruminants in Spain is limited. The aim of this study was to identify 
the C. burnetii genotypes infecting livestock in Northern Spain and compare them to 
other European genotypes. A commercial real-time PCR targeting the IS1111a insertion 
element was used to detect the presence of C. burnetii DNA in domestic ruminants 
from Spain. Genotypes were determined by a 6-loci Multiple Locus Variable number 
tandem repeat analysis (MLVA) panel and Multispacer Sequence Typing (MST).
A total of 45 samples from 4 goat herds (placentas, N=4), 12 dairy cattle herds (vaginal 
mucus, individual milk, bulk tank milk, aerosols, N=20) and 5 sheep flocks (placenta, 
vaginal swabs, faeces, air samples, dust, N=21) were included in the study. Samples from 
goats and sheep were obtained from herds which had suffered abortions suspected 
to be caused by C. burnetii, whereas cattle samples were obtained from animals with 
reproductive problems compatible with C. burnetii infection, or consisted of bulk tank 
milk (BTM) samples from a Q fever surveillance programme. C. burnetii genotypes 
identified in ruminants from Spain were compared to those detected in other countries. 
Three MLVA genotypes were found in 4 goat farms, 7 MLVA genotypes were identified 
in 12 cattle herds and 4 MLVA genotypes were identified in 5 sheep flocks. Clustering 
of the MLVA genotypes using the minimum spanning tree method showed a high 
degree of genetic similarity between most MLVA genotypes. Overall 11 different MLVA 
genotypes were obtained corresponding to 4 different MST genotypes: MST genotype 
13, identified in goat, sheep and cattle from Spain; MST genotype 18, only identified 
in goats; and, MST genotypes 8 and 20, identified in small ruminants and cattle, 
respectively. All these genotypes had been previously identified in animal and human 
clinical samples from several European countries, but some of the MLVA genotypes are 
described here for the first time.
Genotyping revealed a substantial genetic diversity among domestic ruminants from 
Northern Spain.
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Introduction
 Coxiella burnetii is ubiquitous and the causative agent of Q fever, a zoonotic 
disease 1. Domestic ruminants are often asymptomatic carriers of C. burnetii and are 
considered the most important reservoir and source for human Q fever infection 2. 
However, other animal species like birds, reptiles, arthropods or pets can also be 
infected and possibly transmit the disease to humans 1. C. burnetii can cause abortions 
and stillbirths in goats and sheep, and infertility and endometritis in cattle 3. Infected 
animals shed bacteria mainly through milk, faeces, vaginal mucus and birth products 
4. Inhalation of C. burnetii contaminated aerosols is the main route of infection for 
humans. C. burnetii can be transported by the wind several kilometres far from the 
original infected source; direct contact with animals or C. burnetii infected birth 
products is not always necessary 5.
Considering the impact of C. burnetii on human and animal health, the study of 
potential sources of infection and the characterization of strains present in an area is of 
great epidemiological importance. Genotypic characterization of Coxiella burnetii is a 
prerequisite for surveillance purposes and for epidemiological investigation of Q fever 
outbreaks. This information is necessary to evaluate the epidemiological link between 
the source of the outbreak and human cases, with the final objective of establishing 
control measures in potential animal hosts involved in the life cycle.
Several techniques have been used to genotype and characterize C. burnetii strains. 
Techniques such as pulsed field gel electrophoresis were able to classify C. burnetii 
isolates in different groups 6.  DNA restriction fingerprints and separation by SDS-
PAGE differentiated six genomic groups 7. The analysis of the sequences of certain genes 
such as com1, icd or mucZ has been used for differentiating C. burnetii isolates 8-10. 
More recently, multiple locus variable number tandem repeats analysis (MLVA) 11-15 and 
multispacer sequence typing (MST) 16, 17 proved to be reliable techniques, reproducible, 
and with a high discriminatory power. In addition, these techniques do not require 
previous cultivation of the bacteria which is very difficult and requires biosafety level 
3 conditions, and can be implemented directly on clinical and/or environmental 
samples.
Q fever is an endemic disease in ruminants in several regions of Spain. Recent 
seroprevalence studies carried out in Northern, Central and Southern Spain revealed 
the importance of domestic ruminants as reservoir for this zoonosis 18-20, with herd 
seroprevalence ranging between 30% and 75% depending on the ruminant species, and 
individual seroprevalence ranging between 6% and 60%. However, information on the 
genotypic diversity of C. burnetii isolates from domestic ruminants in Spain is limited 
21. The aim of this study was to identify the C. burnetii MLVA and MST genotypes that 
infect livestock in Spain and to compare them to other European genotypes.
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Materials and Methods
Samples
 A total of 45 samples from 4 goat herds (N=4), 12 dairy cattle herds (N=20) and 
5 sheep flocks (N=21) were included in the study. Details on the geographic origin of 
the samples, year of collection, type of reproductive disorders at the time of sampling, 
and number and type of samples collected in each farm are shown in Table 1. Ovine and 
caprine samples were collected for laboratory diagnosis by clinical veterinarians as part 
of the usual clinical practice on farms with abortions or reproductive problems, and 
Spanish ethical guidelines (RD 1201/2005) and animal welfare regulations were strictly 
respected. All herd owners had given an informed consent prior to the study. Samples 
from cattle farms were collected within a research project on Q fever in dairy cattle 
farms and experimental work was officially approved by competent local authorities 
(Diputación Foral de Bizkaia, reference 10559, 3rd November 2010). Environmental 
samples consisted on aerosol samples and dust taken from animal premises. Air 
was sampled using a Sartorius air sampler (Air Sampler, MD8 airscan, Goettingen, 
Germany) at a flow rate of 100 l/min for 10 min. and particles were collected in gelatine 
filters which were processed for DNA extraction.  
DNA extraction and PCR
 All the samples were subjected to DNA extraction using the BioSprint 96 DNA 
Blood Kit (Qiagen, Hilden, Germany) following the procedure as described before 22, 23. 
To rule out contamination, negative controls were included during the DNA extraction 
process every ten (milk, vaginals swab or environmental) samples or after each placenta 
sample. Extraction controls and PCR negative (water) controls were subjected to PCR 
amplification along with the field samples. Conventional PCR 24 was used to detect 
the presence of C. burnetii DNA. After PCR confirmation, samples were analyzed by 
quantitative real time PCR (qPCR) in order to quantify the bacterial burden using 
the commercial Kit LSI Taq-Vet Coxiella burnetii (Laboratoire Service International, 
Lissieu, France) according to the manufacturer`s instructions. This is a duplex qPCR 
assay that targets the IS1111a insertion element of C. burnetii and includes a probe 
targeting the housekeeping gene GAPDH used as internal amplification control (IAC) 
to reveal possible inhibitors. PCR was performed using an ABI 7500 FAST thermocycler 
(Applied Biosystems, Foster City, CA, USA).
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Table 1. Description of material examined for C. burnetii genotyping.
Farma Locationb Year Reproductive disorders Sample type
Gt1 AL 2010 Abortion 1 Placenta
Gt2 BI 2010 Abortion 1 Placenta
Gt3 TO 2010 Abortion 1 Placenta
Gt4 ZA 2005 Abortion 1 Placenta
DC1 GI 2011 Infertility, abortion 3 vaginal mucus, 2 milk, 1 aerosol
DC2 BI 2010 Infertility 1 BTM, 2 milk
DC3 BI 2010 Infertility 2 individual milk
DC4 BI 2011 Abortion, infertility 1 vaginal mucus
DC5 NA 2011 Infertility 1 individual milk
DC6 CA 2011 Metritis, infertility 1 BTM
DC7 LU 2011 Abortion, infertility 1 individual milk
DC8 BI 2009 No 1 BTM
DC9 BI 2009 No 1 BTM
DC10 BI 2010 No 1 BTM
DC11 BI 2009 No 1 BTM
DC12 BI 2009 Metritis 1 BTM
Sh1 AL 2004 Abortion 1 Placenta
Sh2 SS 2007-09 Abortion 1 vaginal mucus, 1 individual milk, 2 
faeces, 2 aerosols
Sh3 SS 2008-11 Abortion 3 vaginal mucus, 1 placenta, 1 aerosol
Sh4 SS 2008-11 Abortion 2 vaginal mucus, 1 aerosol, 2 dust 
samples
Sh5 SS 2008-11 Abortion 1 vaginal mucus, 1 faeces, 1 aerosol, 1 
dust sample
a Farm designation according to animal species hosted:  Gt1-4 = Goat farms; DC1-12 = Dairy cattle 
farms; Sh1-5 = Sheep farms. b AL, Alava; BI, Bizkaia; TO, Toledo; ZA, Zamora; GI, Girona; NA, 
Navarra; CA, Cantabria; LU, Lugo; SS, Gipuzkoa.
Multiple-locus variable number tandem-repeat analysis (MLVA) 
 Two multicolor multiplex PCR assays were applied targeting six microsatellite 
markers containing either six or seven base pairs (bp) repeat units: 3 hexanucleotide 
repeat markers (Ms27, Ms28 and Ms34) and 3 heptanucleotide repeat markers (Ms23, 
Ms24 and Ms33). Primer sequences were used as described before 13, 25. PCR was performed 
in a total volume of 20 µl containing 1 U of FastStart Taq DNA polymerase (Roche 
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diagnostics, Almere, the Netherlands), 0.2 mM dNTP’s, 4 mM MgCl2 in 1x reaction 
buffer, 0.1 – 1.0 µM of amplification primers and 5 µl of DNA sample. Amplification 
products were analyzed on a MegaBACE 500 automated DNA analysis platform (GE 
Healthcare, Diegem, Belgium). Electropherograms were analyzed using Fragment 
Profiler 1.2 (GE Healthcare, Diegem, Belgium). DNA from the Nine Mile strain (RSA 
493) was used as a reference. The number of repeats in each marker was determined by 
extrapolation using the sizes of the obtained fragments relative to those obtained using 
DNA from the Nine Mile strain. According to the in silico analysis, the genotype of 
the Nine Mile strain is 9-27-4-6-4-5 for markers Ms23-Ms24-Ms27-Ms28-Ms33-Ms34, 
respectively. To study the genetic similarity between the MLVA genotypes obtained in 
the different ruminant species the minimum spanning tree method was used.
Multispacer sequence typing (MST)
 A subset of 15 samples was selected for MST analyses according to animal 
species, sample source and origin. Methods and all sequences of primers have been 
previously detailed 16, and 8 out of the 10 spacers that exhibited higher variation (Cox2, 
Cox5, Cox18, Cox22, Cox37, Cox51, Cox56 and Cox61) were selected for genotyping. Each 
20 µl amplification reaction contained 0.5 µM of amplification primers, 1 U of FastStart 
Taq DNA polymerase (Roche diagnostics, Almere, the Netherlands), 0.2 mM dNTP’s, 
1.5 mM MgCl2 in 1x reaction buffer and 5 µl of DNA sample. After amplification, PCR 
products were cleaned and sequencing was performed using the forward and reverse 
primers. Sequence products were analyzed on a MegaBACE 500 automated DNA 
analysis platform (GE Healthcare, Diegem, Belgium) and using BioNumerics software 
(Applied Math, Sint-Martens-Latem, Belgium). The genotypes identified by MST were 
compared to genotypes included in the MST database containing C. burnetii genotypes 
from countries throughout Europe and from several non-European countries (http://
ifr48.timone.univ-mrs.fr/MST_Coxiella/mst/).
Results
 All 45 samples were qPCR positive with cycle threshold (Ct) values below 35 
and all of them were genotyped by MLVA. Eleven MLVA genotypes were identified in 35 
(77.8 %) of the goat, sheep and cattle specimens; partial MLVA genotypes were obtained 
in 6 samples (13.3 %), and in 4 samples (8.9 %) no MLVA profile was obtained (Table 2). 
In 2 of the samples (low DNA load; high Ct-value) that yielded a partial genotype (from 
farms DC4 and Sh2), the combination of identified alleles did not match with any of 
the full MLVA genotypes found, suggesting that they corresponded to different types. 
Three different MLVA genotypes were found in 4 goat farms; 7 MLVA genotypes were 
identified in 12 cattle herds; and 4 MLVA genotypes were identified in 5 sheep flocks 
(Table 2). Genotype S was the most abundant and present in all three ruminant species 
(goats, sheep and cattle), being particularly widespread in sheep (present in 3 of the 4 
ovine farms sampled). Genotype T was found in goats and sheep. Multiple genotypes 
were identified in different samples obtained from the same farm, e.g. in farm Sh2, 
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genotype AA was identified in samples taken from aborted ewes, and two different 
genotypes (Z and a partial genotype) were identified in air samples sampled during 
the next two reproductive seasons (Table 2). Figure 1 shows the relationships between 
all identified genotypes from goats, sheep and cattle in Spain. Clustering of the MLVA 
genotypes using the minimum spanning tree method showed a high diversity between 
the strains. Totally, three different clusters were defined. The genotypes in cluster one 
(I, J, M, AB and AC) were all obtained from cattle and are interconnected by repeated 
number changes in one of the six markers. In addition, one cattle isolate (genotype AD) 
differed in three markers with the cattle strains of cluster one, and also differed in at 
least two markers with the genotypes in cluster two (S and Z). MLVA genotype AA of 
cluster three, detected in sheep, differed in only one allele from genotype T found in a 
goat and a sheep sample. 
Figure 1. Minimum spanning tree showing the relationship between the obtained MLVA 
genotypes identified in this study and five sequenced C. burnetii strains, i.e. Dugway (Genbank 
accession number CP000733), RSA331 (CP000890), Nine Mile RSA493 (AE016828), CbuG 
Q212 (CP001019) and CbuK Q154 (CP001020) were determined in silico 13 using the published 
sequences. Each circle represents a unique genotype; the size of the circle corresponds to the 
number of samples with that genotype. Only full MLVA genotypes were included in this analysis. 
Branch labels and connecting lines correspond to the number of different markers between the 
genotypes. Genotypes connected by a grey background differ in only one marker from each other 
and may represent microvariants of one founder genotype. One cluster represents genotypes (I, 
J, M, AB and AC) obtained exclusively in cattle. The genotypes from cattle, goats and sheep (S, Z, 
AA and T) are clustered in two other groups.
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MST analysis of the 15 samples selected (4 goats, 4 sheep, 7 cattle) revealed 4 different 
MST genotypes 8, 13, 18 and 20 (Table 3). MST13 was identified in all three ruminant 
species (goats, sheep and cattle); MST20 was detected more than once, but always in 
cattle; MST18 was only identified once in a goat placenta; and, MST8 was identified in 
goat. In addition, some partial MST genotypes found in sheep (samples from farms Sh1 
and Sh2) might also correspond to MST8. Correspondence between genotyping results 
by MLVA and MST are shown in Table 3. MLVA genotypes belonging to the same MLVA 
cluster all yielded the same MST genotype.
Discussion
 Molecular methods are used to characterize strains and to determine 
relationships between isolates causing disease. In the case of Q fever, MLVA and 
MST techniques have been incorporated for genotyping of C. burnetii strains since 
both techniques can be performed directly on clinical and environmental samples 
without previous cultivation of bacteria 11, 16. In the current study MLVA typing has 
been performed based on 6 loci on 45 C. burnetii-positive samples to study the genetic 
background of this bacterium in domestic ruminants in Spain. 
MLVA typing revealed a substantial genetic diversity among C. burnetii from domestic 
ruminants in Northern Spain as shown in the minimum spanning tree, with 11 distinct 
genotypes being identified. None of the MLVA profiles found here were similar to the 
profiles identified in the Q fever outbreak episodes in the Netherlands 13 or Poland 26. 
The MLVA genotypes (I, J, M, S and T) described in the current study have been found 
before, indicating a wide dissemination of the described MLVA genotypes throughout 
Europe. MLVA genotypes I, J and M have been found in cattle milk from France, the 
Netherlands, Portugal, Spain and Switzerland 14, and have also been incidentally found 
in 8 human clinical samples (placenta and heart valve) from France, according to an 
in-house database containing 61 different C. burnetii MLVA genotypes from 231 human, 
caprine, ovine and cattle clinical samples and cows milk obtained from Canada, France, 
Germany, the Netherlands, Portugal, Qatar, Russia, Saudi Arabia, Slovak Republic, 
Spain, Switzerland, United Kingdom and USA. Moreover, MLVA genotypes S and T 
have also been incidentally found in 8 human clinical samples (blood and valve) from 
France and Portugal and in 6 ruminant samples (goat and sheep) from Portugal 27.
In addition, 6 new MLVA profiles were identified (Z and AA in sheep, AE in goats, and AB, 
AC, and AD in cattle) which so far have not been detected in human or animal samples. 
However, some of these new genotypes differ in only one marker from other previously 
defined and may represent microvariants of the founder genotype. Interestingly, 
variations in MLVA genotypes were observed throughout consecutive reproductive 
seasons in some sheep farms. This was the case on Farm Sh2, where genotypes detected 
in air samples were different from those detected in aborted ewes. This also happened 
in farms Sh4 and Sh5, where partial genotypes in environmental or animal samples 
were different. Typing data provided important epidemiological information about the 
sources of infection, and explained previous observations when C. burnetii appeared in 
environmental surfaces while no animal shedders were present in the sheep flocks 28. 
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Since several C. burnetii genotypes can be present on a farm, BTM samples might be 
contaminated with several different genotypes. However, apart from one sample (from 
farm DC10) that could not be typed, clean chromatograms were obtained by MST in 
all BTM samples tested in this study, suggesting the presence of only one genotype per 
BTM sample. This was also supported by the MLVA results.
Looking at MLVA genotyping results on individual milk samples, apart from one sample 
from farm DC2, only one genotype was detected per individual milk sample and per 
farm, as shown in farms DC1 and DC3. In the sample from farm DC2 (Bizkaia region), 
more than one allele per locus was observed, suggesting the presence of at least two or 
more different MLVA genotypes. In addition, the presence of highly similar C. burnetii 
genotypes (I, J, M, AB and AC) in cattle milk may indicate a widespread dissemination 
of a specific cattle-adapted strain, as previously reported 14.  
MLVA typing has shown to be less laborious and more discriminatory than MST 15. 
However, MST has the advantage of using standardized nomenclature, and having 
databases that allow easy comparison of results between laboratories and studies. It 
is interesting that the MST genotype involved in the human Q fever outbreak in The 
Netherlands (MST33), linked to goats and sheep and found also in Germany and France 
17, was not detected in the present study. However, the most common genotype (MST13), 
which was identified in the three ruminant species in Spain, had been identified before 
in human Q fever cases in France, and recently in Portugal 27. Other MST genotypes 
detected in this study, had also been previously reported. MST8, detected here in goats 
and probably present in sheep (partial profile), has been found before in human samples 
and in one ovine sample from Spain, France and USA, and in human Q fever chronic 
cases from Portugal 27. MST18, found only on 1 goat farm was isolated before from human 
and animal (sheep and goats) clinical samples in France, Italy, Romania, Greece, Slovak 
Republic and Germany according to the MST database (http://ifr48.timone.univ-mrs.
fr/MST_Coxiella/mst/). Finally, MST20, found here in cattle, had been identified in 
animal and human clinical samples from France, Germany, the Netherlands and USA 16, 
17. Human isolates need to be genotyped with the same techniques used here on animal 
samples to identify the most important animal source for human Q fever infection in 
this Spanish region. The only genotyping study carried out in Spain, used PCR and 
RLB hybridization to determine the presence/absence of 8 ORFs in order to compare 
C. burnetii isolates from domestic ruminants (n = 29) and human cases (n = 24). The 
authors identified some related genomic groups in C. burnetii isolated from humans, 
sheep and goats, but not from cattle 21. This is in agreement with the results obtained 
in the Netherlands, where prevalence of C. burnetii DNA in dairy cattle is high 29 but 
MLVA and MST genotypes detected in cattle are different from those involved in the 
human Q fever outbreak 12-14, 17.
Conclusions
 Understanding the distribution of C. burnetii genotypes present in a region is 
critical to identify the major sources of infection, and implement efficient farm-based 
control measures to reduce human exposure to the pathogen. However, it is necessary 
8115
Genotyping of Coxiella burnetii from ruminants in Northern Spain
to harmonize genotyping techniques to be used in Coxiella epidemiological studies, so 
that results can be exchanged and readily comparable among different laboratories and 
studies. Likewise, a common website where all typing data can be submitted and easily 
accessed is necessary for timely identification of new strains.
List of abbreviations
 MLVA: Multiple locus variable number tandem repeats analysis; MST: 
Multispacer sequence typing; qPCR: Real-time PCR; IAC: Internal amplification 
control; Ct: Cycle threshold.
Competing interests
 Authors declare that there are no financial competing interests.
Authors´ contributions
 JA and JT were responsible for laboratorial analyses and assisted with 
interpretation of data; AP provided samples and made DNA extractions; JT and AH 
assisted with discussion of results and writing the manuscript. ALG coordinated 
sample selection and wrote the manuscript; MNF and CK supervised laboratory work 
and critically revised the manuscript. All authors revised the manuscript and approved 
it in its final version. 
Acknowledgments
 This study was supported by Spanish National Institute for Agricultural and 
Food Research and Technology (INIA RTA 2009-00017-00) and the European Regional 
Development Fund (ERDF). AP is the recipient of a predoctoral fellowship from INIA.
116
Chapter 8
References
Angelakis E, Raoult D. Q fever. Veterinary Microbiology 2010; 140: 297-309.1. 
Woldehiwet Z. Q fever (Coxiellosis): epidemiology and pathogenesis. Research in 2. 
Veterinary Science 2004; 77: 93–100.
Arricau-Bouvery N, Rodolakis A. Is Q fever an emerging or re-emerging zoonosis? 3. 
Veterinary Research 2005; 36: 327-349.
Rodolakis A, Berri M, Hechard C, et al. Comparison of 4. Coxiella burnetii shedding in 
milk of dairy bovine, caprine, and ovine herds. Journal of Dairy Science 2007; 90: 5352-
5360.
Tissot-Dupont H, Amadei MA, Nezri M, et al. Wind in November, Q fever in December. 5. 
Emerging Infectious Diseases 2004; 10: 1264-1269.
Jager C, Willems H, Thiele D, et al. Molecular characterization of 6. Coxiella burnetii 
isolates. Epidemiology and Infection 1998; 120: 157-164.
Hendrix LR, Samuel JE, Mallavia LP. Differentiation of 7. Coxiella burnetii isolates by 
analysis of restriction-endonuclease-digested DNA separated by SDS-PAGE. Journal of 
General Microbiology 1991; 137: 269-276.
Nguyen SV, Hirai K. Differentiation of 8. Coxiella burnetii isolates by sequence 
determination and PCR-restriction fragment length polymorphism analysis of isocitrate 
dehydrogenase gene. FEMS Microbiology Letters 1999; 180: 249-254.
Sekeyova Z, Roux V, Raoult D. Intraspecies diversity of 9. Coxiella burnetii as revealed by 
com1 and mucZ sequence comparison. FEMS Microbiology Letters 1999; 180: 61-67.
Zhang GQ, To H, Yamaguchi T, et al. Differentiation of 10. Coxiella burnetii by sequence 
analysis of the gene (com1) encoding a 27-kDa outer membrane protein. Microbiology 
and Immunology 1997; 41: 871-877.
Arricau-Bouvery N, Hauck Y, Bejaoui A, et al. Molecular characterization of 11. Coxiella 
burnetii isolates by infrequent restriction site-PCR and MLVA typing. BMC Microbiology 
2006; 6: 38.
Roest HIJ, Ruuls RC, Tilburg JJHC, et al. Molecular epidemiology of 12. Coxiella burnetii 
from ruminants in Q fever outbreak, the Netherlands. Emerging Infectious Disease 
2011; 17: 668-675.
Tilburg JJHC, Rossen JW, van Hannen EJ, et al. Genotypic diversity of 13. Coxiella burnetii 
in the 2007-2010 Q fever outbreak episodes in The Netherlands. Journal of Clinical 
Microbiology 2012; 50: 1076-1078.
Tilburg JJHC, Roest HIJ, Nabuurs-Franssen MH, et al. Genotyping Reveals the Presence 14. 
of a Predominant Genotype of Coxiella burnetii in Consumer Milk Products. Journal of 
Clinical Microbiology 2012; 50: 2156-2158.
Tilburg JJHC, Roest HIJ, Buffet S, et al. Evaluation of three different genotyping 15. 
methods for the molecular characterization of C. burnetii. 6th International Meeting 
on Rickettsiae and Rickettsial Diseases. Crete (Greece) 5-7th June 2011. pp 84.
Glazunova O, Roux V, Freylikman O, et al. 16. Coxiella burnetii genotyping. Emerging 
Infectious Diseases 2005; 11: 1211-1217.
Tilburg JJHC, Roest HIJ, Buffet S, et al. Epidemic genotype of 17. Coxiella burnetii among 
goats, sheep, and humans in the Netherlands. Emerging Infectious Disease 2012; 18: 
887-889.
Alvarez J, Perez A, Mardones FO, et al. Epidemiological factors associated with the 18. 
exposure of cattle to Coxiella burnetii in the Madrid region of Spain. Veterinary Journal 
8117
Genotyping of Coxiella burnetii from ruminants in Northern Spain
2012 (in press).
Rodríguez NF, Carranza C, Bolaños M, et al. Seroprevalence of 19. Coxiella burnetii in 
domestic ruminants in Gran Canaria Island, Spain. Transboundary and Emerging 
Diseases 2010; 57: 66-67.
Ruiz-Fons F, Astobiza I, Barandika JF, et al. Seroepidemiological study of Q fever in 20. 
domestic ruminants in semi-extensive grazing systems. BMC Veterinary Research 2010; 
6: 3.
Jado I, Carranza-Rodriguez C, Barandika JF, et al. Molecular method for the 21. 
characterization of Coxiella burnetii from clinical and environmental samples: 
variability of genotypes in Spain. BMC Microbiology 2012; 12: 91.
Astobiza I, Barandika JF, Ruiz-Fons F, et al. 22. Coxiella burnetii shedding and environmental 
contamination at lambing in two highly naturally-infected dairy sheep flocks after 
vaccination. Research Veterinary Science 2010; 91: 58-63.
Astobiza I, Barandika JF, Hurtado A, et al. Kinetics of 23. Coxiella burnetii excretion in a 
commercial dairy sheep flock after treatment with oxytetracycline. Veterinary Journal 
2010; 184: 172-175.
Willems H, Thiele D, Frolich-Ritter R, et al. Detection of 24. Coxiella burnetii in cow’s milk 
using the polymerase chain reaction (PCR). Zentralblatt fűr Veterinarmedicin 1994; 41: 
580-587.
Klaassen CHW, Nabuurs-Franssen MH, Tilburg JJHC, et al. Multigenotype Q fever 25. 
outbreak, the Netherlands. Emerging Infectious Disease 2009; 15: 613-614.
Chmielewski T, Sidi-Boumedine K, Duquesne V, et al. Molecular epidemiology of Q 26. 
fever in Poland. Polish Journal of Microbiology 2009; 58: 9-13.
Santos AS, Tilburg JJ, Botelho A, et al. Genotypic characterization of human and animal 27. 
Coxiella burnetii isolates from Portugal. International Journal of Medical Microbiology 
2012; 302: 253-256.
Astobiza I, Barandika JF, Ruiz-Fons F, et al. Four-Year Evaluation of the Effect 28. 
of Vaccination against Coxiella burnetii on Reduction of Animal Infection and 
Environmental Contamination in a Naturally Infected Dairy Sheep Flock. Applied and 
Environmental Microbiology 2011; 77: 7405-7407.
Muskens J, van Engelen E, van Maanen C, et al. Prevalence of 29. Coxiella burnetii infection 
in Dutch dairy herds based on testing bulk tank milk and individual samples by PCR 
and ELISA. Veterinary Records 2011; 168: 79.

Chapter 9
Evaluation of three genotyping methods
for Coxiella burnetii
J.J.H.C. Tilburg, H.I.J. Roest, S. Buffet, R.C. Ruuls,
P.Th.J. Willemsen, M.H. Nabuurs-Franssen, A.M. Horrevorts,
G. Vergnaud, D. Raoult, C.H.W. Klaassen 
Submitted for publication.
120
Chapter 9
Abstract
 We compared the performance of two different multiple-locus variable number 
tandem-repeat analysis (MLVA) panels and the multispacer sequence typing (MST) 
method for genotyping C. burnetii from 134 human and animal samples selected from 
the Dutch MLVA database. More different genotypes could be identified by the MLVA-6 
method compared to MST. A comparable number of genotypes could be identified by 
both MLVA-6 and MLVA-10. The diversity index was calculated at 0.89 for MST versus 
0.93 and 0.95 for the two MLVA panels. All loci of the MLVA-6 method yielded a result 
in contrast to MST and MLVA-10. We demonstrate that both MST and the MLVA 
panels are suitable for genotypic characterization of C. burnetii directly in clinical 
samples without specific biosafety handling. MLVA-6 offers an easy to use and clearly 
distinguishable genotyping method for epidemiological studies and to understand the 
distribution of genotypes present in a region.
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Introduction
 Q fever is a zoonosis caused by the pathogen Coxiella burnetii, with a worldwide 
appearance 1. Q fever can cause serious illness in humans, e.g. self-limited febrile 
illness, pneumonia, hepatitis or chronic endocarditis 1. Ruminants have been identified 
as an important source of human Q fever outbreaks worldwide 1, 16. Q fever is mainly 
diagnosed by serology and/or by molecular detection of C. burnetii DNA in clinical 
samples using PCR based techniques 5, 7, 24, 29.
Molecular characterization of C. burnetii by genotyping is instrumental for recognition 
of specific strains. This is an indispensable tool for epidemiological investigations of Q 
fever outbreaks and for surveillance purposes 16, 17, 28. Genotyping may allow identification 
of the source of the outbreak so that specific measures can be implemented to contain 
the source. Specific strain identification has also shown to be very useful to identify a 
laboratory contamination 25. 
Over the years various genotyping techniques for C. burnetii have been published. 
Methods such as pulsed field gel electrophoresis and PCR restriction fragment length 
polymorphism analysis (PCR-RFLP) have been used to recognize different groups 
of C. burnetii isolates 12, 23, 30. Differentiation between strains could also be achieved 
by sequence based determination of the Com1 and MucZ encoding genes, by whole-
genome comparison using a microarray-based method as well as by studying differences 
in plasmid types 4, 13, 18, 20. Furthermore, Infrequent Restriction Site-PCR (IRS-PCR), 
IS1111a insertion sequence PCR-based and tandem mass spectrometry coupled to 
nanoscale ultra performance liquid chromatography (LC-MS/MS) have been developed 
for typing of C. burnetii isolates 2, 6, 10. All these methods however, have relied on the 
cultivation of the isolate prior to analysis using cell culture techniques or embryonated 
chicken eggs, which requires specific expertise as well as biosafety level 3 conditions 
2, 6, 9, 10, 12, 13, 15, 23. Cultivation of the isolates prior to analyses creates also a potential for 
generation of genotypic variation due to multiple sequential cell divisions. Several 
other genotyping methods have the potential to be used directly in clinical samples 
eliminating this caveat, in particular; multispacer sequence typing (MST), single-
nucleotide polymorphism (SNP) based typing and multiple-locus variable number 
tandem-repeat analysis (MLVA) 2, 3, 8, 11, 14, 17, 19, 22, 26, 28. Both MST and MLVA can be used 
for large scale investigation and have also been widely used in the investigations of the 
Dutch Q fever outbreak 12, 26, 28. However, an independent comparison between these 
methods is lacking up to now. 
The aim of this study was to compare the performance of MST and two different MLVA 
panels, for molecular characterization of C. burnetii from human and animal clinical 
samples.
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Table 1. MLVA-6 database containing 64 different MLVA genotypes from 241 human and 
animal samples a.
Ms
23
Ms
24
Ms
27
Ms
28
Ms
33
Ms
34
Sample type
No. of 
samples 
/ MLVA
MLVA
type
MST
type
MLVA-
10 type
6 11 3 3 2 7 Human (NLb; BAL, blood, sputum, throat swab, urine; 2008) 6 A
6 11 3 3 2 8 Human (NL; throat swab; 2008) 1 B
6 11 4 3 2 7 Human (NL; sputum; 2008) 1 C
6 13 3 3 2 8 Human (NL; blood; 2008) 1 D
3 11 3 3 2 8 Human (France, NL; valve, BAL, blood; 1998, 2008-2010) 4 E 33 VII, partc
Sheep (NL; throat swab, vaginal swab; 2008) 6
3 10 3 3 2 7 Human (NL; BAL; 2009) 1 F
3 11 3 3 2 7 Cattle (NL; placenta; 2011) 1 G 33 VI, part
Goats (France, NL; vaginal swab; 2008, 2009) 23
Human (France, NL; valve, BAL, blood, sputum; 1996, 1999, 
2009, 2010, 2012)
24
Sheep (Germany; placenta; 1992) 1
4 11 3 3 3 8 Human (Netherlands; BAL; 2009) 1 H
6 13 2 7 4 9 Cattle (France, Italy, NL, Portugal, Spain, Switzerland; milk, 
placenta, vaginal swab; 2009, 2010, 2011, 2012)
20 I 20 IX, part
Goat (NL; placenta; 2009) 1
Human (France; placenta, valve; 1994, 1996-1999) 7
Sheep (NL; 2011) 1
6 13 2 7 4 10 Cattle (France, NL, SAb, Spain, Qatar; milk; 2010, 2011) 11 J 20 X
Human (France; valve; 2000) 1
6 13 2 6 4 10 Cattle (Germany; milk; 2010) 1 K 20
6 13 2 7 5 10 Cattle (Slovak Republic; milk; 2011) 1 L
6 13 2 7 4 11 Cattle (Spain; milk; 2009) 1 M
5 13 2 7 4 9 Cattle (Spain; milk; 2010) 1 N
6 13 2 7 5 9 Cattle (United Kingdom; milk; 2010) 1 O
6 12 4 7 4 5 Cattle (Slovak Republic; milk; 2011) 1 P
6 12 4 5 4 2 Cattle (Qatar; milk; 2011) 1 Q
4 14 2 6 3 11 Cattle (Russia; milk;2011) 1 R
1 11 2 3 2 3 Cattle (Spain; milk; 2009) 1 S 12, 13 IV
Goat (Spain, Portugal; placenta; 2005, 2009, 2010) 6
Human (France; blood, valve vegetation; 1996) 2
Sheep (Spain; aerosol, environ sample, faeces, placenta, 
vaginal swab; 2008-2011)
9
3 9 4 5 2 2 Goat (Spain; placenta; 2005, 2010) 2 T 8 XIX
Sheep (Portugal; 2011) 2
Human (France, Portugal, NL; blood, spleen, valve; 1992, 
1993, 1997, 2007, 2010, 2012)
7
2 14 3 7 1 2 Human (Portugal; blood; 2006, 2007, 2010) 4 U 4
3 16 3 7 2 2 Human (Portugal; blood; 2006) 5 V 4
3 16 2 7 2 2 Human (Portugal; blood; 2006) 1 W 4
3 18 3 7 2 2 Human (Portugal; blood; 2010) 1 X 4
3 14 3 7 2 2 Human (France, Portugal; blood; 1991, 1996, 2006) 4 Y 4 XIII
1 11 2 3 2 2 Sheep (Spain; aerosol; 2008) 1 Z
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3 9 5 5 2 2 Sheep (Spain; faeces, milk, vaginal swab; 2007) 4 AA
6 13 2 7 4 12 Cattle (Spain; milk; 2009) 1 AB
6 15 2 7 4 12 Cattle (Spain; milk; 2011) 1 AC 20
6 11 2 3 4 3 Cattle (Spain; milk; 2011) 1 AD 13
4 9 3 3 3 4 Goat (Spain; placenta; 2010) 1 AE
2 15 3 7 1 2 Human (France; blood, valve) 1 AF 1 part
2 16 3 7 1 2 Human (France; valve, blood, placenta; ‘89, ‘92, ‘96, ‘00, ‘02) 9 AG 1, 2, 5 XIV, part
2 17 3 7 1 2 Human (France; blood; 1992) 1 AH 1
2 19 3 7 1 2 Human (France; placenta; 1992, 1994) 2 AI 1 part
2 12 3 7 1 2 Human (France; blood; 1998) 1 AJ 1 XV
2 11 3 7 1 2 Human (France; valve mitral; 2004) 1 AK 3 XVI
3 15 3 7 2 2 Human (Spain; placenta; 1995) 1 AL 4
3 26 3 7 2 2 Human (France; blood; 1993) 1 AM 2 XII
3 12 3 7 2 2 Human (France; aortic valve; 2003) 1 AN 5 XV
6 14 3 7 2 2 Human (France; blood; 1996) 1 AO 4
1 12 2 3 2 3 Human (France; aorta, blood, valve; 1988, 1995, 2001) 5 AP 12, 13, 
32
II, III, 
part
1 14 2 3 2 3 Human (France; valve; 1995) 1 AQ 12 V
1 10 2 3 2 3 Human (France; blood; 1990) 1 AR 12
1 13 2 3 2 3 Human (France; aortic valve; 1993) 1 AS 12 Part
3 12 2 3 2 3 Human (France; valve; 1993) 3 AT 11 III
4 9 4 5 3 2 Goats, cattle (Italy; placenta, milk; 2011, 2012) 2 AU 8 part
Human (France; valve, blood, valve mitral;‘91,‘92,‘96, ‘99, ‘00) 6
6 13 4 5 3 2 Human (France; valve mitral; 1990) 1 AV 8 XVIII
Ovin (France; placenta; 2002) 1
3 12 4 5 2 2 Human (France; aortic valve; 1992) 1 AW 9
3 8 4 5 2 2 Human (Spain; valve mitral; 1994) 1 AX 8 part
6 8 4 5 2 2 Human (France; aortic valve; 1996) 1 AY 10 Part
3 9 3 4 2 2 Human (Canada, France; valve; 1982, 1988, 2003) 3 AZ 21 XI, part
4 17 3 9 3 2 Human (France; aortic valve; 1993) 1 BA 7 XVII
4 18 3 5 3 2 Human (France; aortic valve; 1993) 1 BB 6
4 8 3 3 3 3 Human (France) 1 BC 18 VIII
6 11 3 5 7 6 Human (France; valve; 1998) 1 BD 17
6 12 2 7 4 9 Goat (France; 2011 1 BE 20
3 12 4 3 2 11 Antelope (Dubai; 2011) 1 BF Newd
6 13 2 7 4 8 Cattle (NL; placenta; 2011) 1 BG
5 11 3 3 4 7 Human (NL; wound; 2012) 1 BH
6 13 2 7 4 13 Cattle (Italy; milk; 2012) 2 BI
6 13 2 7 4 6 Cattle (Italy; milk; 2012) 1 BJ
6 14 2 7 4 11 Cattle, Goats (Italy; milk; 2011) 2 BK
9 27 4 6 4 5 Ticks (USA; 1935) 1 NM 16 I
Human (France, Canada; blood, valve; 1988, 1991, 1992, 2003) 9
a MLVA-6 type designation (A-BK) was attributed to different types in order of publication; MLVA-6 genotypes A-H, I-R, S-Y and Z-AE have 
been published before 3, 19, 27, 28; MLVA-6 genotypes AF-BK are described here for the first time; open spaces indicate that these samples have not 
been included in set 1 and/or 2. b NL = the Netherlands, SA = Saudi-Arabia; c part = partial MLVA-10 genotype; d MSTnew this genotype yielded 
3, 8, 1, 6, 5, 4, 5, 4, 6 and 10 for spacers Cox2, 5, 18, 20, 22, 37, 51, 56, 57 and 61 respectively.
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Material and methods
 Two sets of samples were used. Set 1 consisted of 134 samples and Set 2 contains 
69 samples. The 134 samples of Set 1 contain cultivated human and animal C. burnetii 
isolates and clinical samples  selected from the in-house Dutch MLVA database according 
to species, sample source and origin. This database contains 64 different C. burnetii 
MLVA-6 genotypes from 241 human and animal clinical samples (antelope, caprine, 
cattle and ovine), cows milk and ticks obtained from Canada, Dubai, France, Germany, 
Italy, the Netherlands, Portugal, Qatar, Russia, Saudi Arabia, Slovak Republic, Spain, 
Switzerland, United Kingdom and USA (Table 1). This collection of samples includes 
previously published samples from the C. burnetii strain collection maintained in 
Marseille 8, the Q fever outbreak in the Netherlands 14, 28, consumer milk products 27, and 
human and animal clinical samples from Portugal 19 and Spain 3. Set 2 is a subset of Set 
1 and contains 69 samples of the C. burnetii strain collection maintained in Marseille. 
Set 1 was used to evaluate the MST and MLVA, including 6 loci, and Set 2 was used to 
evaluate 2 MLVA methods including 6 and 10 loci. MST was performed as described 
before and consisted of 10 different spacers of the C. burnetii genome 8. MLVA was 
performed using 2 MLVA panels consisting of respectively 6 (MLVA-6) and 10 (MLVA-
10) loci of the 17 loci originally described by Arricau-Bouvery et al. 2. The MLVA-6 
method consisted of 2 multiplex PCR assays each amplifying 3 markers whereas the 10 
markers of the MLVA-10 panel were amplified as monoplex PCR reactions, as described 
before 14, 17, 28. DNA was isolated from human and animal clinical samples as described 
earlier 24 and stored at 4°C or -20°C. To rule out contamination, negative controls were 
included during the DNA extraction process. Extraction controls and PCR negative 
(water) controls were subjected to PCR amplification along with the samples.
The amplification products were either analyzed on a 3130 Genetic Analyzer (Applied 
Biosystems) or on a MegaBACE 500 automated DNA analysis platform (GE Healthcare). 
The obtained MST sequences were entered at the following website: http://ifr48.
timone.univ-mrs.fr/MST_Coxiella/mst to determine the spacer and MST genotype. 
MLVA-6 electropherograms were analyzed using Fragment Profiler 1.2 (GE Healthcare). 
The sizing of the MLVA-10 fragments was performed using GeneMapper v4.0 software 
(Applied Biosystems). The number of repeats in each MLVA marker was determined 
by extrapolation using the sizes of the obtained fragments relative to those obtained 
using DNA from the Nine Mile strain. According to the in silico analysis, the genotype 
of the Nine Mile strain is 7-6-6-9-27-4-6-6-5-4-5-4 for markers Ms03-Ms21-Ms22-Ms23-
Ms24-Ms27-Ms28-Ms30-Ms31-Ms33-Ms34-Ms36, respectively.
Data analysis
 Numerical typing data obtained from both MST and MLVA typing was 
imported into BioNumerics v. 6.0 (Applied Maths, Sint-Martens-Latem, Belgium) and 
analyzed using the minimum spanning tree method for categorical data. The diversity 
index (D) of the MST and MLVA methods was calculated according to the Simpson’s 
Index of Diversity 21. 
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Table 2. MLVA-10 genotypes compare to MLVA-6 genotypes identified in 69 C. burnetii positive 
human and animal samples (set 2) a.
Ms
3
Ms
21
Ms
22
Ms
24
Ms
27
Ms
28
Ms
30
Ms
31
Ms
34
Ms
36
No. of samples 
per MLVA-10 
type
MLVA-
10 type
MLVA-
6 type
7 6 6 27 4 6 6 5 5 4 6 I NM
7 6 6 12 2 3 5 3 3 1 partb AP
7 6 6 12 2 3 5 3 3 4 1 II AP
7 6 6 12 2 3 5 3 3 13 5 III AP, AT
7 6 6 11 2 3 5 3 3 13 1 IV S
7 6 6 13 2 3 3 3 13 1 partc AS
7 7 6 14 2 3 5 3 3 4 1 V AQ
7 6 11 3 3 5 3 7 13 1 part G
7 6 6 11 3 3 5 3 7 13 8 VI G
7 6 6 11 3 3 5 3 8 13 2 VII E
7 6 3 3 5 3 8 1 part E
7 6 6 8 3 3 5 2 3 13 1 VIII BC
6 6 6 13 2 7 6 3 9 4 8 IX I
13 2 7 9 2 part I
13 2 7 9 4 1 part I
6 6 13 7 6 3 9 1 part I
6 6 6 13 2 7 6 3 10 4 1 X J
6 6 6 9 3 4 6 4 2 4 2 XI AZ
6 6 6 9 3 6 4 2 4 1 part AZ
6 7 6 26 3 7 6 3 2 11 1 XII AM
6 7 6 14 3 7 6 3 2 11 2 XIII Y
6 7 6 3 7 6 3 2 11 6 part AF, AG, 
AI
6 7 6 16 3 7 6 3 2 11 1 XIV AG
6 7 6 12 3 7 6 3 2 11 2 XV AJ, AN
6 7 6 11 3 7 6 3 2 11 1 XVI AK
6 7 6 3 7 6 3 2 4 1 partc AG
6 7 6 17 3 9 6 3 2 11 1 XVII BA
6 7 6 8 4 5 3 2 4 1 partc AY
6 7 7 4 5 6 3 2 4 part AU
6 7 7 13 4 5 6 3 2 2 2 XVIII AV
6 7 7 4 5 6 3 2 2 1 part AX
6 7 7 9 4 5 6 3 2 2 1 XIX T
a Sample information see table 1; b part = partial MLVA-10 genotype; c this partial MLVA-10 
genotype is unique; open spots indicate missing values.
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Results
 A minimum spanning tree of the MLVA-6 genotypes compared to the MST 
genotypes identified in 134 human and animal samples (Set 1) is shown in Figure 1. In 
total, 42 different MLVA-6 genotypes and 21 different MST genotypes including one 
new MST genotype were identified (Table 1). Three MLVA-6 genotypes S, AG and AP 
could be divided into a total of 6 closely related MST genotypes (MST1, 2, 5, 12, 13 and 
32)8. Nine MST genotypes (MST1, 2, 4, 5, 8, 12, 13, 20 and 33) however, could be divided 
into 31 multiple different MLVA-6 genotypes (Table 1). All 134 samples yielded a full 
MLVA-6 profile whereas 35 out of 134 human and animal samples yielded no result in 
1 or 2 spacers of the MST method, especially in spacer Cox20 and/or Cox57 (data not 
shown). Thus with MLVA-6 more different genotypes could be identified compared to 
MST.
Figure 1. Minimum spanning tree showing the MLVA-6 genotypes compared to MST genotypes 
identified in 134 C. burnetii positive human and animal samples (Set 1; Table 1). Each circle 
represents a different MLVA-6 genotype; the size of the circle corresponds to the number of 
samples with that genotype. Symbols correspond to a unique MLVA genotype (Table 1). Each 
colour corresponds to a different MST genotype. Branch labels and connecting lines correspond to 
the number of different markers between the MLVA-6 genotypes. MLVA-6 genotypes connected 
by a grey background differ in only one marker from each other.
A minimum spanning tree of the MLVA-6 genotypes compared to the MLVA-10 
genotypes identified in 69 human and animal samples (Set 2) is shown in Figure 2. In 
total, 26 different MLVA-6 genotypes, 19 different MLVA-10 genotypes and 13 partial 
MLVA-10 genotypes were identified (Figure 2, Table 2). All 69 samples yielded a full 
MLVA-6 profile whereas 22 human and animal samples yielded no result with one of 
the loci of the MLVA-10 method. Although partial, a unique MLVA-10 profile could 
be identified in 3 samples corresponding to MLVA-6 genotype AG, AS and AY. In all 
other human and animal samples that yielded a partial genotype, the same alleles were 
identified as those found in samples yielding a full genotype (Table 2). By both MLVA-6 
2
2
2
2
2
22
22
22
3
3
3
4
4
BA
BB
BC
AU
T
AV
AY
AX
AW
W
V
Y
AOAL
AN
X
AM
AZ
U
AG AI AF
AL
AJ
AH
E G
BD
BFATAP
AQ
AS
S
AR
AD
I
J
AC
BE
K
NM
9127
Evaluation of three genotyping methods for Coxiella burnetii
and MLVA-10, the same alleles were identified with loci Ms24, Ms27, Ms28 or Ms34. 
The use of additional loci by the MLVA-10 method provided no added value compared 
to the MLVA-6 method with two exceptions based on the results obtained with locus 
Ms36 only (Figure 2, Table 2); MLVA-6 genotype AP could be divided into MLVA-10 
genotype II, III and one different partial genotype; MLVA-6 genotype AG could be 
divided into MLVA-10 genotype XIV and two different partial genotypes. On the other 
hand, MLVA-10 genotype III could be divided into 2 different MLVA-6 genotypes AP 
and AT based on the results with locus Ms23 only. Furthermore, MLVA-10 genotype 
XV could be divided into MLVA-6 genotype AJ and AN based on the results with loci 
Ms23 and Ms33 used by the MLVA-6 method. Taken together a comparable number of 
genotypes could be identified by both MLVA-6 and MLVA-10.
Figure 2. Minimum spanning tree showing the MLVA-6 genotypes compared to MLVA-10 
genotypes identified in 69 C. burnetii human and animal samples (Set 2; Table 2). Each circle 
represents a different MLVA-6 genotype; the size of the circle corresponds to the number of 
samples with that genotype. Symbols correspond to a unique MLVA genotype (Table 1). The 
colours correspond to a different MLVA-10 genotype. Partial MLVA-10 genotypes are left blank. 
Branch labels and connecting lines correspond to the number of different markers between the 
MLVA-6 genotypes. MLVA-6 genotypes connected by a grey background differ in only one marker 
from each other.
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In four additional clinical samples we observed more than one allele per locus, 
suggesting the presence of at least two or more different genotypes in these samples 
and therefore these samples were not included in the comparison. None of the negative 
control samples yielded MST, MLVA-6 or MLVA-10 profiles.
The diversity indices yielded 0.89 and 0.95 for the MST and MLVA-6 method respectively 
(set 1, Table 3) and 0.93 for both MLVA-6 and MLVA-10 methods (set 2, Table 3).
Table 3. Diversity indices for the C. burnetii typing methods.
Method No. of samples No. of types Diversity indexa
MLVA-6 (Set 1) 134 42 0.95
MLVA-6 (Set 2) 69 26 0.93
MLVA-10 69 22b 0.93b
MST 134 21 0.89
a According to Simpson 21; b 19 full genotypes and 3 unique partial MLVA-10 genotypes are 
included.
Discussion
 Molecular characterization is an indispensable tool for epidemiological 
investigations of outbreaks and for surveillance purposes 16, 17, 28. In case of Q fever, MST 
and MLVA have been used to characterize C. burnetii and to determine relationships 
between genotypes 2, 3, 8, 14, 17, 19, 22, 25-28. Both techniques can be performed directly on 
clinical samples without previous cultivation of the isolates. In the current study the 
performance of MST and two different MLVA panels for the molecular characterization 
of C. burnetii were compared using human and animal clinical samples (antelope, 
caprine, cattle and ovine), cows’ milk and ticks obtained from 15 different countries. 
More different genotypes could be identified by the MLVA-6 method compared to 
MST. Totally, 9 MST genotypes could be divided into 31 multiple different MLVA-6 
genotypes. The obtained results by MST showed the close relatedness between certain 
MLVA genotypes. These MLVA genotypes are interconnected by repeat number 
changes in one of the six markers and may represent microvariants of one founder 
genotype, as described before 3, 19, 27, 28. The slight difference in discriminatory power 
is expressed in a lower diversity index of the MST compared to the MLVA-6 method. 
Comparison of the MLVA-6 and MLVA-10 revealed consistency in 4 loci (Ms24, Ms27, 
Ms28 and Ms34), which were used by both MLVA methods. Eight loci were used either 
by MLVA-6 (Ms23 and Ms33) or MLVA-10 (Ms03, Ms21, Ms22, Ms30, Ms31 and Ms36). 
The use of 4 additional loci by the MLVA-10 method did not result in an increased 
variety of genotypes. However, differentiation depends on the selected loci included in 
both methods. All loci of the MLVA-6 method yielded a result in contrast to MST and 
MLVA-10. Whether the lack of results in some of the MLVA-10 loci and MST spacers 
are due to difference in sensitivity of the involved PCR assays, the significantly larger 
PCR products that is targeted 8, 17 or possible sequence polymorphisms in the target 
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sequence needs to be further investigated. Another advantage of the MLVA-6 method 
is that only 2 multiplex PCR assays are used each amplifying 3 markers compared to 10 
monoplex PCR assays by both MLVA-10 and MST 8, 17, 27.
An advantage of MST and MLVA above other typing methods is the portability of data 
which allows comparison to the web based MST database (http://ifr48.timone.univ-
mrs.fr/MST_Coxiella/mst database) and the Multiple loci VNTR Analysis database 
(http://minisatellites.upsud.fr/MLVAnet/index. php?&largeur=1024). Comparison 
of C. burnetii genotypes increases understanding in the occurrence and spread of 
C. burnetii worldwide. Thus, it is necessary to harmonize genotyping techniques to 
be used in Coxiella epidemiological studies, so that results can be exchanged and 
readily comparable among different laboratories using a common website for timely 
identification of new or emerging genotypes.
In summary, we have demonstrated that both MST and the different MLVA panels are 
suitable for molecular characterization of C. burnetii directly in clinical samples without 
specific biosafety handling. MLVA-6 offers an easy to use and clearly distinguishable 
genotyping method for epidemiological studies and to understand the distribution 
of genotypes present in a region. However, depending on the organization of the 
laboratory, preference may be given to sequence analysis.
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Abstract
 In the Netherlands, there is an ongoing and unparalleled outbreak of Q fever. 
Rapid and reliable methods to identify patients infected with Coxiella burnetii, the 
causative agent of Q fever, are urgently needed. We evaluated the performance of 
different DNA extraction methods and real-time PCR assays that are in use in seven 
diagnostic or reference laboratories in the Netherlands. A low degree of variation in the 
sensitivities of most of the developed real-time PCR assays was observed. However, PCR 
assays amplifying short DNA fragments yielded better results than those producing large 
DNA fragments. With regard to DNA extraction, the automated MagNA Pure Compact 
system and the manual QIAamp DNA mini kit consistently yielded better results than 
either the MagNA Pure LC system and NucliSens EasyMag (both automated) or the 
High Pure viral nucleic acid kit (manual).
The present study shows that multiple combinations of DNA extraction kits and real-
time PCR assays offer equivalent solutions to detect C. burnetii DNA in serum samples 
from patients suspected to have Q fever.
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Introduction
 Q fever is a worldwide zoonosis caused by Coxiella burnetii, an obligate 
intracellular bacterium 11. Whereas animals such as sheep and goats are generally 
asymptomatic carriers, infection with C. burnetii in these animals may become manifest 
by abortion. Although asymptomatic in ~60% of infected persons, C. burnetii can cause 
serious illness in humans. Q fever can cause acute or chronic infection depending on 
the patient’s condition or immune status. Acute Q fever may present as a self-limiting 
flu-like atypical pneumonia accompanied by severe headache and sometimes hepatitis. 
Approximately 5% of all Q fever cases may progress in a chronic infection leading to 
life-threatening endocarditis 1, 3, 5, 7-9. C. burnetii is highly infectious and can survive for 
long periods in the environment. Human outbreaks have been associated with farms, 
slaughterhouses, and wind dispersion from farms where infected animals were kept. 
Ticks and pets, including cats and dogs, have also been demonstrated to be potential 
sources of Q fever 1, 4, 10. Laboratory diagnosis of Q fever is usually performed by 
serological methods such as the indirect immunofluorescence assay (IFA), complement 
fixation test (CFT), or enzymelinked immunosorbent assay (ELISA), but these tests 
are of limited use in the early phase of the disease, as it may take up to 2 weeks for a 
detectable immune response to develop. Several PCR-based diagnostic methods, such 
as conventional PCR, nested PCR, or real-time PCR, have successfully been applied for 
the direct detection of C. burnetii DNA in clinical samples. The sequences targeted by 
these tests varied from plasmids (QpH1 or QpRS) to chromosomal genes, such as the 
isocitrate dehydrogenase gene (NADP) or the transposase gene of the C. burnetii IS1111a 
insertion element 3, 4, 14-16. The multicopy IS1111a insertion element is present in 20 copies 
in the genome of the C. burnetii Nine Mile RSA493 strain. Copy numbers per isolate 
vary and can reach up to ~100 copies per genome 7. Due to the multicopy nature of this 
DNA element, it provides a highly sensitive target for detection of C. burnetii DNA 
in serum samples. Furthermore, real-time PCR can be useful for diagnosis of chronic 
Q fever, since in these patients C. burnetii DNA can be detected in serum over long 
periods of time 3.
In the Netherlands, as of 2007, there is an unprecedented and ongoing outbreak of Q 
fever 12, 17. At present, more than 3,000 cases have been reported in the Netherlands. 
In order to improve diagnosis for Q fever, medical microbiology laboratories have 
implemented molecular methods to close the diagnostic gap between onset of the 
disease and the presence of specific antibodies in serum. The aim of this study was to 
compare the performances of different DNA extraction methods and real-time PCR 
assays, all targeting the C. burnetii IS1111a insertion element, that are being used in 
seven diagnostic or public health laboratories in the Netherlands.
Materials and methods
 Study design. The study was set up to separately assess the performances of the 
DNA extraction methods and of the real-time PCR assays. The analytical sensitivities 
of the different PCR methods were determined using a dilution series of genomic DNA 
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extracted from the Nine Mile strain (RSA493). The concentration of the DNA was 
determined by UV measurements and adjusted to approximately 50 fg/µl. Three-fold 
serial dilutions (nine steps) were prepared in duplicate. Each DNA sample was tested 
in duplicate, and thus four PCR results were obtained per sample. Based on a genome 
size of 2 Mbp and the presence of 20 IS1111a copies per Nine Mile genome, the starting 
dilution (9-fold) contains approximately 50 target copies/µl DNA. The samples were 
blinded. All laboratories used a fixed amount of 5 µl DNA in their PCRs according 
the procedure of each individual laboratory (Table 1). Furthermore, all laboratories 
received three serum samples to compare the relative efficiencies of the different DNA 
extraction methods. Two Q fever positive clinical samples were actual clinical samples 
from patients suffering from acute Q fever. The clinical samples were qualified based on 
the threshold cycle (CT) value that was obtained during initial screening of the samples. 
Sample A represents a strong positive sample, and sample B is on the lower end of the 
normal range for positive samples and repeatedly tested positive. The third sample (C) 
was a negative control.
All samples were provided in duplicate and blinded such that the person handling 
the samples had no prior knowledge of the contents. According to the protocol, each 
laboratory was instructed to isolate DNA from 200 µl of each serum sample, using 
their routine DNA extraction method. Details of the DNA extraction procedures and 
amplification protocols are described in Table 1. DNA was eluted in 100 µl of elution 
buffer, supplemented with 5 µl of bovine serum albumin (New England Biolabs, Ipswich, 
MA) to a final concentration of 0.1 mg/ml, and stored at -20°C until further use. All DNA 
samples were subsequently collected by a central laboratory and redistributed among 
the participating laboratories for PCR analysis. Each real-time PCR mixture contained 
5 µl of DNA extract. PCR analysis of each DNA extract was performed in duplicate, and 
thus four PCR results were obtained per original sample. The locations of the primers 
and probe combinations used by the participating laboratories are shown in Fig. 1 and 
described in Table 2.
All samples were shipped on dry ice using an overnight delivery service. Laboratories 
were instructed to keep the samples frozen until they were processed. 
Figure 1. Location of amplicon with PCR primers and probes from each laboratory (A to G) on 
the IS1111a insertion element.
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Results
 In the first experiment, the analytical sensitivities of the different real-time 
PCR procedures were evaluated using nine samples of 3-fold serial dilutions of DNA 
extracted from the Nine Mile strain (RSA493). From each DNA dilution, four PCR 
results were obtained per laboratory. A minimum difference in PCR assay sensitivity 
was observed between the laboratories when evaluated on a dilution series of genomic 
DNA (Table 3). 
Table 3. Number of positive PCRs using a 3-fold serial dilution series of Nine Mile 
DNA tested with four replicates per laboratory (A-G).
Dilution 
(fold)
Approximate copy nr. per 
DNA sample (5 µl) A B C D E F G
9 250 4 4 4 4 4 4 4
27 83 4 4 4 4 4 4 4
81 28 4 4 2 4 3 4 1
243        9.3 2 1 3 2 2 2 1
729        3.1 3 1 0 0 0 1 0
2,187        1.0 1 0 1 0 0 1 1
6,561         0.34 0 1 0 0 1 0 0
19,683         0.11 0 0 0 0 0 0 0
59,049         0.04 0 0 0 0 0 0 0
All laboratories were able to demonstrate the presence of C. burnetii DNA in four out of 
four replicates in the first two dilutions. Five laboratories were able to demonstrate the 
presence of C. burnetii DNA in at least two out of four replicates in the fourth dilution 
step. One laboratory was able to demonstrate the presence of C. burnetii DNA in three 
out of four replicates in the fifth dilution step. Incidentally, a single positive PCR result 
was obtained with some of the higher DNA dilutions, while a lower dilution remained 
PCR negative. We believe that this is the result of the stochastic distribution of the 
DNA molecules over these high dilutions.
By the design of the study, we were able to assess the relative efficiencies of the DNA 
extraction methods that were used as well as the sensitivities of the PCR assays being 
used. These were evaluated with clinical samples from Q fever patients. The results are 
shown in Table 4. For sample A, the percentages of positive PCRs were similar, indicating 
that all extraction methods performed equally well on this sample (71 to 89%). All but 
one of the laboratories were able to produce at least three out of four positive PCR 
results. With one exception, a positive PCR result was obtained in 89 to 97% of samples 
across all DNA extraction methods. More variation in the results was seen with sample 
140
Chapter 10
B. Depending on the DNA extraction method used, a positive PCR result was obtained 
in 25 to 64% across all real-time PCR assays. A positive PCR result was obtained in 3 to 
78% of samples across all DNA extraction methods. Apparently, the sensitivity of one 
of the PCR assays was much lower for both samples on DNA extracted from clinical 
samples than those of the other assays (laboratory G). The PCR assay that was used 
by laboratories C and D showed the highest overall sensitivity on DNA extracted from 
serum. With one exception (laboratory G), none of the laboratories obtained a positive 
PCR result on the negative control sample (sample C) (data not shown).
All PCR primers and probes were designed using various primer and probe design 
programs targeting the DNA sequence of the IS1111a insertion element from the 
genome of the Nine Mile strain RSA493 (GenBank accession number AE016828). More 
recently, the genomic sequences of four additional C. burnetii strains, i.e., Dugway 
(accession number CP000733), RSA331 (CP000890), CbuG Q212 (CP001019), and Cbuk 
Q154 (CP001020), have become available from the National Center for Biotechnology 
Information (NCBI) nucleotide database (http://www.ncbi.nlm.nih.gov). The insertion 
elements of these strains may contain polymorphisms that have not been taken into 
account in development of the PCR primers and probes. Since any mismatch between 
the primer or probe sequence and the target sequence may lead to less efficient or less 
sensitive PCR assays, the suitability of the developed primers and probes was reassessed 
in silico using these additionally available genomic sequences. As it turns out, certain 
primer and probe combinations contain mismatches in the target sequences that may 
affect the performance of the PCR assays (Table 5).
Discussion
 Reliable detection of C. burnetii DNA in serum requires highly efficient 
DNA extraction procedures and sensitive PCR methods. In this study we compared 
the analytical procedures that were developed by diagnostic laboratories in the 
Netherlands to aid in identification of patients with Q fever. All PCR assays targeted the 
C. burnetii IS1111a element, a multicopy element that has been reported to be specific 
for Coxiella burnetii 2, 7, 16. By the design of this study, we were able to separately analyze 
the performance of the DNA extraction procedure and of the PCR assays. In this study, 
we used actual clinical serum samples containing different loads of C. burnetii(DNA) 
instead of serum samples that were spiked with highmolecular-weight genomic DNA 
from C. burnetii DNA to get a more representative measure of the efficiency of the 
DNA extraction methods used. Manual extraction procedures performed equally as 
well as some automated extraction platforms. Despite the fact that most commercial 
DNA extraction kits are based on the similar chemistries, the automated MagNA Pure 
Compact system and the manual QIAamp DNA mini kit consistently yielded better 
results than either the MagNA Pure LC system and the NucliSens EasyMag (both 
automated) or the High Pure viral nucleic acid kit (manual).
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Table 5. Numbers of IS1111a insertion elements with exact matches to the primer and probe 
sequences in the genomes of five different C. burnetii isolates.
Laboratory(ies) RSA 493 (20)
Dugway 
(12)
RSA 331 
(47)
CbuG Q212 
(28)
CbuK Q154 
(48)
A 20 12 43b 28 48
B 20 12 47 28 48
C, D 20 12 47 28 40e
E, F 20 0a 47 28 46f
G 20 12 46c 0d 8g
a This involves a single nucleotide mismatch at the 5_ end of the forward primer; b This involves 
various mismatches in both forward and reverse primers in 4 of the 47 copies of the IS1111a 
insertion element; c This involves six mismatches in the reverse primer in 1 of the 47 copies of the 
IS1111a insertion element; d This involves a single nucleotide mismatch at a central position of the 
28-base CbIS1111aFL probe; e This involves a single nucleotide mismatch at the second position of 
the forward primer in 8 of the 48 copies of the IS1111a insertion element; f This involves a single 
nucleotide mismatch and a double nucleotide mismatch in the reverse primer, both in 1 of the 48 
copies of the IS1111a insertion element; g This involves a single nucleotide mismatch at the 5’ end of 
the reverse primer in 29 of the 48 copies of the IS1111a insertion element and various mismatches 
in the reverse primers in another 10 of the 48 copies of the IS1111a insertion element.
Less variation was observed in the sensitivity of the different PCR assays, with one major 
exception: the PCR that was in use in laboratory G was much less sensitive than the 
other PCR assays. This PCR performed similarly to the other assays on a dilution series 
of high-molecular-weight genomic DNA from the Nine Mile strain but was less sensitive 
on DNA extracted from clinical samples. Unfortunately, insufficient material was left 
to confirm these findings. However, there appears to be a very plausible explanation 
for these results: the lack in sensitivity may possibly be explained by the significantly 
larger PCR product that is targeted by laboratory G (202 bp, versus 70 to 87 bp in the 
other laboratories). In general cell-free DNA in serum is very likely to be degraded to 
a certain extent. Therefore, short sequences are likely to represent better targets than 
larger sequences. The highest overall sensitivity on DNA extracted from serum was 
obtained by the PCR assay that was in use in laboratories C and D. Notably, although 
the differences from most other PCR assays were relatively small, this assay targeted the 
shortest DNA fragment (70 bp). Another explanation for this difference may reside in 
sequence polymorphisms in the target sequences. All PCR assays were developed using 
the IS1111a sequence from the Nine Mile RSA493 strain. Analysis of IS1111a sequences 
from various other C. burnetii genomes shows the presence of multiple nucleotide 
polymorphisms that may affect PCR performance. Certain PCR amplification primers 
or detection probes do not match the target sequences of certain genomes equally well 
(Table 5). Depending on the location of the present mismatch(es), this may have had 
a detrimental effect on the performance of the PCR, especially for those near the 3’ 
end of the primers or near the 5’ end of a hydrolysis probe. It has been shown that C. 
burnetii genotypes from the Netherlands display a considerable degree of homogeneity, 
indicating a clonal origin 6. Therefore, DNA sequence polymorphisms in the IS1111a 
elements in this Dutch clone may also affect the different PCR assays studied here and 
may also explain the poor performance of the PCR used by laboratory G. Whether or 
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not this is a likely explanation remains to be established. Obviously, in samples with a 
very low target concentration, sampling variation may explain part of the heterogeneity 
seen in the results from the dilution series of genomic DNA from the Nine Mile strain 
(Table 3). For the evaluation of the performance of the DNA extraction methods, all 
participating laboratories analyzed all of the extracted DNA samples, and any effect of 
sampling variation on the interpretation of the results would be minimized. Two different 
real-time PCR platforms were used by the participating laboratories (LightCycler 480 or 
ABI Prism 7500). Although this could have contributed to differences in sensitivities for 
the various assays, in the context of the results presented in Table 3 and the alternative 
explanations for the lower sensitivity of the assay used by laboratory G, this appears 
unlikely to be a contributing factor.
In conclusion, we show that multiple combinations of DNA extraction kits and real-
time PCR assays offer equivalent solutions for the screening of patients suspected to 
have Q fever.
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Abstract
 Contamination of an in-house diagnostic real-time PCR for Q fever was traced 
back to a commercially obtained PCR Master Mix. It was established that this Master 
Mix contained DNA from Coxiella burnetii, probably as a result of the use of compounds 
of animal origin such as bovine serum albumin.
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Introduction
 As of 2007 and up to the present time, there has been a large ongoing outbreak 
of Q fever in the Netherlands that is unprecedented both in the number of affected 
individuals and in its duration 5. Real-time PCR has rapidly been implemented in many 
diagnostic laboratories in the Netherlands as a first-line diagnostic test to identify 
patients infected with Coxiella burnetii in the acute phase of the disease. In a recent 
Interlaboratory study, it has been shown that multiple PCR approaches based on 
different combinations of extraction procedures, amplification primers and probes, 
PCR Master Mixes, and real-time PCR platforms offer equivalent solutions to screening 
for Q fever 6. In the spring of 2009, the medical microbiology laboratory of the Canisius 
Wilhelmina Hospital (CWZ) was suddenly confronted with positive PCR results in a 
no-template control (NTC), indicating contamination of the diagnostic pathway.
Methods and results
 Analysis of multiple NTCs showed that 10 to 30% yielded a positive PCR 
result with threshold cycle values such as those found in many clinical samples. The 
laboratory enforces strict precautionary measures to avoid amplicon or DNA carryover 
during the entire diagnostic process. Since the contamination coincided with the 
first use of a new batch of PCR primers and probe, it was suspected that one of these 
was contaminated off synthesis. A newly ordered batch of primers and probe did not 
alleviate the problem. Around the same time, the medical microbiology laboratory 
of the Radboud University Nijmegen Medical Center (RUNMC) experienced similar 
problems, with important clinical consequences. A patient with a history of a Ross 
procedure was admitted with fever and probable endocarditis with gradual degradation 
of the aortic homograft and deterioration of cardiac function despite broad-spectrum 
antibiotics. All blood cultures were negative, and additional serological tests for 
culture-negative endocarditis (including Q fever) were performed. During this time, 
hemodynamic problems occurred and a second cardiac surgery was necessary. The day 
before surgery, the Q-fever PCR was positive but serological tests (complement fixation 
test and IgM antibodies) were negative, making chronic Q fever unlikely. It was decided 
to postpone the cardiac surgery and to repeat the PCR in another laboratory. This PCR 
was negative, confirming the suspicion of a false-positive PCR result. Fortunately, no 
serious hemodynamic problems occurred during the time while the operation was 
deferred. According to protocol and good laboratory practice, numerous measures were 
undertaken to eliminate any potential source of contamination, but without success.
The laboratories of the CWZ and RUNMC used different PCR primers and probes 
targeting a different part of the C. burnetii specific IS1111a element, but both used the 
same commercially available PCR Master Mix. The presence of C. burnetii DNA in this 
Master Mix was then suspected. This could very well be the result of the presence of 
compounds of animal origin (such as bovine serum albumin [BSA]) that are commonly 
used in PCR assays. Since many farm animals can be carriers of C. burnetii 1, 4, addition 
of BSA originating from such animals may explain the contamination of the Master 
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Mix with C. burnetii DNA. An unopened vial of this Master Mix was sent to the St. 
Antonius Hospital in Nieuwegein (a laboratory that routinely uses a different Master 
Mix; uses another, nonoverlapping, DNA target in its Q fever PCR; and had experienced 
no contamination issues). This again led to ~30% positive PCR results with NTCs, 
confirming the presence of C. burnetii DNA in the Master Mix. These findings were 
communicated to the manufacturer of the Master Mix, who initiated their own research 
and later confirmed the contamination of the Master Mix with DNA from C. burnetii. 
The manufacturer also notified users of the product of this contamination issue.
Discussion
 With the application of molecular techniques to detect microbial DNA 
in clinical samples, it has become apparent that there are many caveats at multiple 
stages in the diagnostic process that may lead to false-positive PCR results. Not only 
PCR enzymes may be contaminated with bacterial DNA 2 but in the DNA extraction 
procedures, reagents and disposables (such as spin columns) may also expose clinical 
samples to exogenous DNA 3.
We report here the contamination of a commercially available PCR Master Mix with DNA 
from C. burnetii. This problem is probably related to the use of compounds of animal 
origin. Use of such compounds in PCR Master Mixes requires additional measures to 
ensure the absence of contaminating DNA. Problems similar to that reported here 
may be possible with other microorganisms that may be asymptomatically present in 
animals, such as Campylobacter, Brucella, Listeria, Mycobacterium, and Toxoplasma. It 
is highly unlikely that the problem described here is restricted to a single manufacturer 
of PCR Master Mixes. These findings highlight the requirement for extensive controls 
at multiple levels in PCR-based procedures to validate their use with clinical samples.
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Abstract
 By performing genotyping, a laboratory contamination involving Q fever was 
traced back to the antigen preparation used in a commercially available complement 
fixation test. It was established that such antigen preparations contain relatively 
high loads of DNA/RNA, making them potential sources of contamination but also 
convenient preparations for control material.
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Introduction
 Q fever is a zoonosis caused by the ubiquitous pathogen Coxiella burnetii 1. 
Laboratory diagnosis of Q fever is classically performed by serological methods, such as 
the complement fixation test (CFT) or immunofluorescence assay (IFA) 2. In addition, 
real-time PCR-based methods are increasingly being used to overcome the diagnostic 
gap in the acute phase of the disease when a serological response is still absent 4. 
Multiple-locus variable number tandem-repeat analysis (MLVA) was used to study the 
distribution of C. burnetii genotypes of an ongoing Dutch Q fever outbreak 3. In five 
serum samples analyzed from one of the diagnostic laboratories, a completely different 
genotypic group was found. This suggests that the ongoing outbreak has a multifocal 
origin. However, this genotype was identical to that of the C. burnetii Nine Mile 
strain (RSA493), a genotype that has never been observed before in the Netherlands. 
Moreover, these samples had relatively high DNA loads as determined by a real-time 
PCR targeting the C. burnetii-specific IS1111a element 5, and these were among the 
highest values observed. We therefore suspected that these five serum samples had 
somehow been contaminated with Nine Mile DNA.
Methods and results
 In the involved laboratory, diagnosis of Q fever is performed by a CFT by using 
commercially available antigen preparations (Institut Virion/Serion GmbH, Würzburg, 
Germany) and by real-time PCR. According to the kit insert, these antigen preparations 
contain “antigens isolated from infected cells.” We expected that one of the components 
of the CFT kit might also contain DNA from the C. burnetii Nine Mile strain.DNA was 
extracted from the control antigen preparations in this kit and analyzed by real-time 
PCR and MLVA genotyping. A very low threshold cycle (CT) value (14.4) confirmed 
the presence of very high DNA loads in the antigen preparation. MLVA genotyping 
confirmed the identity of the Nine Mile strain. Our results confirm the commercial 
antigen preparation as the source of contamination of the serum samples. Lack of a 
serological response after 8 weeks of follow-up in the involved five patients confirmed 
that the original positive PCR results were indeed most likely the result of a laboratory 
contamination. Moreover, in another 11 samples, a possible false-positive PCR result 
was generated, as no serological response was found in these patients either. Although 
the lack of a serological response might also be explained by other factors, a laboratory 
contamination could not be excluded for these samples. However, it could not be 
confirmed since these other samples contained insufficient DNA to allow genotyping.
Discussion
 The most likely way in which contamination might have taken place is by 
the formation of aerosols. The CFT procedure includes incubation and subsequent 
centrifugation of 96-well plates that are sealed but perforated. These steps were 
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performed close to the workstation where patient sera are added to the plates. Standard 
laboratory guidelines recommended for the prevention of nucleic acid contamination 
in molecular testing procedures are operational in the laboratory, but these do not 
consider the presence of large amounts of DNA in commercial antigen preparations. 
Samples that appeared to be contaminated had been present in the room where the CFT 
was performed before they were transferred to the molecular facilities. This diagnostic 
workflow was not because of logistic problems but mostly because a PCR was requested 
as an additional diagnostic test in the same sample after the results of the CFT had 
become available. This part of the workflow has now been adapted to avoid similar 
future contamination problems. If a PCR test is requested after the blood sample has 
been in the CFT room, a new blood sample is requested and both the original and new 
blood sample are tested. If only the original sample is positive, a definitive test result is 
given only after the infection has been confirmed by serological methods.
Table 1. Relative DNA/RNA loads of several commercially available antigen preparations as 
determined by target specific (reverse transcription) real-time PCR.
Target                            CT value
Adenovirus 21.1
Echovirus 34.5
Coxsackie B virus 23.7
Herpes simplex virus 1 25.4
Herpes simplex virus 2 24.8
Influenza A virus 31.8
Influenza B virus 32.5
Mycoplasma pneumoniae 37.3
Parainfluenza 1 virus Negative
Parainfluenza 2 virus 29.1
Parainfluenza 3 virus Negative
Coxiella burnetii 14.4
Coxiella burnetii phase1 24.9
Respiratory syncytial virus 25.5
Varicella-zoster virus 21.4
To demonstrate that problems similar to those reported here may be realistic with 
other microorganisms, we also checked several other commercially available antigen 
preparations from the same supplier for the presence of target-specific nucleic acids. 
The results show that almost all tested antigen preparations still contain considerable 
amounts of target nucleic acids (either DNA or RNA) (Table 1). The presence of such 
large DNA or RNA quantities in these antigen preparations poses a serious risk for 
laboratory contamination. On the other hand, the unexpected advantage of our findings 
is that such preparations can be used as convenient control material for molecular 
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diagnostic test procedures. The high loads of target nucleic acid in commercially 
available antigen preparations indicate that molecular diagnostic methods should be 
performed in a location physically separated from where serological methods are being 
used. In addition, it should preferably be performed on an aliquot of a sample that has 
not already been used for serological testing.
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The Dutch Q fever outbreak
 The Q fever outbreak in humans in the Netherlands attracted attention due 
to its magnitude and duration and is referred to as the largest outbreak of Q fever ever 
reported in literature. The total number of Q fever cases increased from 11 annual cases 
between 1997-2006 to 4,176 human cases and 25 notified deaths related to Q fever from 
2007-2012 1. Q fever was present in the Netherlands long before it became a problem in 
public health and animal husbandry (chapter 2). In this period, Q fever appeared to 
be neither a major health problem for humans, or for domestic animals. This situation, 
with high seroprevalence in animal populations but few human cases, exists in most 
European countries. In the years 2005 and 2006, Q fever became a problem in the 
dairy goat and dairy sheep industry. Several factors could have facilitated a change in 
epidemiology in goats: first, an increase in goat density in the highly populated province 
of Noord-Brabant (497 inhabitants / km2) and second, extension of the farms over the 
years. These two factors could have affected in-herd and between-herd dynamics of 
Q fever, resulting in outbreaks. Third, there could be pathogen-related factors with 
circulation of a highly virulent C. burnetii strain. The clinical outcome of the C. burnetii 
strain in the Dutch human population appears to be different compared to Q fever 
cases abroad. In the year 2007 and 2008 it became clear that Q fever posed a problem 
to public health (chapter 2). 
Several research projects in the Netherlands focussed on identification of risk factors 
for Q fever, non-human reservoirs, transmission routes for Coxiella burnetii in humans 
and animals, evaluation of intervention measures, long-term effect, host response 
and efficacy of treatment strategies. The aim of the study described in this thesis was 
to investigate the C. burnetii genotypes in ruminants and humans in collaboration 
with nationally and internationally research laboratories (part 1). Furthermore, the 
molecular detection of C. burnetii in serum samples was compared and possible caveats 
in the diagnostic pathway are highlighted (part 2).
Part 1 Genotypic diversity of Coxiella burnetii in ruminants 
and humans
 The connection between Q fever problems in the dairy goat and dairy sheep 
industry and in the human population was made by several authors solely based on 
epidemiological findings 2-6. Molecular characterization by genotyping however, is 
a prerequisite for surveillance purposes and for epidemiological investigations of 
outbreaks. This information is necessary to evaluate the epidemiological link between 
the source of the outbreak and human cases. With this information effective outbreak 
control measurements can be taken and the genotype can be compared to internationally 
known genotypes.
The genetic background of C. burnetii in domestic ruminants responsible for the 
human Q fever outbreak was determined in chapter 3. In total, 126 C. burnetii positive 
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samples from ruminants were typed by an updated 10-locus multi-locus variable 
number tandem-repeat analyses (MLVA) panel. One predominant genotype was found 
on all 11 dairy goat farms in the human Q fever outbreak area in the southern part of 
the Netherlands and on a farm in the eastern part of the country. This predominant C. 
burnetii genotype is expected to have played a key role in the Q fever outbreak in small 
ruminants in the Netherlands and strongly suggests a clonal spread of C. burnetii over 
the dairy goat farms in the south-eastern part of the Netherlands. The clonal spread 
of one genotype of C. burnetii could be explained by 2 phenomena. First, the dairy 
goat industry in the Netherlands sharply increased from almost 100,000 dairy goats in 
2000 to >230,000 dairy goats on ~350 farms in 2009 7. Most of these goats were bred in 
the Netherlands, which probably resulted in a microbial relationship between many of 
the dairy goat herds. Second, clonal spread could have been facilitated by emergence 
of a genotype of C. burnetii causing abortion in dairy goats that could then spread 
successfully over the dense goat population in the south-eastern part of the country. 
Several factors such as little vegetation in combination with deep groundwater could 
have contributed to the transmission of C. burnetii contaminated dust from infected 
farms to the human population 8.
The link between animal and human Q fever cases was investigated by an improved 
6-locus MLVA panel. Chapter 4, describes the temporal and spatial genotypic diversity 
of C. burnetii in Q fever positive human clinical samples collected during the 2007 – 
2010 Q fever outbreak episodes from the entire affected part of the Netherlands. Thirty-
three clinical samples covering both acute Q fever patients (e.g. sputa, bronchoalveolar 
[BAL] fluid, throat swabs) as well as chronic Q fever patients (e.g. heart valves, aorta 
tissue) and 20 additional goat placentas from 3 different locations in the outbreak area 
were included in the study. Closely related MLVA genotypes representing microvariants 
of one founder genotype were found at several locations spread across the entire 
affected area during the Q fever outbreak years of 2007 – 2010, indicating a clonal 
spread of C. burnetii across the Netherlands, as observed before in goats (chapter 
3). One predominant genotype was found in human and animal clinical samples, 
illustrating the genotypic identity between C. burnetii from humans and goats 9. The 
results are consistent with a scenario where one MLVA genotype was introduced in the 
dairy animal population where it is gradually diversifying over time whilst spreading 
over the country and being transmitted to humans.
MLVA, being based on relatively unstable repetitive DNA elements, is sometimes 
criticized for producing results that are too discriminatory or difficult to reproduce in 
different settings 10. Because of their instability, use of tandem repeats as genotyping 
targets can lead to problems with data interpretation, and to an overestimation of 
genotypic diversity, by showing small variations in MLVA genotypes in isolates of 
otherwise identical background. Therefore the correlation between human and animal 
Q fever cases was further investigated by multispacer sequence typing (MST) 11 in 
cooperation with researchers from France (chapter 5). The correlation of the Dutch 
genotypes to genotypes from abroad were determined by an internationally MST 
database. Genotype MST33 was identified in clinical samples from humans, goats and 
sheep, confirming the previous observations by MLVA (chapter 3 and 4) 9, 12. MST 
genotype 20 was identified in samples from Dutch cattle, one goat and cow’s milk. 
Interestingly, the Dutch outbreak genotype (MST33) has been found before incidentally 
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in human clinical samples obtained from France isolated in 1996 and 1999 and from 
an ewe’s placenta from Germany isolated in 1992. This genotype MST33 belongs to a 
genogroup that has previously been associated to QpH1 plasmid, found in both acute 
and chronic infections 11, comparable to what has been observed in the Netherlands 
(chapter 4). Genotype MST20 is also related to QpH1 plasmid, but has been isolated 
only in chronic Q fever patients including one human placenta in France between 
1994 and 2000 11. This implicates an association between certain genotypes and clinical 
outcome. The study described in chapter 5 shows moreover that the increase in the 
number of diagnosed Q fever cases in the Netherlands among humans since 2007 is 
the likely result of the presence of MST33 in the Dutch animal goat population and may 
have been facilitated by intensive goat farming in the affected area and its proximity 
to the human population. This study also indicates that the current outbreak situation 
among humans is not linked to the presence of C. burnetii in cattle, although the 
infection is widespread among Dutch diary herds 13, exemplifying that most outbreaks 
are related to goats/sheep rather than to cattle.
In addition to its presence among ruminants, cattle can shed C. burnetii in milk, even 
in asymptomatic herds 14-20. Although consumption of raw or insufficiently pasteurized 
milk is very rarely identified as a source of Q fever infection, asymptomatic cattle herds 
can be considered potential C. burnetii reservoirs capable of transmitting the disease 
to humans. In chapter 6, the prevalence and genotypes of C. burnetii in consumer 
milk products was investigated by real-time PCR 21 and a MLVA-6 panel 12. The study 
included commercially available semi-skimmed milk samples from cows (obtained 
from large supermarket chains) and milk products such as coffee creamer obtained 
throughout Europe and from an additional 10 non-European countries. Samples were 
collected from different brands and produced by the local dairy industry. Eighty-eight 
out of 116 (76 %) milk samples or milk products from 28 countries contained significant 
amounts of C. burnetii DNA, indicating a high prevalence of C. burnetii among the 
dairy cattle population worldwide. The presence of highly similar C. burnetii genotypes 
in consumer milk products indicates a widespread dissemination of a specific cattle-
adapted strain. Alternatively, this genotype may have been introduced into different 
countries by transport of asymptomatic C. burnetii positive cattle, as well by export of 
milk (-products) from a restricted number of countries to other countries. These MLVA 
genotypes differ from the genotypes identified in human, ovine and caprine clinical 
samples from the Q fever outbreak in the Netherlands (chapter 3 and chapter 4). The 
study demonstrated a possible clonal spread of C. burnetii among the European dairy 
cattle population. Since, the involved genotype is only incidentally found in humans 
(placenta and heart valve) from France, the risk of obtaining Q fever via exposure to 
infected cattle may be much lower than via exposure to infected small ruminants. 
Most Q fever cases are correlated to infection via aerosols rather than to ingestion of 
contaminated raw milk. Hepatitis correlated to Q fever was only incidentally reported 
during the Q fever outbreak episodes in the Netherlands.
Recently, two different studies were performed to identify possible additional sources 
of human Q fever in the Netherlands 22, 23. In one study, placentas from cats, dogs, 
horses, sheep, goats, pigs and cattle were collected from different veterinary practices 
in the north and south of the Netherlands and tested by real-time PCR and genotyping 
(MLVA and MST) 22. The other study involved free living wildlife, roe deer (Capreolus 
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capreolus) 23. Although C. burnetii DNA was present in placentas from dogs and horses, 
the amount of DNA was too low to be suitable for typing. Dogs and horses however, can 
serve as possible reservoirs for C. burnetii. Different MLVA patterns were identified in roe 
deer compared to human, goats and sheep 9, 12. Furthermore, all but one of the placentas 
from cattle revealed the same cattle specific genotype, indicating the circulation of a 
cattle specific genotype of C. burnetii as described in chapter 5 and 6 24, 25. One out 
of 33 placentas from cattle however, revealed a similar genotype as found earlier in 
goats and humans (chapter 3 and 4). This observation implicates that cattle may be a 
reservoir of the epidemic genotype, an aspects that requires further investigation. So 
far, no indication could be found for a spill over of this epidemic genotype from goats 
to cattle during the Q fever outbreak in the Netherlands.
The connection between the increase in human Q fever cases and abortion among 
goats was made solely based on epidemiological findings 2-6. Control measures in the 
veterinary field (vaccination and culling) were therefore restricted to goat herds. The 
dairy cattle population in the Netherlands is larger compared to goats and although 
excretion patterns between these species differ, an introduction of a more virulent 
genotype in the cattle population could increase the incidence of Q fever among cattle. 
Consequently, this may have an effect on future outcomes and could have a higher 
economic impact. This however, is pure speculative and needs further investigation. 
Ongoing molecular characterization of C. burnetii in cattle is therefore important not 
only for surveillance purposes, but also for epidemiological investigation to prevent 
spreading throughout the Dutch cattle population. Livestock screening in Belgium 
Limburg revealed a seroprevalence in 42 % of tested cattle farms and Coxiella was 
found in 17 % of 129 reported cattle abortions 26. In contrast, no C. burnetii was found 
in four goat and three sheep abortions and analysis of bulk tank milk showed evidence 
for C. burnetii only on 1 out of 9 goat farms. These data indicate a high prevalence of 
C. burnetii among cattle in Belgium, comparable to the Netherlands. Acute Q fever 
among humans in Belgium was found by PCR in three patients (3 %) living close to 
the Dutch border. The authors suggest that the high prevalence of C. burnetii among 
cattle have resulted in human Q fever infection. This however, is pure speculative, 
since no evidence of genotypic resemblance between human and cattle isolates was 
presented 26. A more plausible explanation however, would be infection caused by the 
Dutch predominant genotype; all three patients lived in the border region with the 
Netherlands. This case shows more over that molecular characterization by genotyping 
should be performed in case of epidemiological investigation.
Molecular investigation in cooperation with internationally research groups is 
important to understand the European context of Q fever epidemiology (chapter 
7 and 8). Chapter 7 describes the genotypic diversity of C. burnetii in 10 confirmed 
acute and 3 confirmed chronic Q fever patients and ruminants (goat and sheep) 
from Portugal determined by MLVA 12 and MST 11 in cooperation with researchers 
from Portugal. A genotypic diversity of C. burnetii consistent with a non-outbreak 
situation was identified. The study showed the involvement of distinct genotypes in 
acute and chronic Q fever cases in Portugal which has been described before in other 
Mediterranean countries 11. Genotyping revealed an association between the C. burnetii 
genotype found in goats from the Central Eastern region of the country and a chronic 
Q fever patient. This genotype correlates to QpH1 plasmid associated to acute and 
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chronic infections 11. In two other chronic Q fever patients a genotype was obtained 
correlated to QpRS plasmid, found almost exclusively in chronic infections. Both 
genotypes had been previously identified in France and Spain associated to sheep, goats 
and human infection, including chronic cases. The genotypes from Portuguese acute 
Q fever patients were only described before in humans from France and Spain, and 
are associated mainly with QpDV plasmid, correlated to acute infections 11. This report 
shows a genotypic diversity among C. burnetii strains from Portugal and an association 
between certain genotypes and clinical outcome.
The genetic background of C. burnetii from domestic ruminants in Northern Spain 
is described in chapter 8. MLVA typing revealed a substantial diversity among C. 
burnetii from domestic ruminants in Northern Spain. Three different clusters of MLVA 
genotypes were identified from goat farms, cattle herds and sheep flocks. The genotypes 
described in this study had been found before in human and animal clinical samples 
from France Germany, Greece, Italy, Romania, Slovakia, Spain and USA and in cow’s 
milk from France, the Netherlands, Portugal and Switzerland. The obtained results 
illustrate a wide dissemination of the described genotypes throughout Europe. None of 
the MLVA profiles found were similar to the profiles identified in the Q fever outbreak 
episodes in the Netherlands (chapter 4).  Interestingly, variations in genotypes were 
observed throughout consecutive reproductive seasons in some sheep farms. Typing 
data provided important epidemiological information about the sources of infection, 
and explained previous observations when C. burnetii appeared in environmental 
surfaces while no animal shedders were present in the sheep flocks 27. The presence of 
one C. burnetii genotype among cattle in Spain indicate a widespread dissemination of 
a specific cattle adapted strain, as shown before in chapter 6 and by Roest et al 22.
Molecular methods are used to characterize strains and to determine relationships 
between isolates causing disease 9, 11, 12, 24, 25, 28, 29. In the case of Q fever, MLVA and MST 
techniques have been incorporated for genotyping of C. burnetii strains (chapter 3 to 
8). Both techniques can be performed directly on clinical and environmental samples 
without previous cultivation of bacteria and can be performed even in laboratories 
without specific biosafety level 3 facilities 30. Most of the other C. burnetii typing 
methods however, are based on cultivation of the isolates prior to analyses creating a 
potential for generation of genotypic variation due to multiple sequential cell divisions 
31-36. Chapter 9 describes the evaluation of two concordant MLVA typing methods 
(chapter 3 and chapter 4) and MST (chapter 5) using a selection of the in-house Dutch 
MLVA database containing 64 different C. burnetii MLVA genotypes from 241 human, 
caprine, ovine and cattle clinical samples and cows milk from different European 
countries. In total 134 DNA samples from cultivated clinical and animal C. burnetii 
isolates and clinical samples were selected according to species, sample source and 
origin. The majority of the obtained MST genotypes could be sub typed into multiple 
different but closely related MLVA-6 and MLVA-10 genotypes, with differences in only 
one of the MLVA loci. The use of 4 additional loci by the MLVA-10 method did not 
result in a higher variety of genotypes. We demonstrate that both MST and the MLVA 
panels are suitable for genotypic characterization of C. burnetii directly in clinical 
samples without specific biosafety handling. MLVA-6 offers an easy to use and clearly 
distinguishable genotyping method for epidemiological studies and to understand the 
distribution of genotypes present in a region.
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In general good monitoring and surveillance systems are necessary to assess the real 
magnitude of Q fever. Genotyping of human and animal clinical samples using our 
improved MLVA-6 method in collaborating with nationally and internationally hospital 
and research laboratories would increase the MLVA database, which is important for 
understanding the epidemiology of Q fever worldwide. Q fever outbreaks can easily be 
missed in the human field as well in the veterinary field.
Part 2 Molecular detection of Coxiella burnetii in humans
 The reported prevalence of Q fever worldwide is increasing due to improved 
quality of diagnostic methods and true prevalence. Although there is a growing 
interest of physicians and epidemiologists focussing on the disease, the total number 
of infected humans can be under diagnosed or underreported due to asymptomatic 
cases and patients who did not visit general practitioners. Under these conditions, it 
is very difficult to evaluate the true incidence of Q fever, and it is highly likely that 
some epidemics have gone completely unnoticed. Hoek et al. estimated that the 3,522 
acute Q fever cases that were notified from 2007-2009 correspond to more than 44,000 
infections in the same period 37. So every notification of clinical Q fever represented 
more than 12 infections with C. burnetii.
The proportion of under-diagnosed and under-reported acute Q fever cases is likely 
to vary per region and is expected to be even higher in low-incidence areas. Thus, the 
reported incidence of Q fever depends on three distinct elements; (i) it depends on 
the true incidence of the disease including existence of epidemics; (ii) the reported 
incidence depends on sensitivity and specificity of the diagnostic tools used. The 
disadvantage of the commonly used serological methods, is that specific antibodies 
are absent in the early phases of the disease and therefore these methods alone are 
not suitable for routine diagnostics and early clinical treatment of Q fever. Real-time 
PCR specific for C. burnetii however, can contribute to the diagnosis of acute Q fever 
as a first-line screening in the acute phase of the disease and consequently close the 
diagnostic gap between onset of the disease and the presence of specific antibodies. The 
use of serological tests in combination with molecular methods (real-time PCR) allows 
a better assessment of the incidence of acute Q fever; (iii), the interest of clinicians and 
the awareness of the general public incontestably reinforce the quality of detection and 
the percentage of detected patients.
With monitoring systems more cases might be detected, but few data exist on large-
scale monitoring of Q fever in the human population. Schimmer et al. recently 
estimated a low seroprevalence of 2.4 % among humans in the period (February 2006 
– June 2007) before the start of the outbreak in the Netherlands 38. Sera were available 
from randomly selected municipalities throughout the Netherlands from the National 
Immunization Programme. The municipalities in the endemic Q fever area of 2007-
2010 however, were not included in the study. The question whether those areas were 
confronted with a newly emerging Q fever problem in the spring of 2007 remains 
therefore unanswered.
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Twenty-five notified deaths related to Q fever were reported between 2007-2012 1. 
Patients had often serious, often coinciding, underlying conditions including chronic 
cardiovascular disease, chronic lung disease, diabetes mellitus and malignancy. Also 
co-infection has been reported 39. The number of deaths related to Q fever can be 
underreported, due to unawareness of clinicians in the beginning of the outbreak. 
Acute Q fever could easily be overlooked due to mild symptoms or overlap with clinical 
symptoms with other febrile diseases, consequently no tests to diagnose Q fever were 
ordered 39, 40. PCR was not introduced in all laboratories before 2009 and therefore 
serology negative patients may have died from pneumonia or febrile disease caused by 
C. burnetii without the diagnosis by molecular methods. A retrospective PCR analysis 
on stored serum from patients in whom the diagnosis of acute Q fever had not been 
made by serology revealed the presence of C. burnetii DNA in 10 % of the cases 41. 
This indicates that molecular methods and serology together should be used for the 
diagnosis of Q fever.
The high numbers of under-diagnosed infections may also have an effect on the number 
of chronic Q fever cases in the years to come 37, 41. General practitioners and clinicians 
in endemic areas should be alert for chronic Q fever, even if no acute Q fever has been 
reported 42. Most acute Q fever cases may be unnoticed due to minor or no symptoms 
at all. Previous valvular surgery, vascular prosthesis, aneurysms, renal insufficiency, 
pre-existent cardiac valvulopathy, vascular grafts, immunosuppression and pregnancy 
are identified as major risk for the development of chronic Q fever 43, 44. Acute Q fever 
patients with these identified risk factors should be monitored thoroughly by serological 
follow-up or even prophylactic treatment in these high-risk groups is required 45-47. The 
diagnosis of chronic Q fever by serology alone however, can be a real challenge; (i) 
diagnosis is often made when significant valvular damage has already been occurred; 
(ii) in 2.5 to 31 % of all infective endocarditis cases, routine blood cultures  can be found 
negative; (iii) diagnosis of chronic Q fever can be made up to 10 years after the primary 
infection 45-48. Difficulties in interpretation of serology results also occur due to the lack 
of validated cut-off values 48. Real-time PCR can contribute to the diagnosis of chronic 
Q fever, especially among immunocompromised patients with atypical low phase 
I antibodies and clinically suspected chronic Q fever 43. This also illustrates that low 
phase I antibodies does not exclude chronic Q fever. The sensitivity of the PCR might 
be up to 100 % in chronic Q fever cases when performed on valve tissue compared 
to blood samples. An association between high phase I antibodies and real-time PCR 
positivity in serum has also been observed 43, 44.
Although serology is the main tool for the diagnosis of Q fever, molecular techniques 
have an added value to the diagnosis of acute Q fever and for the clinical follow-up. 
These techniques have now been implemented in the Dutch guideline on acute and 
chronic Q fever diagnostics. Chronic Q fever is a combined diagnosis based on C. 
burnetii diagnostics (PCR and IFA-phase I IgG antibodies), presence of risk factors, 
clinical symptoms and radiological findings 43, 44. Chronic Q fever is classified as (i) 
proven (positive PCR in tissue and/or blood in the absence of acute Q fever infection; 
or IFA-phase I IgG titer ≥ 1:1.024 and evidence of endocarditis according to the Duke 
criteria; or IFA-phase I IgG titer ≥ 1:1,024 and evidence of vascular infection with PET-
CT, CT and/or ultrasound), (ii) probable (IFA-phase I IgG titer ≥ 1:1,024 with valvular 
heart disease without Duke criteria, known aneurysm and/or vascular and cardiac valve 
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prosthesis without evidence of infection with TEE, PET-CT, CT and/or ultrasound; or 
suspected chronic Q fever, located in other regions, such as hepatitis; or osteomyelitis; 
or pregnancy; or clinical symptoms of chronic infection such as fever, weight loss, 
glomerulonephritis and night sweats; or proven granulomatous inflammation of tissues 
by pathological examination; or severe immune disorders) and (iii) possible (IFA IgG 
phase I titer ≥ 1:1,024 without (clinical) events, as described in categories proven and 
probable chronic Q fever). On the basis of prospective clinical data available from the 
national database chronic Q fever, the consensus can be adjusted 43, 44. With the expected 
increasing number of chronic infections the number of molecular and serological tests 
will increase with financial and logistic consequences 49.
Till 2007, Q fever was mainly diagnosed in the Netherlands by serological methods, 
such as: indirect immunofluorescence assay (IFA), complement fixation test (CFT), or 
enzymelinked immunosorbent assay (ELISA) 47, 48, 50. In order to improve the diagnosis 
for acute and chronic Q fever in the Netherlands, medical microbiology laboratories 
have implemented molecular methods. The study described in chapter 10 compares 
the performances of different DNA extraction methods and real-time PCR assays, 
all targeting the C. burnetii IS1111a insertion element, that are being used in seven 
diagnostic or public health laboratories in the Netherlands. The performance of the 
DNA extraction procedure and the PCR assays were separately analyzed using actual 
clinical serum samples containing different loads of C. burnetii (DNA) to get a more 
representative measure of the efficiency of the DNA extraction methods used. Multiple 
combinations of DNA extraction kits and real-time PCR assays showed equivalent 
solutions for screening of patients suspected to have Q fever.
With the application of these molecular techniques to detect microbial DNA in clinical 
samples, it has become apparent that there are many caveats at multiple stages in the 
diagnostic process that may lead to false-positive PCR results. Not only PCR enzymes 
may be contaminated with bacterial DNA but in the DNA extraction procedures, 
reagents and disposables (such as spin columns) may also expose clinical samples to 
exogenous DNA 51. A contamination of an in-house diagnostic real-time PCR for Q 
fever described in chapter 11, was traced back to a commercially obtained PCR Master 
Mix with important clinical consequences. This Master Mix contained DNA from 
Coxiella burnetii, probably as a result of the use of compounds of animal origin such as 
bovine serum albumin. These findings highlight the requirement for extensive controls 
at multiple levels in PCR-based procedures to validate their use with clinical samples.
Chapter 12 describes a laboratory contamination involving Q fever traced back to the 
antigen preparation used in a commercially available complement fixation test (CFT). 
Relatively high DNA loads were determined in Dutch serum samples by a real-time 
PCR targeting the C. burnetii-specific IS1111a element 21. MLVA 12  revealed a genotype 
in these serum samples and in the components of the CFT identical to that of the C. 
burnetii Nine Mile strain (RSA493), a genotype that has never been observed before in 
the Netherlands. We therefore suspected that these serum samples had somehow been 
contaminated with Nine Mile DNA. The most likely way in which contamination might 
have taken place is by the formation of aerosols during the CFT procedure. The high 
loads of target nucleic acid in commercially available antigen preparations indicate that 
molecular diagnostic methods should be performed in a location physically separated 
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from where serological methods are being used. In addition, it should preferably be 
performed on an aliquot of a sample that has not already been used for serological 
testing.
With the introduction of real-time PCR together with serology as a first line diagnostic 
tool, discrepancies between molecular and serological methods and clinical outcome 
have also been observed. For instance, the clinical significance of real-time PCR positive 
and serology negative patients in the follow-up needs to be further investigated. These 
patients need to be followed by both serology and real-time PCR for a long period of 
time to exclude chronic Q fever. C. burnetii DNA has also been detected by real-time 
PCR in different sample types (BAL, Buffy coat, faces, liquor, placenta, plasma, serum, 
sputum, throat- and vaginal swabs and urine). These sample types may be of value 
especially in patients difficult to determine by serology such as immune compromised 
patients.
Pregnant women and persons at risk for chronic Q fever, such as patients with 
cardiovascular complications (endocarditis, aortic aneurysms and vascular-graft 
infection) are recommended to avoid visiting infected farms 52. In 2010, the Health 
Council of the Netherlands recommended vaccination of risk groups with specific 
cardiac valve and vascular disorders. Although a human vaccine for Q fever is available, 
it is not registered outside of Australia and a serological and skin test is mandatory 
before a person can be vaccinated. Vaccination was implemented from January to June 
2011 of in total 1,366 patients 53, 54.
Although the effectiveness of certain control measures in the dairy goat industry is 
still unclear and the lag time of the measures and the contribution of environmental 
contamination with C. burnetii to the exposure of humans are unknown, the decrease 
in the number of human cases implicate that the implementation of these hygiene 
measures in combination with a rise in the human population with antibodies against 
C. burnetii, have most likely ended the outbreak. Lifelong vaccination of herds maybe 
necessary due to possible (re)introduction of C. burnetii to ruminants from the 
contaminated environment by the presence of infected rodents 55 or by transmission of 
C. burnetii strains between animals species such as goats and cattle. Future surveillance 
studies should reveal whether the introduction of the Dutch predominant strain will 
cause problems in the cattle population and may lead to a revival of Q fever in the human 
population. In the autumn of 2011, the Ministry of Economic Affairs, Agriculture and 
Innovation and Ministry of Health, Welfare and Sport reduced the measures against Q 
fever; the storage period of manure was reduced and the ban of extending goat farms 
was lifted. Without increasing the distance between goats and sheep farms and urban 
areas a new Q fever outbreak may occur.
The Q fever outbreak in the Netherlands was evaluated by the “van Dijk Committee” 
commissioned by the Dutch government. This committee indicates that insufficient 
attention has been paid to the standardization of detection methods. Furthermore, 
it indicates that there are uncertainties in the scientific relationship between Q fever 
in goats and humans. However, molecular and serological detection methods were 
already implemented in routinely diagnostics in many public health laboratories in 
the Netherlands at the end of the first outbreak year. Genotypic characterization of C. 
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burnetii was already described in the first outbreak years by the Canisius Wilhelmina 
Hospital in cooperation with the Central Veterinary Institute of Wageningen UR 
(CVI). The Q fever outbreak in the Netherlands is a learning process both on scientific 
and administrative level in performance between the many parties on veterinary and 
public health level. An integrated veterinary and human surveillance system was 
recommended by the “van Dijk” committee to exchange data between different parties 
in case of new outbreaks.
Conclusion
 This thesis was focussed on the molecular detection of C. burnetii in humans, 
possible caveats in the diagnostic pathway and on the molecular characterization of 
C. burnetii in ruminants and humans. Molecular methods have shown to be of value 
for the diagnosis of Q fever and real-time PCR has now been adapted in the Dutch 
consensus guideline on acute and chronic Q fever diagnostics.
Genotypic characterization in collaboration with nationally and internationally 
research laboratories, gave fundamental insight into the epidemiology of Q fever in 
the Netherlands and displayed a correlation between human Q fever cases and goats/
sheep. The resemblance with genotypes from France and Germany might give a clue 
about the origin of the Dutch Q fever outbreak. Genotypic characterization displayed 
a correlation between certain genotypes and difference in clinical outcome. Whether 
the Dutch genotype (associated to acute and chronic infections) is from a more 
hypervirulent lineage that may be disseminating more rapidly than other genotypes 
needs to be further investigated. The uniqueness of this predominant genotype can be 
part of the explanation why the magnitude of the Q fever outbreak in the Netherlands 
has never been seen elsewhere. A high prevalence of C. burnetii among the dairy cattle 
population worldwide was determined and genotyping revealed the presence of one 
specific cattle-adapted strain. The predominant Dutch genotype has not been identified 
in other animal species in the Netherlands, except in one placenta from cattle. This 
observation implicates that cattle may also be a reservoir of the epidemic genotype, 
aspects that needs further investigation. An increase of Q fever related to cattle will have 
high economical consequences. These findings indicate moreover the importance of 
ongoing molecular characterization in case of outbreaks and for surveillance purposes. 
Future studies should reveal whether (re-)introduction of C. burnetii in ruminants 
(cattle, goats and sheep) may lead to a revival of Q fever in the human population.
Understanding the distribution of C. burnetii genotypes present in a region, is critical 
to identify the major sources of infection, and implement efficient farm-based control 
measures to reduce human exposure to the pathogen. However, it is necessary to 
harmonize genotyping techniques to be used in Coxiella epidemiological studies, so 
that results can be exchanged and readily comparable among different laboratories. 
Likewise, a common website where all typing data can be submitted and easily accessed 
would be necessary for timely identification of new strains.
13
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Nederlandse samenvatting
 De humane Q-koorts uitbraak in Nederland trok de aandacht vanwege de 
omvang en duur en wordt in de literatuur aangeduid als de grootste uitbraak van 
Q-koorts ooit. Het totaal aantal Q-koorts patiënten steeg van gemiddeld 11 per jaar 
tussen 1997-2006 tot 4.176 patiënten en 25 sterfgevallen gerelateerd aan Q-koorts 
tussen 2007-2012. Q-koorts was in Nederland aanwezig lang voordat het een probleem 
in de volksgezondheid en de veeteelt werd (hoofdstuk 2). In deze periode bleek 
Q-koorts geen belangrijk gezondheidsprobleem voor mensen. Deze situatie, met een 
hoge seroprevalentie in dierpopulaties maar weinig gevallen bij de mens, bestaat in de 
meeste Europese landen. In 2005 en 2006, werd Q-koorts een probleem op melkgeiten 
en melkschapen bedrijven. Verschillende factoren kunnen hebben bijgedragen 
aan een verandering in de epidemiologie bij geiten: ten eerste, een toename van de 
dichtheid van geiten in de dichtbevolkte provincie Noord-Brabant (497 inwoners / 
km2) en ten tweede uitbreiding van de geitenboerderijen door de jaren heen. Deze twee 
factoren kunnen de dynamiek van Q-koorts in en tussen kuddes hebben beïnvloed, 
wat resulteerde in uitbraken. Ten derde kunnen pathogeen gerelateerde factoren 
zoals de circulatie van een zeer virulente C. burnetii stam een rol hebben gespeeld. 
Het klinisch beeld van deze C. burnetii stam in de Nederlandse bevolking is anders in 
vergelijking met Q-koorts gevallen in het buitenland. In het jaar 2007 en 2008 werd 
duidelijk dat Q-koorts ook een probleem voor de volksgezondheid werd (hoofdstuk 2). 
Verschillende onderzoeksprojecten in Nederland zijn gericht op de identificatie van 
risicofactoren voor Q-koorts, niet-menselijke reservoirs, transmissieroutes voor C. 
burnetii bij mens en dier, de evaluatie van de interventiemaatregelen, lange termijn 
effect, gastheer respons en de werkzaamheid van de behandeling strategieën. Het 
doel van het onderzoek zoals beschreven in dit proefschrift was om de C. burnetii 
genotypes bij herkauwers en in de humane populatie te onderzoeken in samenwerking 
met nationale en internationale onderzoek laboratoria (deel 1). Bovendien werd de 
moleculaire detectie van C. burnetii in serum vergeleken en mogelijke valkuilen in de 
diagnostiek aangetoond (deel 2).
Deel 1 Genotypische diversiteit van Coxiella burnetii
 bij herkauwers en mensen
 De correlatie tussen Q-koorts problemen bij melkgeiten, melkschapen 
en bij de mens is door meerdere onderzoekers gerapporteerd, uitsluitend op basis 
van epidemiologische bevindingen. Moleculaire karakterisering door middel van 
genotypering is echter belangrijk voor surveillance doeleinden en voor epidemiologisch 
onderzoek naar uitbraken. Deze informatie is belangrijk om een verband tussen 
de bron van de uitbraak en humane gevallen te leggen. Met deze informatie 
kunnen Nederlandse genotypen met internationaal bekende genotypen worden 
vergeleken en preventieve maatregelen in de veterinaire sector genomen worden. 
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De genotypische diversiteit van C. burnetii in herkauwers werd bepaald in hoofdstuk 
3. In totaal werden 126 C. burnetii positieve monsters van herkauwers getypeerd met 
behulp van een geüpdate 10-locus Multilocus Variable-nummer tandem-repeat Analyses 
(MLVA) panel. Één overheersend genotype werd gevonden op alle 11 melkgeiten 
bedrijven in het humane Q-koorts uibraak gebied in het zuiden van Nederland en op 
een boerderij in het oosten van het land. Dit C. burnetii genotype heeft een belangrijke 
rol gespeeld in de Q-koorts uitbraak bij kleine herkauwers in Nederland. Een mogelijke 
klonale verspreiding van C. burnetii op de melkgeiten bedrijven in het zuidoostelijk 
deel van Nederland werd aangetoond. Verschillende factoren, zoals weinig vegetatie 
in combinatie met het diepe grondwater zouden kunnen hebben bijgedragen aan de 
verspreiding van met C. burnetii besmette stof van besmette bedrijven naar de humane 
populatie.
Het verband tussen dierlijke en humane Q-koorts gevallen werd onderzocht 
met behulp van een verbeterde 6-locus MLVA panel. Hoofdstuk 4 beschrijft de 
genotypische diversiteit van C. burnetii in acute en chronische Q-koorts patiënten 
en geiten tijdens de 2007 - 2010 Q-koorts uitbraak episodes in Nederland. Meerdere 
verschillende maar nauw verwante MLVA genotypen werden gevonden op diverse 
locaties verspreid over het hele getroffen gebied tijdens de opeenvolgende jaren, 
wat wijst op een klonale verspreiding van C. burnetii door heel Nederland, zoals 
waargenomen bij geiten (hoofdstuk 3). Één overheersend genotype werd zowel bij de 
mens als bij geiten gevonden, wat de genotypische identiteit van C. burnetii bij mensen 
en geiten illustreert. De resultaten zijn consistent met een scenario waar één MLVA 
genotype werd geïntroduceerd bij geiten waar het geleidelijk veranderde in de loop van 
de tijd, terwijl deze zich over het land verspreidde en werd overgedragen op de mens. 
 
De correlatie tussen humane en dierlijke Q-koorts gevallen werd verder onderzocht met 
behulp van Multispacer Sequence Typing (MST) in samenwerking met onderzoekers 
uit Frankrijk en vergeleken met een internationale MST database (hoofdstuk 5). 
Genotype MST33 werd geïdentificeerd in patiënten, geiten en schapen, zoals eerder 
waargenomen met MLVA (hoofdstuk 3 en 4). MST genotype 20 werd geïdentificeerd in 
Nederlandse koeien, een geit en koemelk. Het Nederlandse uitbraak genotype (MST33) 
werd al eerder incidenteel gevonden in Frankrijk in 1996 en 1999 en in Duitsland in 1992. 
Een verband tussen bepaalde genotypes en de klinische uitkomst werd aangetoond. 
Hoewel Q-koorts wijdverbreidt voorkomt onder koeien, kunnen koeien tot nu toe 
niet in verband worden gebracht met de humane Q-koorts uitbraak in Nederland. 
 
In hoofdstuk 6 werd de prevalentie en de genotypen van C. burnetii in consumenten 
melk en melkproducten onderzocht met behulp van real-time PCR en een MLVA-6-
panel afkomstig uit heel Europa en van 10 niet-Europese landen. Achtentachtig van 
de 116 (76%) melkmonsters of melkproducten uit 28 landen bevatten aanzienlijke 
hoeveelheden C. burnetii DNA dat wijst op een hoge prevalentie van C. burnetii bij 
melkvee wereldwijd. Genotypering toonde de aanwezigheid van één specifiek rundvee 
type aan, wat een mogelijke klonale verspreiding van C. burnetii bij Europese runderen 
illustreert. Dit genotype is slechts incidenteel aangetroffen bij patiënten in Frankrijk; 
een risico van het verkrijgen van Q-koorts via blootstelling aan besmette runderen is 
waarschijnlijk veel lager dan via blootstelling aan geïnfecteerde kleine herkauwers. 
De meeste Q-koorts gevallen zijn gecorreleerd aan besmetting via aërosolen in 
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plaats van door inname van besmette rauwe melk. Hepatitis gecorreleerd aan 
Q-koorts werd slechts sporadisch gemeld tijdens de Q-koorts uitbraak in Nederland. 
Onlangs werd het overheersende humane en geiten genotype in één placenta van 
een rund aangetoond. Onderzoek kon geen mogelijke spillover van dit genotype van 
geiten op runderen aantonen. Waarschijnlijk betreft het hier een incidenteel geval. Een 
mogelijke toename in het aantal Q-koorts gevallen, gerelateerd aan runderen met dit 
genotype, kan tot grote economische gevolgen leiden. Dit is echter puur speculatief 
en vraagt  verder onderzoek. Moleculaire karakterisering van C. burnetii bij runderen 
blijft daarom belangrijk, niet alleen voor surveillance doeleinden, maar ook voor 
epidemiologisch onderzoek om verspreiding in het Nederlandse rundvee populatie te 
voorkomen.
Moleculair onderzoek in samenwerking met internationale onderzoeksgroepen 
is belangrijk om de Europese context van de Q-koorts epidemiologie beter te 
begrijpen. Hoofdstuk 7 en hoofdstuk 8 beschrijft de genetische diversiteit van 
C. burnetii in herkauwers en de mens in Portugal en Spanje in samenwerking 
met onderzoekers afkomstig uit beide landen. Een genetische diversiteit van 
C. burnetii consistent met een niet-uitbraak situatie werd geïdentificeerd. 
De studie toonde de betrokkenheid van verschillende genotypen bij acute en 
chronische Q-koorts gevallen aan. Deze genotypen werden eerder in heel Europa 
geïdentificeerd. Genotypering leverde belangrijke epidemiologische informatie 
over de bronnen van infectie en de verspreiding van de betreffende genotypen op. 
Hoofdstuk 9 beschrijft de evaluatie van twee overeenstemmende MLVA 
typeringsmethoden (hoofdstuk 3 en hoofdstuk 4) en MST (hoofdstuk 5).
Deel 2 Moleculaire detectie van Coxiella burnetii
 bij mensen
 
 De gerapporteerde prevalentie van Q-koorts neemt wereldwijd toe als 
gevolg van verbetering van de kwaliteit van de diagnostische methoden en werkelijke 
prevalentie. Het totaal aantal geïnfecteerde mensen kan ondergerapporteerd zijn door 
asymptomatische gevallen en patiënten die niet de huisarts bezochten. Geschat wordt dat 
per gerapporteerde patiënt meer dan 12 infecties met C. burnetii niet zijn gerapporteerd. 
Hoek berekende dat het aantal gerapporteerde acute Q-koorts infecties van 3.522 tussen 
2007-2009 overeenkomt met ongeveer 44.000 ongerapporteerde infecties in dezelfde 
periode. Het aandeel niet gediagnosticeerde of gerapporteerde acute Q-koorts gevallen 
kan variëren per regio en zal naar verwachting nog hoger zijn in lage incidentie gebieden. 
Vijfentwintig sterfgevallen gerelateerd aan Q-koorts zijn gemeld tussen 2007-2012. 
Patiënten hadden vaak ernstige onderliggende aandoeningen, waaronder chronische 
hart -en vaatziekten, chronische longziekten en diabetes of hadden een co-infectie. Het 
aantal sterfgevallen in verband met Q-koorts kan door onderrapportage, als gevolg van 
onbekendheid bij clinici in het begin van de uitbraak, zelfs nog hoger zijn. Acute Q-koorts 
kan gemakkelijk als gevolg van milde symptomen over het hoofd gezien worden of de 
diagnostiek op Q-koorts werd zelfs niet aangevraagd. Moleculaire diagnostiek werd niet 
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in alle laboratoria vóór 2009 ingevoerd en dus serologische negatieve patiënten kunnen 
zijn overleden aan longontsteking veroorzaakt door C. burnetii, zonder dat de diagnose 
met behulp van moleculaire methoden werd vastgesteld. Een retrospectieve analyse 
van PCR op opgeslagen serum van patiënten bij wie de diagnose van acute Q-koorts 
niet door serologie werd vastgesteld, onthulde de aanwezigheid van C. burnetii DNA 
in 10% van de gevallen. Dit geeft aan dat moleculaire methoden en serologie samen 
moeten worden gebruikt om de diagnose van Q-koorts te kunnen vaststellen.
Het hoge aantal niet gediagnosticeerde infecties kunnen ook een effect op het aantal 
chronische Q-koorts gevallen in de komende jaren hebben. Huisartsen en clinici in 
endemische gebieden moeten alert zijn op chronische Q-koorts, zelfs als er geen acute 
Q-koorts is gemeld. De meeste acute Q-koorts gevallen kunnen onopgemerkt blijven als 
gevolg van milde of zelfs helemaal geen symptomen. Voorafgaande valvulaire chirurgie, 
vaatprothese, aneurysma, nierinsufficiëntie, pre-existente hartklepaandoeningen, 
immunosuppressie en zwangerschap zijn geïdentificeerd als belangrijke risicofactor 
voor de ontwikkeling van chronische Q-koorts. Acute Q-koorts patiënten met 
deze geïdentificeerde risicofactoren moeten grondig worden gecontroleerd door 
serologische follow-up of zelfs profylactische behandeling is nodig. De diagnose van 
chronische Q-koorts middels serologie kan een echte uitdaging zijn; (i) vaak wordt de 
diagnose gemaakt wanneer significante valvulaire schade al is opgetreden; (ii) in 2.5 tot 
31.0 % van alle infectieuze endocarditis gevallen wordt de routine bloedkweek negatief 
bevonden; (iii) de diagnose chronische Q-koorts kan tot 10 jaar na de primaire infectie 
nog worden vastgesteld. Interpretatie van de serologische resultaten kan door het 
ontbreken van gevalideerde cut-off waarden moeilijk zijn. Real-time PCR kan bijdragen 
aan de diagnose van chronische Q-koorts, vooral bij immuun gecompromitteerde 
patiënten met atypische lage fase I antilichamen en klinische verdenking op chronische 
Q-koorts. Dit illustreert ook dat lage fase I antilichamen chronische Q-koorts 
niet uitsluit. De gevoeligheid van de PCR kan oplopen tot 100% bij de bepaling van 
chronische Q-koorts, wanneer klepweefsel wordt gebruikt in vergelijking met bloed. 
Serologie is het belangrijkste instrument voor de diagnose van Q-koorts, echter 
moleculaire technieken zijn een toegevoegde waarde voor de diagnose van acute 
Q-koorts en voor de klinische follow-up. PCR is nu geïmplementeerd in de Nederlandse 
richtlijn over acute en chronische Q-koorts diagnostiek. Chronische Q-koorts is een 
gecombineerde diagnose gebaseerd op C. burnetii-diagnostiek (PCR en IFA-fase I IgG-
antistoffen), aanwezigheid van risicofactoren, klinische symptomen en radiologische 
bevindingen. Chronische Q-koorts wordt ingedeeld in (i) bewezen (positieve PCR in 
weefsel en/of bloed in afwezigheid van een acute Q-koortsinfectie; of IFA-fase I IgG-titer 
≥ 1:1,024 én bewijs voor endocarditis volgens de Duke-criteria; of IFA-fase I IgG-titer ≥ 
1:1,024 én bewijs voor vaatwandinfectie met PET-CT, CT en/of echo), (ii) waarschijnlijk 
(IFA-fase I IgG-titer ≥ 1:1,024 samen met hartklepafwijkingen die niet voldoen aan de 
Duke-criteria; of bekend aneurysma en/of vaat- en hartklepprothese zonder aanwijzing 
voor infectie met TEE, PET-CT, CT en/of echo; of verdenking van chronische Q-koorts, 
elders gelokaliseerd, zoals hepatitis; of osteomyelitis; of zwangerschap; of klinische 
symptomen van chronische infectie zoals koorts, gewichtverlies, glomerulonephritis en 
nachtzweten; of bewezen granulomateuze ontsteking van weefsel middels pathologisch 
onderzoek; of ernstige immuunstoornissen) en (iii) mogelijk (IFA-IgG-fase I titer ≥ 
1:1,024 zonder (klinische) manifestaties, zoals die beschreven staan in categorieën 
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bewezen en waarschijnlijke chronische Q-koorts). Op basis van klinische prospectieve 
data die beschikbaar komen uit de landelijke chronische Q-koorts database kan de 
richtlijn worden aangepast.
Tot 2007 werd Q-koorts vooral gediagnostiseerd in Nederland met behulp van serologische 
methodes. Medische microbiologische laboratoria hebben moleculaire methoden 
geïmplementeerd om de diagnostiek van acute en chronische Q-koorts in Nederland 
te  verbeteren. De studie beschreven in hoofdstuk 10 vergelijkt de  verschillende DNA-
extractie methoden en real-time PCR testen, allen gericht op het C. burnetii IS1111a 
insertie-element, die worden gebruikt in zeven diagnostische laboratoria in Nederland. 
Meerdere combinaties van DNA extractie kits en real-time PCR analyses toonden 
gelijkwaardige oplossingen aan voor het screenen van patiënten verdacht van Q-koorts. 
Bij toepassing van moleculaire technieken om microbiële DNA te detecteren in klinisch 
materiaal, kunnen meerdere problemen in het diagnostisch proces ontstaan die kunnen 
resulteren in vals positieve PCR resultaten. Niet alleen PCR enzymen kunnen besmet 
zijn met bacterieel DNA, maar de in de DNA extractie procedures gebruikte reagentia 
en disposables (zoals spin kolommen) kunnen exogeen DNA bevatten. Een besmetting 
van een diagnostische real-time PCR met belangrijke klinische consequenties als gevolg 
als beschreven in hoofdstuk 11, was herleidbaar naar een commercieel verkregen PCR 
Master Mix. Deze Master Mix bevatte DNA van C. burnetii, waarschijnlijk als gevolg 
van het gebruik van dierlijke componenten, zoals bovine serum albumine. Deze 
bevindingen tonen de noodzaak aan van uitgebreide controles op meerdere niveaus 
in de PCR procedure. Hoofdstuk 12 beschrijft een laboratorium besmetting met Q- 
koorts welke herleidbaar was naar het gebruik van antigeen preparaten afkomstig 
van een commercieel verkrijgbare complementbinding reactie (CFT). De meest 
waarschijnlijke manier waarop besmetting kan hebben plaatsgevonden is door de 
vorming van aërosolen tijdens de CFT procedure. De hoge concentraties DNA in het 
commercieel verkrijgbare antigeen, tonen aan dat moleculaire diagnostische methoden 
moeten worden uitgevoerd op een locatie welke fysiek gescheiden is van die waar de 
serologische methoden worden uitgevoerd. Daarnaast moet bij voorkeur materiaal van 
patiënten worden gebruikt dat nog niet voor serologisch onderzoek is gebruikt.
 
In 2010 heeft de Gezondheidsraad in Nederland de vaccinatie van risicogroepen met 
specifieke hartklep -en vaatziekten aanbevolen. Een menselijk vaccin tegen Q-koorts 
is beschikbaar, deze is echter niet geregistreerd buiten Australië en daarom is een 
serologische en huidtest verplicht voordat een persoon kan worden gevaccineerd. 
Vaccinatie is uitgevoerd van januari tot juni 2011 bij in totaal 1.366 patiënten.
De effectiviteit van bepaalde controlemaatregelen in de geitenhouderij zijn nog steeds 
onduidelijk. De bijdrage van verontreiniging van C. burnetii vanuit het milieu tot de 
blootstelling aan de mens zijn onbekend. De afname van het aantal humane gevallen 
is waarschijnlijk  het  gevolg van  de uitvoering van deze hygiënische maatregelen in 
combinatie met een toename  van  antistoffen tegen C. burnetii in de humane populatie met 
als gevolg het einde van de uitbraak. Levenslange vaccinatie van de veestapel is misschien 
nodig door een mogelijke (her)introductie van C. burnetii uit de verontreinigde omgeving, 
door de aanwezigheid van besmette knaagdieren of door de transmissie van C. burnetii 
stammen tussen diersoorten zoals geiten en runderen. Toekomstige studies moeten 
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uitwijzen of de introductie van de Nederlandse stam problemen in de rundveepopulatie 
zal veroorzaken en kan leiden tot een opleving van Q-koorts in de humane populatie. 
In het najaar van 2011 heeft het Ministerie van Economische Zaken, Landbouw 
en Innovatie en het ministerie van Volksgezondheid, Welzijn en Sport de 
maatregelen tegen Q-koorts versoepeld, de opslagperiode van mest werd 
verminderd en het verbod van de uitbreiding van geitenhouderijen werd opgeheven. 
Zonder verhoging van de afstand tussen de geiten en schapen bedrijven en 
stedelijke gebieden kan een nieuwe Q-koorts uitbraak niet worden uitgesloten. 
 
De Q-koorts uitbraak in Nederland werd geëvalueerd door de “Commissie van Dijk” 
in opdracht van de Nederlandse overheid. Deze commissie heeft aangegeven dat er 
onvoldoende aandacht is besteed aan de standaardisatie van de detectiemethoden 
en er geen duidelijk wetenschappelijk bewijs van de relatie tussen Q-koorts bij geiten 
en mensen werd gegeven. Echter, moleculaire en serologische detectiemethoden 
werden snel na de eerste uitbraak geïmplementeerd in de routinematige diagnostiek 
in veel laboratoria  in Nederland. Een  overeenkomst tussen geiten en patiënten door 
genotypische karakterisering van C. burnetii werd al beschreven in het begin van de 
uitbraak door het Canisius Wilhelmina Ziekenhuis in samenwerking met het Centraal 
Veterinair Instituut van de Wageningen UR (CVI). De Q-koorts uitbraak in Nederland is 
een leerproces, zowel op wetenschappelijk als bestuurlijk niveau tussen de vele partijen 
op het gebied van diergezondheid en volksgezondheid. Een geïntegreerde veterinair en 
humaan surveillance systeem werd aanbevolen door de “Commissie van Dijk” om sneller 
gegevens uit te wisselen tussen de verschillende partijen in het geval van nieuwe uitbraken. 
Conclusie
 Dit proefschrift is gericht op de moleculaire detectie van C. burnetii bij 
mensen, mogelijke valkuilen in de diagnostiek en de moleculaire karakterisering van 
C. burnetii bij herkauwers en mensen. Moleculaire methoden zijn belangrijk bij de 
diagnose van Q-koorts, als aanvulling op de serologie, real-time PCR is nu toegevoegd 
aan de Nederlandse consensus richtlijn over acute en chronische Q-koorts diagnostiek. 
Fundamenteel inzicht in de epidemiologie van Q-koorts werd verkregen door 
genotypische karakterisering van C. burnetii in samenwerking met nationale en 
internationale onderzoekslaboratoria. Een correlatie tussen humane Q-koorts gevallen 
en geiten/schapen werd in Nederland aangetoond. De gelijkenis met genotypes uit 
Frankrijk en Duitsland geven een mogelijke oorsprong van de Nederlandse Q-koorts 
uitbraak aan. Genotypische karakterisering toonde een correlatie tussen bepaalde 
genotypes  en verschil in klinische uitkomst.
Of het Nederlandse genotype hypervirulenter is en zich sneller verspreidt 
dan andere genotypen moet verder worden onderzocht. Het unieke van 
het overheersende genotype kan een deel van de verklaring zijn waarom de 
omvang van de Q-koorts uitbraak in Nederland nooit eerder is waargenomen. 
Een hoge prevalentie van C. burnetii onder de melkveepopulatie wereldwijd werd 
bepaald en genotypering onthulde de aanwezigheid van een specifiek rundvee 
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genotype aan. Het overheersende Nederlandse genotype werd niet in andere 
diersoorten in Nederland aangetoond, met uitzondering in één placenta van een 
rund. Deze waarneming impliceert dat rundvee mogelijk ook een reservoir van het 
overheersende genotype kan zijn met mogelijk grote economische gevolgen. Dit moet 
echter nog verder worden onderzocht. De bevindingen geven bovendien het belang 
van moleculaire karakterisering bij uitbraken aan. Toekomstige studies moeten 
uitwijzen of (her-)introductie van C. burnetii bij herkauwers (runderen, geiten en 
schapen) kan leiden tot een opleving van de Q-koorts in de humane populatie. 
 
Inzicht in de C. burnetii genotypen aanwezig in een regio, is van cruciaal belang om de 
belangrijkste bronnen van infectie te identificeren en om efficiënte controle maatregelen 
te implementeren om humane blootstelling aan de ziekteverwekker te verminderen. 
Genotyperings technieken moet worden geharmoniseerd in epidemiologische studies 
wereldwijd, zodat de resultaten kunnen worden uitgewisseld en vergelijkingen tussen 
verschillende onderzoeks laboratoria kunnen worden gemaakt. Een gemeenschappelijke 
website waar alle gegevens kunnen worden ingevoerd en welke gemakkelijk bereikbaar 
is voor de tijdige identificatie van nieuwe stammen is noodzakelijk.
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Dankwoord
 Dit proefschrift zou niet compleet zijn zonder een woord van dank aan al die 
mensen, die hebben bijgedragen tot het tot stand komen van dit proefschrift.
Professor Dr. A. Voss (promotor). Ik wil u bedanken voor de mogelijkheid om te 
promoveren. U bent de afgelopen jaren hoofdzakelijk zijdelings betrokken geweest 
bij het onderzoek, maar in het zicht van de finale was u samen met Dr. M.H. 
Nabuurs-Franssen (copromotor) daar om de hobbels glad te strijken. Marrigje jouw 
enthousiasme en betrokkenheid bij het onderzoek waardeer ik enorm. Je hebt een 
buitengewone grote kennis van Q-koorts. Dr. C.H.W. Klaassen (copromotor), Corné 
bedankt voor je onuitputtelijke moleculaire kennis en je bijdrage tot het onderzoek. Dr. 
A.M. Horrevorts, Dr. H. Berkhout en Dr. J.F.G.M. Meis wil ik bedanken voor de tips bij 
de projectbesprekingen tijdens het wekelijkse innovatieoverleg.  
Hendrik-Jan Roest, vanaf het begin van de Q-koorts uitbraak in 2007 is het contact tussen 
de onderzoeksgroepen van het Centraal Veterinair Instituut Lelystad en het Canisius- 
Wilhelmina Ziekenhuis uitstekend en heeft geleid tot meerdere gemeenschappelijke 
publicaties en presentaties op symposia in Kreta, Amsterdam en Berlijn. Hendrik-Jan 
graag wil ik je bedanken voor de substantiële bijdrage die je geleverd hebt aan het tot 
stand komen van enkele artikelen in dit boekje.
Dank ben ik ook verschuldigd aan alle leden van de PCR werkgroep. Willem Melchers 
(RUNMC), Annika Petterson (VU), John Rossen (st. Elisabeth Ziekenhuis, UMCG), 
Mirjam Hermans (JBZ), Erik van Hannen (St. Antonius), Maaike de Vries (RIVM) en 
Daan Notermans (RIVM) onze gemeenschappelijke lunch meetings hebben geleid tot 
een gezamenlijk artikel, een poster op de ECCMID 2010 in Vienna en bovendien is de PCR 
nu opgenomen in de consensus landelijke diagnostiek acute en chronische Q-koorts. 
Ik wil jullie als ook Jeroen van de Bovenkamp (PAMM) bedanken voor het aanleveren 
van patiëntenmateriaal om zo een duidelijk beeld te krijgen in het voorkomen van de 
Coxiella burnetii genotypen in Nederland.
Professeur D. Raoult (Université de la Méditerranée Marseille) et G. Vergnaud (Université 
Paris-Sud), je suis très reconnaissant pour fournir des échantillons de plusieurs patients. 
Merci à tous pour la contribution à la recherche de fièvre Q et les publications. Prof. 
D. Raoult, je suis reconnaissant de l’hospitalité dans votre laboratoire de Faculté de 
Médecine de Marseille. Annick et Veronique merci pour le génotypage des explications 
MST. Merci Sylvain pour l’analyse et l’explication de l’utilisation du web site de MST. 
Ana Santos (National Institute of Health, Aguas de Moura, Portugal) thank you very 
much for our collaboration. I enjoyed your visit to our laboratory to teach you about 
the genotyping. I’ am very pleased that we could work together in typing the C. burnetii 
strains from Portugal (ref PTDC/SAU-SAP/115266/2009) supported by the Portuguese 
Foundation for Science and Technology – FCT. Our work has been published recently and 
presented at the ECCMID in London 2012. Ana obrigado por visitar o nosso laboratório. 
Mantemos contato e espero que possamos trabalhar juntos mais no futuro.
Ianire Jakobiza and Ana Garcia-Pérez (Department of Animal Health, NEIKER-
Instituto, Bizkaia, Spain); Ianire we met at the Q fever symposium in Crete, Greece 2011. 
I’ am very pleased that I could help you and Ana typing the Spanish C. burnetii strains. 
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The results have been presented at the ECCMID in London 2012 and are published 
recently. Ianire Gracias por venir a nuestro laboratorio. Nos mantenemos en contacto y 
espero que podamos trabajar juntos en el futuro.
The work described in this thesis has resulted in a collaboration with many more 
research groups. Therefore, I would also like to thank Rudolf Toman (Slovak Republic), 
Alda Natale and Letizia Ceglie (Italy), Sara Åkerström (Sweden) and Francois 
Beaudeau (France). Dimitrios Frangoulidis and Pauline Bleichert from the Institut für 
Mikrobiologie der Bundeswehr in München, thank you for the improved amplification 
primer (Cox57) and the discussion about the genotyping in 2011 in Crete.
Verder wil ik iedereen die een bijdrage heeft geleverd aan de totstandkoming van dit 
proefschrift hartelijk bedanken, met name Robin Ruuls, Peter Willemsen, Rob Buijs, 
Albert de Boer en Fred van Zijderveld (CVI), Piet Vellema, Rene van den Brom, Daan 
Dercksen en Willem Wouda  (GD) Marcel Spierenburg, Arco van der Spek (nVWA) en 
Wim van der Hoek en Arnoud de Bruin (RIVM). Geweldig om op veterinair en humaan 
gebied samen te werken. 
Corina, het was natuurlijk meteen duidelijk dat jij één van de paranimfen zou zijn. Ik ben 
je dankbaar dat je altijd voor mij hebt klaar gestaan. We hebben heel wat meegemaakt 
op het CWZ. Onze gesprekken over de diagnostiek, het Q-koorts onderzoek, maar 
vooral ook over onze eigen belevenissen buiten het werk heb ik enorm gewaardeerd. 
Wat hebben we gelachen samen op de tandemfiets. We moeten zeker vaker een ijsje 
gaan eten. Hopelijk komt er nu meer tijd vrij voor die fotosessie met de kinderen.
Tom, ik ben blij dat je een van mijn paranimfen wilt zijn. Jouw interesse in mijn 
onderzoek heb ik zeer gewaardeerd. Je was getuige bij ons huwelijk en ik ben blij dat je 
nu getuige wilt zijn van mijn promotie.
Alle medewerkers van de moleculaire biologie, Corina, Ferry, Maaike, Maikel, Antoinette 
en Kim wil ik bijzonder bedanken voor alle interesse en morele steun die jullie hebben 
getoond. Ferry, ik heb genoten van onze trip naar de ECCMID 2013 in Berlijn. We hebben 
veel gezien en dubbel gelegen van het lachen met onze zelfde humor. Dorien, Mary en 
Bea van de serologie ben ik dankbaar voor de belangstelling tijdens mijn onderzoek 
en voor alle hulp bij het opzoeken van de vele Q-koorts samples. Verder wil ik alle 
medewerkers van de afdeling medische microbiologie en infectieziekten en Carel, 
Clemens, Marcel, Dorien en Yvonne van de afdeling pathologie en klinische chemie 
van het Canisius-Wilhelmina Ziekenhuis, bedanken voor jullie belangstelling, die jullie 
getoond hebben tijdens mijn onderzoek.
Tot slot wil ik de familie en vrienden bedanken voor hun interesse tijdens mijn 
onderzoek. Q-koorts was de afgelopen jaren wel het gespreksonderwerp bij ons in 
Brabant. Mijn schoonouders Lambert en Will ben ik bijzonder dankbaar voor alle 
steun en de vele krantenknipsels. Jullie waren altijd belangstellend naar de vorderingen 
van mijn onderzoek en staan altijd klaar voor ons vijfjes. Debbie zonder jou was het er 
natuurlijk nooit van gekomen. Ik kan wel een proefschrift vol schrijven over alles wat 
je voor mij en onze kids betekent. Je bent in mijn roerige loopbaan altijd achter mijn 
beslissingen blijven staan. De afgelopen jaren ben jij degene geweest die altijd bleef 
volhouden dat die promotie er uiteindelijk aan zat te komen. Dat laatste duwtje heeft 
zeker geholpen! Lieke, Maarten en Iris het is tijd voor een feestje!
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